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MODULATION OF THE MDM2 SIGNALING AXIS SENSITIZES TRIPLE-NEGATIVE BREAST 
CANCER CELLS TO CARBOPLATIN 
 
Triple-negative breast cancers (TNBCs) are highly refractive to current treatment 
strategies, and new multi-targeted treatments need to be elucidated. Combination 
therapy that includes targeting the murine double minute 2 (Mdm2) signaling axis offers 
a promising approach. Protein-protein interaction inhibitors such as Nutlin-3a block the 
binding of key signaling molecules such as p53, p73α, and E2F1 to the hydrophobic 
pocket of Mdm2 and can lead to activation of cell-death signaling pathways. Since 
clinical trials for TNBC are evaluating the DNA damaging agent carboplatin, the objective 
of this thesis was to evaluate the therapeutic potential and mechanism of action of 
combination carboplatin and Nutlin-3a to treat TNBC. In TNBC cell lines with a mutant 
p53 background, we determined if modulation of Mdm2 function in the context of 
carboplatin-mediated DNA damage resulted in a synergistic inhibition of cell growth. 
Several ratios of carboplatin:Nutlin-3a were strongly synergistic in increasing cell death, 
with combination indices of 0.5 and lower. Mechanistic studies indicated that drug 
sensitivity and Mdm2 expression were dependent on p73. Mdm2 localized to a larger 
degree in the chromatin fraction isolated from cells treated with the combination 
treatment consistent with observations by others that Mdm2 binds to the 
Mre11/Rad50/Nbs1 complex, inhibits the DNA damage response, and increases drug 
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sensitivity.  In vivo efficacy experiments were conducted in the TMD231 orthotopic 
mammary fat pad model in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. For assessment of 
baseline tumor burden and randomization, fluorescent imaging of E2-Crimson 
expressing TMD231 cells was performed. Following Nutlin-3a and carboplatin 
combination treatment, there was a statistically significant reduction in primary tumor 
volume as well as lung metastases with significantly increased probability of survival 
compared to Vehicle and single drug treatments (p<0.001). While there was a decrease 
in bone-marrow cellularity, this did not lead to bone-marrow aplasia, and body weights 
recovered to normal levels within 7 days post-treatment. The present studies 
demonstrate the promise of Mdm2 as a therapeutic target in combination with 
conventional therapy, increase our understanding of how to potentiate DNA damage in 
cancers, and may lead to new clinical therapies for triple-negative primary and 
metastatic breast cancer. 
 
 Karen E. Pollok, Ph.D., Chair 
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SECTION I: INTRODUCTION AND LITERATURE REVIEW  
 
Chapter 1. Breast Cancer Background 
 
Cancer describes a group of diseases in which cells abnormally grow forming 
tumors within the body. The hallmarks of cancer are described as dysregulation of 
proliferative signaling, evading growth suppressive signaling, resisting cell death 
signaling, replicative immortality, pro-angiogenesis signaling, and enabling invasion and 
metastasis 1. Cancer is classified into different stages that can be helpful in deciding 
courses of treatment and prognosis. Stage 0 is defined by carcinoma in situ in which 
there is an abnormal cluster of cells that has not begun spreading to any surrounding 
tissues. Stages I-III are described as more extensive disease in which the size and grade 
of the tumor increases with increasing stage number. Additionally, the spread of cancer 
beyond the organ of origin into nearby lymph nodes and tissues increases with stage. 
Stage IV classifies cancer tumors that have spread to distant tissues or organs through 
the process of metastasis. There are different types of medical tests that can be used to 
determine the stage of cancer including physical exams, imaging tests, lab tests, 
pathology findings, and surgical observations (cancer.gov). The stage of cancer will also 
determine the treatment schema.  
Breast cancer is the second leading cause of cancer related deaths in women 
after lung cancer. It is estimated that in 2014, there will be over 200,000 new cases with 
about 40,000 women succumbing to the disease. Breast cancer is a multi-faceted 
 1 
disease with many different subtypes. There are numerous risks including genetic 
factors, family history, age, age at first menstrual cycle as well as pregnancy. It is 
estimated that 5-10% of all women harbor mutations in the BReast CAncer 1 and 2 
(BRCA1 and BRCA2) DNA repair genes, which has been shown to lead to increased risk of 
breast cancer 2. In cases where there is a family history of breast cancer, specific 
screening strategies are developed, which may include regular breast exams and an 
earlier onset of mammograms. Breast cancer is a highly metastatic disease with 
estimations that 20-30% of all breast cancers will become metastatic 3. It is also 
estimated that upon initial diagnosis, 6-10% of patients already have metastatic lesions 
4. Breast cancers commonly metastasize to the bone, brain, liver, and lungs. There is a 
critical need to research and develop treatment modalities that will not only treat the 
primary tumor but also treat metastatic sites.  
There are four different breast cancer subtypes with different gene expression 
patterns, which is used to determine the best treatment strategy. Breast cancer can be 
divided into triple-negative/basal-like, human epidermal growth factor receptor 2 
(HER2) positive, luminal A, and luminal B subtypes. Common molecular testing involves 
estrogen receptor (ER), progesterone receptor (PR), and HER2/neu receptor status 
testing. There are specific drug treatments for cancers that express ER, PR, and HER2 
receptors involving antibodies against the receptors; however, these targeted therapies 
are only useful if the target is present.  
Luminal breast cancers present with high levels of hormone receptors and 
comprise about 70% of invasive breast cancers. Luminal breast cancers respond to 
 2 
endocrine therapy due to the high levels of hormone receptors 5. With further gene 
level profiling, Luminal B cancer subtypes express the ER; however, they do not express 
estrogen-regulated genes suggesting that ER signaling is not a major factor in how these 
cancers grow 6. The HER2+ subtype has high levels of HER2 and associated downstream 
gene levels and comprises about 15% of invasive cancers 5. HER2 cancer subtypes 
respond to trastuzumab, which is a monoclonal antibody to the HER2 receptor, but 
generally are associated with poor prognosis 5. Basal breast cancers have high levels of 
basal epithelial genes and have low levels of ER and HER2. Basal breast cancers consist 
of about 15% of invasive cancer with most being triple-negative (ER-, PR-, and HER2 non-
overexpressing) 5. Triple-negative breast cancers (TNBCs) do not respond to endocrine 
therapy due to the lack of hormone receptors. Based on new data analysis, triple-
negative breast cancers are sensitive to platinum-based therapies in conjunction with 
Poly- (ADP) ribose polymerase (PARP) inhibitors especially in cases with BRCA1/2 
mutations 7. PARP is involved in DNA repair, which when inhibited, leads to decreased 
DNA repair leading to increased cell death following treatment with DNA damaging 
chemotherapeutic drugs 7. TNBCs are regarded as more aggressive types of cancer due 
to their lack of targeted therapies as well as the aggressive nature of the cancer cells 8.  
Breast cancer is treated with a combination of surgery, radiation, and 
chemotherapy. Surgery is used to remove the bulk of the tumor from the breast through 
lumpectomy or partial/full mastectomy depending of the invasiveness of the tumor. 
Nearby lymph nodes are also removed as a biopsy to examine if there are any cancer 
cells present to examine the invasiveness of the tumor. Neoadjuvant therapy, or 
 3 
chemotherapy prior to surgery, is used to shrink primary tumors before surgery. 
Radiation therapy can be given internally or externally. Internal radiation therapy 
delivers radioactive substances directly to the cancerous tissue through needles, wires 
or catheters. Chemotherapy is often given throughout the body through intravenous 
(IV) infusion; however, chemotherapy can also be given in a localized area. The type of 
treatment greatly depends on the stage of the tumor. Hormone therapy can be used in 
breast cancers that express hormone receptors, which ablates the naturally occurring 
hormones in the body. Without these hormones circulating in the body, the cancers that 
are dependent on hormone signaling are basically starved causing those cancer cells to 
die.  
Targeted therapies include treatments that affect cells with specific molecular 
characteristics. For example, monoclonal antibodies have been developed against the 
HER2 receptor. This antibody binds to the receptor and blocks the growth signaling used 
by the cancer cells to continue proliferating. A new approach utilizes the concept of 
synthetic lethality to treat cancers. Synthetic lethality is described as the concept that 
mutations in two different genes may not have an effect in cells when only gene is 
mutated, but when both are mutated at the same time, leads cells to cell cycle arrest or 
death 9. It has been described in the literature that the BRCA1/2 genes act as tumor 
suppressors, and people with heterozygous mutations in BRCA1/2 genes have an 
increased risk in breast, ovarian, pancreatic, prostate, and male breast cancer 9. When 
patients have mutations in the DNA repair BRCA1/2 genes, DNA repair is affected, and 
cells with BRCA1/2 mutations are more sensitive to ionizing radiation and 
 4 
chemotherapeutic drugs that induce DNA double strand breaks (DSBs) 9. In the clinic, 
patients are screened for BRCA1/2 mutations, and studies have shown that combination 
treatment with PARP inhibitors will lead to synthetic lethality when coupled with a DNA 
damaging drug, such as platinum drugs 7,9. Both BRCA1/2 and PARP are involved in DNA 
repair pathways and when mutated singly, there is an increased risk of genomic 
instability. However, when BRCA1/2 is mutated and PARP is inhibited together, coupled 
with increased DNA damage induced by chemotherapeutic drugs, the cells are unable to 
cope with the DNA damage and leads to increased cell death 9. The use of genetic 
testing continues to be important as we increase our understanding of cancers and how 
expression profiles affect therapeutic strategies. 
As mentioned earlier, targeted therapies are used including endocrine therapy 
for those types of cancers that express the hormone receptors. There are numerous 
types of treatments for non-endocrine therapies including signal transduction inhibitors, 
gene expression modulators, apoptosis inducers, mitotic inhibitors, angiogenesis 
inhibitors, and immunotherapies. Some of these treatments are FDA approved for 
treating cancer while others are still in development or clinical trials. The first line 
treatment for early stage TNBC include combination cytotoxic chemotherapies 10. 
Taxanes are commonly used in breast cancer treatments and act as a mitotic inhibitor. 
The mechanism of action for the taxanes is the stabilization of microtubules leading to 
interference with normal microtubule deconstruction during cell division. As with any 
drug treatment, there are numerous side effects; however, the most notable is 
neurotoxicity leading to peripheral neuropathy. There has been recent data to suggest 
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that platinum agents used in combination with standard of care drugs offer enhanced 
tumor effects 11,12. This is especially true in those patients who have mutations in 
BRCA1/2 since there is defective DNA repair making the DNA-damaging drugs more 
effective in those patient tumors 13. There are numerous ongoing clinical trials using 
carboplatin specifically treating TNBCs with metastases: NCT01881230, NCT00691379, 
and NCT01281150 (clinicaltrials.gov). Platinum agents are effective by forming DNA-
platinum adducts resulting in intra- and interstrand crosslinks in the DNA leading to 
double strand breaks, which ultimately leads to cell death 14. Later platinum generation 
drugs from cisplatin are often used in clinical settings due to the decreased side effects. 
The toxicity associated with cisplatin is most profound in the kidney whereas carboplatin 
causes little to no nephrotoxicity 15. New treatment modalities need to be developed to 
decrease toxicity and increase efficacy.  
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Chapter 2. Models for Studying Breast Cancer 
 
There are numerous in vitro and in vivo methods to study breast cancer. Many 
researchers begin initial studies utilizing human breast cancer cell lines grown in culture 
due to the quick experiment time and data generation. This method is commonly known 
as 2D monolayer cell growth in which cells are grown on plastic. These methods are 
inexpensive and high throughput with a wide range of experiments that can be derived 
from cells. However, some would argue that cells grown in 2D do not fully represent the 
tumor microenvironment due to the lack of stroma and that cell sensitivity to drugs is 
increased compared to sensitivity in vivo 16. It has been reported by numerous 
laboratories that up to 80% of the breast tissue and the tumor microenvironment is 
comprised of stroma, suggesting that the stroma may play an important role in 
promoting growth of breast cancer cells. To circumvent these limitations, many 
investigators use 3D cultures in which the cells are grown in a matrix allowing the cells 
to grown in 3-dimensional space. With the addition of support cells, there are cell-cell 
and cell-matrix interactions that are able to occur naturally 16. In these 3D settings, 
structure-function responses to drugs can be evaluated more accurately. There are 
numerous methods to study cancers in 3D including scaffold-based, spontaneous cell 
aggregation, and liquid overlay culture 16. There are advantages and disadvantages to 
each of these methods. Briefly, scaffold-based methods can be very costly due to 
purchasing the extracellular matrix scaffold. Spontaneous aggregation only occurs in 
some types of cells, and these aggregates of cells do not form spheroids but only 
 7 
clusters of cells. Also, spontaneous aggregation is an inexpensive and quick assay. Liquid 
overlay methods are also quick and relatively inexpensive. However, this method is a 
static method and only produces a small number of spheroids. It can be difficult to then 
collect these spheroid cells and examine further with Western blot, for example. The 
specific scientific question will determine ultimately which model would be best to use.  
In this project, TNBC cell lines developed from patients were used as a model to 
study human breast cancer in vitro and in vivo to examine the effects of combination 
Nutlin-3a and carboplatin treatment. MDA-MB-231 and MDA-MB-468 cells were 
purchased from American Type Tissue Culture (ATCC). Both of these adenocarcinoma 
cell lines were developed from metastatic pleural effusions. Due to their highly 
tumorigenic ability, the MDA-MB-231 cells have been used by many laboratories to 
study TNBC primary tumors.  For the in vivo studies in this thesis, we utilized the 
TMD231 cell line, which was derived from the parental MDA-MB-231 cell line 17. The 
TMD231 cell line was a kind gift of Harikrishna Nakshatri (IUSM) and was established in 
his laboratory as a cell line that grows consistently in the appropriate microenvironment 
(i.e. mammary fat pad) and has a propensity to metastasize to the lung.  The TMD231 
cell line is more aggressive and has increased growth rates in culture compared to the 
parental MDA-MB-231 cells. To generate the TMD231 cells, MDA-MB-231 cells were 
implanted into the mammary fat pad of Nude mice, and the tumors were allowed to 
grow for a period of 6 weeks. The tumors were resected, dissociated, and grown in 
culture. The surviving cells became known as the TMD231 for ‘tumor’ MDA-MB-231 cells 
(Figure 1). In vivo models of metastasis to lungs, bone, and brain have been studied 
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using either tail vein injections or intracardiac injections of the cells into mice. The MDA-
MB-468 cells are less invasive in vivo compared to the TMD231 cells, and typically 
metastasize to the lymph nodes following mammary fat pad implant 18. Both the MDA-
MB-231 (mtp53 R280K) and MDA-MB-468 (mtp53 R273H) cells have missense 
mutations within p53 in the DNA binding domain leading to abnormally functioning p53 
19. The MDA-MB-231 cells have heterozygous mutations in BRAF and KRAS and 
homozygous mutations in TP53, CDKN2A, and NF2 20. The MDA-MB-468 cells express 
homozygous mutations in PTEN, RB1, SMAD4, and TP53 20. A summary of the cellular 
model systems can be found in Table 1. These cell lines were used to explore to what 
extent nutlin3a could decrease resistance to carboplatin and to evaluate potential 
mechanisms of action associated with this promising combination therapy.  
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 Figure 1. TMD231 triple-negative cell line is derived from MDA-MB-231 parental cells. 
Nude mice were implanted with 1x106 parental MDA-MB-231 cells into the mammary 
fat pad, and the tumors were allowed to grow for 6 weeks. Tumors were surgically 
resected and grown in culture and expanded forming the TMD231 cell line after the 
‘tumor’ MDA-MB-231 cells.  
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 Table 1. Cellular models of triple-negative breast cancer. Both MDA-MB-231 and MDA-
MB-468 cell lines were derived from human triple-negative breast cancer samples. Both 
cell lines have mutations in the DNA binding domain of p53 as well as other mutations 
that may play a role in dysregulation of signaling pathways required for growth, survival, 
and metastasis.  
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While in vitro experiments are clearly important for screening novel therapies 
and for interrogating potential therapy-mediated mechanisms, the need for further 
exploration using animal models is also very important for studying pharmacokinetic 
and pharmacodynamic relationships, efficacy, biomarker development, and off-target 
toxicity. With the generation of highly immune-compromised mouse models, xenograft 
animal models in which human cancers are implanted in mice have improved greatly 
over the years. Ectopic tumors describe tumors that are implanted and propagated in an 
anatomical location of the animal that does not represent the original 
microenvironment of the primary tumor tissue type. For example, a flank tumor of 
breast cancer cells would be considered to be an ectopic tumor. Conversely, if the 
tumor were located within the tissue of origin such as the mammary fat pad for breast 
cancer, the tumor would be considered to be an orthotopic tumor. Initial human cancer 
mouse models utilized Nude athymic mice. These mice are somewhat immune 
compromised compared to other mouse strains. However, Nude mice still have an intact 
innate immune system with circulating natural killer (NK) cells 21. Another downside is 
hematopoietic cancer cells do not engraft efficiently in Nude mice. Nod/scid mice were 
developed following the development of Nude mice to provide an enhanced immune-
compromised mouse strain better equipped to study human cancers. Nod/scid mice 
produce defective NK cells; however, these mice have a high incidence of thymic 
lymphoma and ultimately a short lifespan 22. While the Nod/scid mice produce defective 
NK cells, there are still some functioning NK cells 23. NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) 
mice were developed more recently in an effort to create a mouse strain that would be 
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suitable to study human hematopoietic stem cells. NSG mice allow for the engraftment 
of human peripheral blood and bone marrow 23. NSG mice do not develop NK cells and 
have a very low incidence of thymic lymphoma with increased life expectancy compared 
to Nod/scid mice 23. With these changes in immune system functions, the NSG mouse 
strain has been an ideal mouse model to study human cancers since there are less 
immune cells able to inhibit the human tumor engraftment. While mouse models allow 
for a more clinically relevant model, there are still disadvantages to using mouse 
models. While there is a tumor microenvironment in vivo, it is not a complete tumor 
microenvironment that one would find in humans due to the lack of immune and 
inflammatory cells as well as the fact that it is a mouse cell microenvironment. The 
immune system of mice must be suppressed in order for the human tumors to grow and 
there have been numerous studies to show the effects of the immune system on 
cancers. There are ongoing efforts to provide animal models with a humanized immune 
system 24.  
The use of animal models allows for tumor growth and metastasis to be 
evaluated as well as the efficacy of drug treatment strategies. While there continues to 
be great discussion on the predictive value of mouse models in regards to clinical 
treatment, it is clear these models offer an opportunity to gain an understanding of 
pharmacokinetics (PK) and pharmacodynamics (PD), assess off target effects, and 
demonstrate the therapeutic potential and promise of new treatment strategies for 
cancer. However, animal studies are costly and therefore, appropriate preliminary data 
is needed before moving forward with in vivo animal models. Also, the personnel with 
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the appropriate training need to be utilized so that the animal study is completed in the 
most ethical manner possible. Pharmacokinetic studies of the drugs of interest need to 
be performed as well as animal model validation. The tumor growth kinetics need to be 
evaluated in order to properly assess tumor take rate and variability of base line tumor 
sizes, which ultimately dictate numbers of animals that must be included on a given 
study. The use of animal studies also allows for the drug dosing treatment strategy to be 
evaluated for drug efficacy, normal tissue toxicity in the mice as well as the evaluation 
of the pharmacokinetic properties of the compound in the mice and pharmacodynamic 
effects on the tumor. Additionally, with the use of in vivo models, there exists a tumor-
extracellular matrix interaction that is lacking with traditional in vitro models, as well as 
the appropriate cell-matrix interactions and fluidics with the circulatory system. The 
tumor cells are able to shed naturally into the circulatory system and seed in near and 
distant locations, which better represents what occurs in human disease.  
There are several types of clinical imaging used to visualize tumors including X-
rays, CT scans, MRI, and PET scans. X-ray images are produced due to differential 
absorption of x-rays by different tissues. X-rays can be used to in chest radiographs and 
mammograms. Mammograms use X-rays to look for tumors in the breast area. Tumors 
in the lungs can be visualized easily due to the fact that air absorbs the least amount of 
X-rays, and therefore, the chest often looks black. However, tumors would appear 
shadowy on the films. Computed tomography (CT) scans are computer-controlled X-rays 
forming 2D mages. Multiple scans can be collected forming a 3D picture allowing for the 
size and depth of a tumor to be evaluated. Magnetic Resonance Imaging (MRI) utilizes 
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radio waves in combination with a strong magnetic field. Tissues differentially emit radio 
waves allowing for 3-dimensional images to be visualized. Positron emission 
tomography (PET) scans utilizes nuclear imaging. Low amounts of radioactive sugar 
substances are taken into the body, and when these radioactive substances collect in 
areas of the body and the sugar is metabolized, these collections can be visualized in the 
images. PET scans are more beneficial to detecting larger tumors than small tumors due 
to the nature of the sugar metabolism.  
With the use of animal models, there needs to be sensitive and non-invasive 
methods to determine tumor burden. With in vivo studies, it is more challenging to 
image mice not only due to their small size but difficulty for high throughput imaging so 
that sufficient sample numbers can be generated. Additionally, the cost of small animal 
imaging is quite high per animal. To this end, the need for non-invasive small animal 
imaging that is feasible and cost effective is needed. Bioluminescent imaging (BLI) is a 
sensitive manner in which to measure tumor burden. Tumor cells, which stably express 
luciferase via lentiviral vectors, would be implanted into mice. At the time of imaging, 
mice are injected with the enzyme substrate, luciferin, to be catalyzed by luciferase 
present in the tumor cells. The tumor cells express luciferase, which when exposed to 
luciferin, use ATP and oxygen and catalyze two chemical reactions resulting in light 
being emitted. The light can then be detected by in vivo imaging. The peak of light 
emission can be used to determine the amount of tumor burden. Bioluminescent 
imaging is quite sensitive with signal detected from very small tumor burdens 25. 
However, there are some drawbacks to this method of in vivo animal imaging. The basis 
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of bioluminescent imaging is that the substrate, luciferin, reaches the tumor at maximal 
capacity and while this may be true for tumors at baseline, once therapy ensues, the 
blood supply to the tumors could vary greatly mouse to mouse. Differences in blood 
flow could limit uptake of luciferin and produce confounding data. The blood supply to 
tumors is often leaky and the blood pressure going to the tumor could be a lot different 
than that of the rest of the mouse. There is no way of knowing if the whole tumor is 
exposed to the substrate. Also, bioluminescent imaging can be lengthy and stressful to 
the mouse due to the fact that every tumor will reach the peak of bioluminescence 
emission at a different rate; therefore, multiple snapshots over a predetermined time 
frame (typically 20-45 minutes) need to be taken to evaluate bioluminescent signal. 
With bioluminescent imaging, the imaging times can be quite lengthy compared to 
other imaging modalities, which is an increased stressor to the mice due to long periods 
of time that they are exposed to anesthesia.  
Fluorescent imaging improves upon some of the drawbacks of BLI. A fluorescent 
protein of choice is stably expressed in cancer cells. The excitation and emission spectra 
would be evaluated for optimal use with the optical imaging platform. The use of optical 
imaging would allow for the substrate injection to be removed. In optical imaging, the 
imager has a laser component that acts to excite the fluorescent protein out of the 
resting state into the excited state. As the excited protein moves back to the resting 
state, the protein emits energy, which can be captured and measured. The fluorescent 
intensity would be the read out value for the in vivo imaging. This method would be 
non-invasive and more time saving as a single fluorescent imaging scan can take around 
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5-10 minutes, which is significantly less time than bioluminescent imaging (20-45 
minutes) and ultimately less time under anesthesia for the mice. Fluorescent proteins 
that are in the near-infrared (NIR) spectra would be the best choice for fluorescent 
protein as there is less fluorescent signal lost to surrounding tissues as well as reduced 
autofluorescence 26. However, several fluorescent proteins in the red spectra including 
E2-Crimson 27, mCherry 28, and mPlum 28 have been successfully used for in vivo imaging. 
A disadvantage to fluorescent imaging is the limiting factor of the depth of signal. It is 
unclear at this time the depths to which fluorescent signal can be measured. In some 
animal models, windows are created in the skin to image organs within the mice. Also, 
the sensitivity of the optical imaging apparatus will also need to be validated for each 
fluorescent protein used. Additionally, we have seen some instances in which the 
fluorescent protein levels leads to cellular toxicity. There are clearly advantages and 
disadvantages to both types of in vivo imaging. However, some of these are model 
dependent and validation is necessary for any type of animal model and imaging 
approach.  
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Chapter 3. Targeting the Mdm2 Signaling Network 
 
Targeting the mouse double minute 2 (Mdm2) signaling axis is a novel 
therapeutic approach in cancer since Mdm2 is a multi-faceted protein involved in 
determining cell fate. The mdm2 gene was first described as the gene responsible for 
transforming 3T3 cells 29. In the spontaneously transformed 3T3 cells, it was found that 
the cells expressed 25-30 copies of paired, acentric chromatin bodies, which are known 
as double minutes (DMs). The cell line became known as 3T3-DM for the increased 
levels of double minutes 29. The genes responsible for the production of the double 
minutes was determined to be mdm1 and mdm2 29. Overexpression of mdm2 in cell 
lines led to tumor development in Nude mice showing the growth advantage of mdm2 
overexpressing cells 30. mdm2 knockout mice are embryonic lethal; however, dual 
knockout of p53 results in viable offspring 31,32. Over a third of sarcoma tumors have 
overexpression of Mdm2 while maintaining wild-type p53, which would lead to 
decreased functionality of p53 due to the high levels of Mdm2 33,34. Mdm2 is often 
overexpressed in tumors and in a p53-independent manner can lead to increased 
genome instability by inhibiting Nbs1 function required for repair of DNA double-strand 
breaks 35. There is mounting evidence demonstrating the important role Mdm2 has in 
cell growth regulation and cancer.  
Mdm2 has been described as an oncogene since increased levels of mdm2 led to 
tumor development in nude mice 30. Mdm2 has been found to be overexpressed in a 
number of tumor types 36. Specifically in breast cancers, studies have shown Mdm2 
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protein levels and mdm2 gene amplifications ranging from 10-60% with some studies 
indicating a worse prognosis with overexpression of Mdm2 or gene amplification 36. 
There are also numerous studies suggesting that overexpression of Mdm2 leads to 
increased distant metastasis in vivo 36. A proposed mechanism by which Mdm2 
upregulated metastasis was through a vascular endothelial growth factor (VEGF) 
dependent manner in which increased Mdm2 led to increased VEGF production, which 
led to increased metastatic potential 36. Additionally, it was shown in breast cancer 
patients that Mdm2 levels correlated with disease-free survival with Mdm2 
overexpression leading to decreased survival 37. Chen and colleagues also showed a 
direct relationship between Mdm2 levels and matrix metalloproteinase 9 (MMP9) levels 
in which increased Mdm2 led to increased MMP9 and increased cell migration and 
invasion in vitro 37. Mdm2 plays an important role in cell regulation; however, when 
Mdm2 is dysregulated, the oncogenic functions of Mdm2 can lead to increased 
tumorigenesis.  
The mdm2 gene is located on chromosome 12 and encodes for a 491 amino acid- 
protein with several different domains (Figure 2). Mdm2 has two different promoters, 
P1 and P2, which encode for a shorter, 75kDa, and full-length, 90kDa, proteins, 
respectively. The P1 promoter encodes for a housekeeping version of the protein while 
the P2 promoter leads to full-length protein, which is regulated by p53-mediated 
signaling 38,39 The p53 binding domain of Mdm2 is located at the N-terminal of the 
Mdm2 protein within a deep hydrophobic pocket. This hydrophobic pocket is where 
Mdm2 antagonist Nutlin-3a was designed to bind thus inhibiting the binding of Mdm2 to 
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p53 40,41. Mdm2 is regulated by numerous post-translational modifications, which help 
to determine different cellular processes 42. Mdm2 also has nuclear localization signal 
(NLS) and nuclear export signal (NES) domains, which are posttranslationally modified to 
signal the movement of Mdm2 in and out of the nucleus. It has been shown that 
phosphorylation of S166 and S186 located near the NLS and NES domains of Mdm2 by 
Protein kinase B (Akt) leads to Mdm2 localization to the nucleus 43,44. Mdm2 is able to 
monoubiquitinate p53 while p300 is necessary for polyubiquitination of p53.The C-
terminal RING domain is important for Mdm2 E3 ubiquitin ligase activity to negatively 
regulate p53 due to the interaction of zinc with the RING finger domain 45-48. Within the 
Acidic domain, there is a cluster of phosphorylation sites (Serines 240, 242, 246, 253, 
256, 260, 262), which under normal conditions are phosphorylated. However, following 
DNA damage, these sites become hypophosphorylated leading to decreased p53 
degradation but does not affect the ability of Mdm2 to ubiquitinate p53 49. There are 
upstream effectors that modulate Mdm2 activity including alternate reading frame 
protein (Arf) and Ataxia telangiectasia mutated (ATM), which are important for Mdm2 
localization from the nucleus and phosphorylation-mediated inhibition of p53 
degradation, respectively 50. ATM also indirectly leads to the phosphorylation of two 
tyrosine residues through c-abl, which is also necessary to allow levels of p53 to rise 
following DNA damage 51. The c-abl-mediated phosphorylation of Y394 leads to 
inhibition of ubiquitination of p53 by Mdm2 as well as inhibition of p53 nuclear exports 
52. Also, phosphorylation of Y276 increases interactions with Arf leading to increased 
Mdm2 in the nucleus and decreased p53 turnover 53. Mdm2 plays a role in a large 
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signaling network mediated by numerous effectors and binding partners, which can 
determine certain cell fates 42.   
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 Figure 2. Mdm2 protein has several domains and posttranslational modification sites. 
Mdm2 is an important protein involved determining cell through its interaction with 
numerous protein-binding partners. One of the main roles of Mdm2 is acting as an E3 
ubiquitin ligase that negatively regulates p53 in cells. Interestingly, Mdm2 binds p73, 
which is a family member of p53; however, Mdm2 interaction does not lead to the 
degradation of p73. It appears as though Mdm2 binding to p73 leads to sequestration of 
p73 inhibiting normal functions of p73. Mdm2 has both a nuclear localization signal and 
nuclear export signal so that Mdm2 can localize to both the cytoplasm and nucleus. The 
N-terminal has the p53-binding domain in which Mdm2 can bind to the N-terminal of 
p53 and p73. Nutlin-3a binds to the hydrophobic pocket of Mdm2 in which p53 normally 
binds, thus inhibiting p53 binding as well as p73α, E2F1, and Hif-1 α. The inhibition of 
the interaction of Mdm2 and Hif-1α leads to decreased VEGF levels, which is important 
in angiogenesis signaling. Studies have shown that in p53 null cells, Mdm2 inhibits E2F-
mediated apoptosis through regulating distribution of DP-1 within the cell. The RING 
domain is important for Mdm2 for the E3 ubiquitin ligase activity. Within the Acidic 
domain, there is a cluster of phosphorylation sites (Serines 240, 242, 246, 253, 256, 260, 
262), which under normal conditions are phosphorylated. However, following DNA 
damage, these sites become hypophosphorylated, which leads to decreased p53 
degradation but does not affect the ability of Mdm2 to ubiquitinate p53.  
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 Mdm2 is a multi-functional protein and was first described to physically interact 
with the tumor suppressor p53 54. Mdm2 is an E3 ubiquitin ligase that acts as a negative 
regulator of p53. Under normal conditions p53 levels are relatively low in the cell. When 
the cells are stressed, p53 levels rapidly rise allowing for p53-mediated signaling. Once 
the stress is removed, Mdm2 acts to negatively regulate p53 by ubiquitination of p53 
and targeting it for degradation by the proteasome 54. Following DNA damage, ATM is 
able to phosphorylate Mdm2 at S395, which leads to the inhibition of p53 export from 
the nucleus as well as decreased degradation of p53 42,55-57. Additionally, p53 plays a 
role in this negative feedback loop by activating the transcription of Mdm2 and thus 
negatively regulates itself 58. Mdm2 can also ubiquitinate itself leading to the reduction 
of Mdm2 levels in the cell 50. Interestingly, Mdm2 binds p73, which is a family member 
of p53; however, Mdm2-p73 interaction does not lead to the degradation of p73 59-61. It 
appears as though Mdm2 binding to p73 leads to sequestration of p73 inhibiting normal 
functions of p73. The inhibition of the interaction of Mdm2 and Hif-1α via Mdm2 
protein-protein interaction inhibitors such as Nutlin-3a, ultimately leads to decreased 
VEGF levels, which is important for angiogenesis 62. Studies have shown that in p53 null 
cells, Mdm2 inhibits E2F-mediated apoptosis through regulating distribution of DP-1 
within the cell. Additionally, Mdm2 can be regulated by the adapter protein, 14-3-3σ, 
where decreased levels of 14-3-3σ leads to increases in Mdm2 protein levels 63. 
Interestingly, in the MDA-MB-231 breast cancer cell line, it has been shown that 14-3-3σ 
is highly downregulated 64, which may explain the increased basal Mdm2 protein levels 
in the TMD231 cells (Figure 17). The interaction of Mdm2 and protein binding partners 
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is tightly regulated and dysregulation can lead to inhibition of several signaling pathways 
including apoptosis, metastasis, and invasion, which can have great implications within 
cancers. Targeting the Mdm2 signaling axis, as a possible therapeutic approach, would 
lead to a multi-targeted approach due to the fact that Mdm2 is involved in several 
different signaling pathways.  
Vassilev and colleagues designed a small molecule inhibitor, Nutlin-3a, which 
was initially characterized as blocking protein-protein interactions (PPIs) between 
Mdm2 and p53 40. There are three chemical moieties of Nutlin-3a that were designed to 
be similar to three key residues of p53 (Phe19, Trp23, and Leu26), which binds into the 
hydrophobic pocket of Mdm2 40. Nutlin-3 exists as a chiral enantiomer with enantiomer-
a and enantiomer-b 40. Enantiomer-a was the active compound, whereas, enantiomer-b 
was about 150 times less active 40. Therefore, throughout our studies, we elected to 
continue our studies using purified Nutlin-3a instead of a racemic mixture of Nutlin-
3a/b. Mdm2 also interacts with p73, E2F1, and hypoxia inducible factor-1α (Hif-1α) and 
modulates their downstream effector functions. The interactions of Mdm2 with p73, 
E2F1, and Hif-1α are also inhibited by Nutlin-3a binding 62,65,66. p73, E2F1, and Hif-1α 
share sequence homology with p53 in the region that binds to Mdm2 and thus, Nutlin-
3a would inhibit the binding of Mdm2 from these binding partners 62. Due to the 
numerous binding partners of Mdm2 resulting in a multi-targeted approach, we elected 
to use Nutlin-3a as a research tool to better understand how modulation of the Mdm2 
signaling axis in combination with chemotherapeutic drug, carboplatin, may lead 
increased cell death in triple-negative breast cancers in a mutant p53 background. 
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It is estimated that p53 is mutated in about 30% of all cancers with 60% of basal 
TNBCs bearing mutations in p53 67,68. Approximately 90% of mutations in p53 occur in 
the DNA binding domain with ‘hotspot’ areas; whereas, p73 is rarely mutated in cancers 
69,70 (Figure 3). Additionally, p53 also has been shown to exhibit gain-of-function 
mutations, which further antagonize other tumor suppressing capabilities of cells. 
Specifically, Xu and colleagues showed that some forms of mutant p53 (mtp53) (R282W 
and R110P) led to increased aggregation of mtp53 with p73 in perinuclear aggregates 
causing inhibition of p73 function 71. This gain of function ability of mutant p53 would be 
interesting to study in our model system to see if the p53 mutation in the MDA-MB-231 
(R280K) cells plays a similar role in co-aggregation with p73. Since it has been shown 
that Nutlin-3a inhibits the binding of Mdm2 from p73, E2F1, and Hif-1α, we elected to 
examine the p53-independent functions of Nutlin-3a in combination with clinically 
relevant chemotherapeutic, carboplatin. 
Both p53 and p73 share sequence homology in key domains including the 
transactivation (30%), DNA binding (60%), and oligomerization (38%) domains (Figure 3) 
72. The N-terminal transactivation (TA) domain of p53 and p73 contain the region that 
binds to Mdm2 41. The DNA binding domain is important in the activation of genes 
important in pro-apoptotic signaling. The oligomerization domain is important for 
protein dimerization allowing for proper protein function 73,74. Lau and colleagues 
showed that when cells treated with Nutlin-3a, the binding of Mdm2 from p73 was 
inhibited leading to p73-mediated induction of pro-apoptotic downstream targets and 
increased apoptosis in cells lacking wild-type p53 66. It has also been shown that Mdm2 
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binding to p73 leads to antagonism of p73 signaling but does not result in the 
degradation of p73 59-61. Since Mdm2 does not act as an ubiquitin ligase of p73, others 
have shown that p73 is regulated by Hect ubiquitin-protein ligase, Itch, which results in 
p73 degradation by the proteasome 75. Runt-related transcription factor (Runx) and Yes-
associated protein (Yap1) form a complex that is able to bind to the promoter of Itch 
and increase protein levels resulting in decreased levels of p73 76. Following DNA 
damage, the levels of Itch are reduced through c-abl phosphorylation of Y357 of Yap1 
leading to the inhibition of Yap1 and Runx interaction, which inhibits their activity at the 
promoter of Itch, allowing the levels of p73 to rise enabling pro-apoptotic gene 
upregulation 75,76. Additionally, following DNA damage, Yap1 has been shown to act as a 
transcription co-activator by forming a complex with p73 and Probable transcription 
factor (PML) and helps to stabilize p73 and promotes binding to pro-apoptotic gene 
promoters including Bcl2-associated protein X (Bax) 77. Yap1 plays dual roles in the cell 
by mediating the inhibition of Itch upregulation as well as stabilizing p73 and increasing 
upregulation of pro-apoptotic gene levels.  
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 Figure 3. p53 and p73 have similar protein structure. Family members, p53 and p73, 
share sequence homology in many key domains including the transactivation (30%), 
DNA binding (60%), and oligomerization (38%) domains. The N-terminal transactivation 
domain contains the protein region that binds to Mdm2. The DNA binding domain is 
important in the activation of genes important in pro-apoptotic signaling. The 
oligomerization domain is important for protein dimerization, which allows for proper 
protein function. 90% of mutations in p53 occur in the DNA binding domain; whereas, 
p73 is rarely mutated in cancers.  
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p73 is a family member of p53 and has similar functions relating to the induction 
of pro-apoptotic genes in response to cellular stress 78,79. p73 has several different N-
terminal splice variants in which isoforms lacking the transactivation domain (ΔNp73) 
act as negative regulators of the transactivation domain containing p73 C-terminal 
isoforms (TAp73) 72. The TAp73 isoforms have similar functions to p53 72. The ΔNp73 
isoforms act as negative regulators of transactivating p73 isoforms by inhibiting p73 and 
by competing for DNA binding sites 80,81. Mice lacking all p73 isoforms exhibited 
profound neurological deficiencies indicating the importance of p73 during 
development 80. Jost et al. showed that the p73α isoform has pro-apoptotic functions 78, 
and Melino et al. showed that the p73α isoform has functional transactivation function 
leading to the induction of pro-apoptotic genes. 79. Since the p73α isoform has been 
shown by numerous laboratories to be important for pro-apoptotic signaling, we 
elected to specifically focus on this isoform throughout our studies. When 
overexpressed, p73α has been shown to induce apoptosis and cell cycle arrest as well as 
having similar p53-target genes in relation to apoptosis and cell cycle arrest including 
the cyclin-dependent kinase (CDK) inhibitor, p21, Growth Arrest and DNA Damage-
inducible 45, gadd45, p53 up-regulated modulator of apoptosis (PUMA), and Bcl2-
associated protein X (Bax) through direct and indirect methods 78,79,82. Following both 
genotoxic and non-genotoxic stress signals, GADD45 is quickly activated and mediates 
pro-apoptotic, cell cycle arrest, and DNA repair pathways 83. Melino and colleagues 
showed that p73-mediated apoptosis occurred through upregulation of PUMA, which in 
turn led to the mitochondrial translocation of Bax and subsequent cytochrome C release 
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79. Bax is a pro-apoptotic Bcl-2 family member involved in the intrinsic apoptotic 
pathway, and stress signals can lead to oligomerization of Bax monomers and 
translocation to the mitochondria leading to the release of cytochrome C 84. Free 
cytochrome C binds to Apoptotic protease activating factor 1 (Apaf-1) leading to the 
formation of the apoptosome and activation of pro-caspase-9 84. This activation of pro-
caspase 9 to active caspase-9 leads to a caspase signaling cascade in which caspase-3, -
6, and -7 are activated leading to apoptotic cell death 84.  
It was also shown that p73 is phosphorylated at Y99 by c-abl following DNA 
damage, which leads to increased p73 protein stabilization as well as increased protein 
levels in some cell systems 85-87. Specifically in cells where p53 is not functioning 
normally, there have been links between the lack of p53 and levels of p73. In cells where 
p53 was mutant or reduced with siRNA, p73 levels were increased, which was regulated 
at the transcription level by binding of E2F1 at the promoter region of TAp73 88. In the 
context of DNA damage, there are several proteins that mediate the upregulation of 
p73. It has been shown that Chk1 and Chk2 kinases are important drivers of p73 
upregulation, which in turn are also important for driving E2F1-mediated signaling 
followed by E2F1-mediated upregulation of p73 89.  
The cyclin-dependent kinase inhibitor, p21 also known as p21 WAF1/Cip1, is an 
important signaling mediator in cell cycle signaling by promoting cell cycle arrest 
following stress signals. p21 inhibits the activity of the cyclin-dependent kinases CDK1 
and CDK2, which leads cell cycle arrest in S and G2 phases of the cell cycle 90. p21 also 
acts to inhibit cell proliferation by competing for the DNA polymerase-δ binding site of 
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proliferating cell nuclear antigen, PCNA, which ultimately leads to inhibition of DNA 
synthesis 90. p21 can also bind to E2F1 and inhibit the ability of E2F1 to upregulate cell 
proliferation transcription targets 90. While there are several p53-dependent mediators 
of p21 upregulation including the HRAS-Raf-MapK pathway, there are several p53-
independent drivers of p21 upregulation 90. Since our model system is utilizing cells with 
mutant p53, the p53-indepenent upregulation of p21 is of particular importance. p21 
gene levels can be upregulated through retinoid and vitamin D receptors as well as 
several transcription factors including p73, specificity factor 1 and 3 (SP1 and Sp3), and 
Signal Transducers and Activators of Transcription (STATs) 90. There are several links 
between major players p73, E2F1, and mutant p53 following DNA damage. These 
proteins may drive p21 levels and activity leading to cell cycle arrest and ultimately 
apoptosis in our model system if the levels of DNA damage and stress surpass DNA 
damage stress thresholds set by the cell.  
Ambrosini and colleagues showed that the use of Nutlin-3a inhibited Mdm2 from 
binding to E2F1 and combined with DNA damaging drug, cisplatin, there was increased 
cytotoxicity through E2F1-mediated signaling 65. The use of E2F1 siRNA led to decreased 
amounts of apoptosis in combination Nutlin-3a and cisplatin treated cells 65. E2F1 is a 
transcription factor that plays an important role in cell proliferation, cell cycle, and 
apoptosis depending differential cell signaling 91. Following DNA damage, E2F1 is 
activated and can lead to the transactivation of pro-apoptotic genes including Apaf1 and 
p73 91. It has been shown that Mdm2 inhibits the pro-apoptotic functions of E2F1 
through interplay between Mdm2, E2F1 and DP-1 in the absence of p53 92. Some studies 
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have shown that when E2F1 is knocked out, mice form spontaneous tumors suggesting 
that E2F1 may play a role as a tumor suppressor 93. LaRusch and colleagues also showed 
that Nutlin-3a inhibits Mdm2 from binding to Hif-1α and thus led to decreases in VEGF 
62. Decreased VEGF production would be important in an in vivo setting due to the 
necessity for tumors to form new blood vessels to support prolonged tumor growth 94.  
The combined protein-protein interactions with Mdm2, p53, p73, E2F1, and Hif-
1α that are inhibited by the small molecule inhibitor, Nutlin-3a, may lead to a multi-
targeted approach to treating cancer especially when coupled with clinically relevant 
DNA damaging drugs like carboplatin since many of these binding partners are involved 
in DNA damage responses. There are five major types of DNA repair mechanisms 
including nucleotide excision repair (NER), base excision repair (BER), mismatch repair 
(MMR), non-homologous end joining (NHEJ), and homologous recombination (HR). 
Briefly, NER repairs large, bulky lesions, which cause distortions in the DNA helical 
structure caused by agents like platinums or photoadducts from UV damage 95. NER is 
primarily the DNA repair pathway utilized by cells to repair platinum induced damage. 
BER repairs single strand breaks (SSBs), chemically altered bases as a result of oxidative 
stress, and abasic sites 95. MMR removes incorrect nucleotides on the opposite DNA 
strand often caused by error prone polymerases, which is also utilized in repairing 
platinum based DNA damage 95,96. NHEJ occurs when there are DSBs induced by ionizing 
radiation, oxidative free radicals, and mechanical stress 95. HR also repairs DSBs when 
there is strong sequence homology. HR occurs during late S-G2 phases of the cell cycle 
since sister chromatids can be used as a template 95. HR can also repair damage caused 
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by platinum agents when double strand breaks occur 96.  
The role of Mdm2 in DNA damage and repair in relation to tumorigenesis is an 
emerging area of study. Mdm2 may play a role in NER through Arf mediated signaling. 
Arf is necessary in the absence of p53 to stimulate xeroderma pigmentosum, 
complementation group C (XPC) levels, and XPC is involved in a multi-protein complex 
that is needed for recognition of the DNA damage 95. Arf can bind and inhibit Mdm2; 
however, the mechanism of by which Mdm2 may play a role in NER is not well defined 
95. Also, DNA polymerase eta (PolH) is a Y-type polymerase and is an important protein 
involved in NER. Jung and colleagues showed that Mdm2 acts as an E3 ubiquitin ligase 
leading to polyubiquitination of PolH, which results in degradation through the 
proteasome 97. It was also shown that Mdm2 acts to decrease PolH levels both at basal 
and UV-induced DNA damage conditions 97. Interestingly, there has been recent data to 
suggest that Mdm2 plays a role in HR DNA repair by antagonizing the Mre11, Rad50, 
and Nbs1 (MRN) complex 35. Mdm2 binds directly to Nbs1 and inhibits its function in the 
MRN complex 35. DNA damage persists due the fact that the initial sensing mechanism 
of the MRN complex is unable to continue signaling at sites of DNA damage 35. 
Carboplatin is effective at killing cancer cells by causing DNA damage imparted by 
platinum (Pt) adduct formation in DNA. Platinum agents lead to Pt adducts covalently 
bonding to N7 position of purine bases resulting in intrastrand and interstrand DNA 
crosslinks. DNA repair resulting from platinum-induced DNA damage could be inhibited 
in cells where levels of Mdm2 are increased 35.  
The role of MdmX (Mdm4) has been increasingly studied in the context of cancer 
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in recent years. The p53- and Mdm2-independent functions of MdmX have only recently 
been studied. Like Mdm2, MdmX can be upregulated in cancers, though this 
upregulation is independent of p53. Gilkes and colleagues showed that MdmX levels can 
be upregulated through mitogenic signaling mediated by K-Ras and insulin-like growth 
factor 1 (IGF-1) 98. Since it was shown that Mdm2 increases genomic instability by 
Bouska and colleagues, the authors also studied the effects of MdmX on genomic 
stability in the context of Mdm2- and p53-independence 35. Carillo and colleagues 
showed that following irradiation- (IR) induced DNA DSBs, MdmX inhibited the repair of 
DSBs independent of p53, Arf, and Mdm2 99. Carrillo and colleagues also showed that 
MdmX associated with Nbs1 independent of both p53 and Mdm2 using co-
immunoprecipitation experiments showing a direct connection between MdmX and the 
repair machinery in the MRN complex 99. Based on data from Carrillo et al.99, MdmX also 
plays a similarly important role in genomic instability as Mdm2 and may be important to 
increase our understanding of how MdmX affects cancer growth and survival. It has 
been described that in breast cancers, 27% overexpress MdmX with concurrent p53 
inactivation as well as 30% of aggressive breast cancers also have increased MdmX 
levels with mutant p53 99. It is possible there may be certain subtypes of cancers that 
have MdmX overexpression, which may affect how tumors respond to treatments.  
The overall objective of this thesis was to evaluate the therapeutic potential of a 
new combination therapy to treat TNBC. Based on front-line therapies currently being 
tested in clinical trials for TNBC, the platinum agent, carboplatin was selected for study. 
Novel drug targets need to be elucidated to improve treatment modalities especially in 
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treating aggressive cancers like TNBC. Mdm2 is an unexplored target in breast cancers. 
Histological studies have indicated that up to 56% of breast cancer biopsies contain high 
levels of Mdm2 36. In this thesis, the potentiation of carboplatin-mediated DNA damage 
in the context of blocking some aspects of Mdm2 function was investigated. 
Pharmacodynamic studies were designed to gain insight into and validate molecular 
mechanisms that based on the literature could be operative following treatment. In our 
correlative PD studies, we also sought to identify targets that could potentially serve as 
biomarkers of treatment response and efficacy for future clinical trials of TNBC.  
Nutlin-3a binds to the hydrophobic pocket of Mdm2 and inhibits the interaction 
of binding partners of Mdm2 including p53, p73, E2F1, and Hif-1α. In our model, we are 
utilizing triple-negative breast cancer cells that harbor a p53 mutation (R280K and 
R273H) in the DNA binding domain. These cancers are considered to be more aggressive 
due since there are limited targeted therapies and that mutant p53 drives cell survival 
and metastasis 100,101. Due to the interest of platinum agents in metastatic breast cancer 
trials (NCT01881230, NCT00691379, and NCT01281150) (clinicaltrials.gov), carboplatin 
was selected as the chemotherapeutic drug in which to interrogate the effect of the 
small molecule inhibitor, Nutlin-3a. Carboplatin causes DNA damage by the binding of Pt 
to DNA and leading to intra- and interstrand DNA crosslinks and indirectly DNA strand 
breaks. The hypothesis is modulation of Mdm2 signaling through inhibition of protein-
protein interactions with Nutlin-3a in combination with carboplatin-mediated DNA 
damage will lead to increased cell death. The proposed mechanism of action is that once 
Nutlin-3a is bound to Mdm2, the binding between Mdm2 and p73, E2F1, and Hif-1α is 
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inhibited allowing p73 and E2F1 to activate target genes leading to an increase in pro-
apoptotic gene expression and cell death. Mdm2 levels would increase following Nutlin-
3a treatment through p73-mediated upregulation, and the amount of Mdm2 associating 
at the chromatin could increase following combination treatment. Increased Mdm2 at 
the chromatin can lead to increased Mdm2-Nbs1 interaction, which could inhibit the 
sensing of DNA damage once DNA strand breaks have occurred. This delay in sensing of 
DNA damage could lead to decreased DNA repair, which would result in an increased 
DNA damage window. As the DNA damage window increases, cell signaling mechanisms 
could lead to the determination of cell fate, and ultimately leading to cell death. The 
signaling pathways that could be modulated in our model system can be seen in detail in 
Figure 4. There is a growing consensus in the literature that the levels of Mdm2 and the 
localization of Mdm2 in the cell may dictate in part how a cell senses and responds to 
DNA damage, and whether the outcome of DNA damage will be survival or death.   
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 Figure 4. Nutlin-3a and carboplatin combination treatment increases cell death by 
upregulating pro-apoptotic gene levels and inhibits DNA repair. Nutlin-3a binds to the 
p53 binding pocket of Mdm2 and inhibits the binding of p73, E2F1, and HIF1-α, which 
can enable these proteins to upregulate the transcription of pro-apoptotic genes, cell 
cycle genes, and decrease the levels of VEGF. Carboplatin causes DNA damage by 
creating intra- and interstrand crosslinks in the DNA leading to cell death. Nutlin-3a 
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potentiates carboplatin-mediated DNA damage leading to increased cell death through 
delayed DNA repair. This delayed DNA repair may be mediated by Mdm2 binding at the 
chromatin and based on studies by Dr. Christine Eischen and colleagues showing that 
Mdm2 antagonizes Nbs1, a member of the MRN complex. The MRN complex is 
important in initial DNA damage sensing and recruitment of other DNA damage 
response proteins to sites of DNA damage. Carboplatin mediated-DNA damage leads to 
activation of p73α pro-apoptotic signaling. p73-mediated signaling can lead to increased 
Mdm2 levels since p73 has been shown to bind to the Mdm2 promoter. With increased 
levels of Mdm2, there is more Mdm2 present in the cells that could bind the MRN 
complex at the chromatin. Increased binding of Mdm2 to the MRN complex leads to 
delays in DNA damage detection and thus lead to delays in DNA repair. This delay in 
repair, may allow DNA damage response elements to commit to cell death pathways 
allowing more cells to be affected by the combination treatment than by single drug 
treatments alone.  
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In future studies increased clinically relevant patient-derived xenograft (PDX) 
models and small molecule inhibitors used in clinical trials would be used to expand on 
these efficacy studies. Primary patient tumor samples could be used in mouse models to 
better understand the efficacy of the combination platinum and Mdm2 inhibitor 
treatment. Jackson Laboratories in collaboration with UC Davis Cancer Hospital are 
providing mice that harbor primary patient tumors from women with triple-negative 
breast cancer (http://jaxservices.jax.org/invivo/pdx.html). These tumors have 
undergone extensive genetic screening with gene expression profiles as well as copy 
number variation testing. These tumors would have increased clinical relevance since 
the molecular signatures are fully validated with the primary patient breast cancer 
tissue. Additionally, there are numerous Mdm2 inhibitors, which are in early phase 
clinical trials. There is a second-generation compound to Nutlin-3a, RG7112 (RO5045337 
Roche) that is in Phase I clinical trials. Additionally, there are several other Mdm2 
antagonists being studied including SD-3032b (Baiichi Sankyo Inc.), SAR4058338 (Sanofi), 
CGM-097 (Novartis), and AMG-232 (Amgen) that are currently being investigated. We 
utilized Nutlin-3a as a tool to study the mechanism at which Nutlin-3a synergizes with 
carboplatin to cause increased cell death in TNBC with mutant p53 as there is a critical 
need to find new treatments for metastatic TNBC harboring mtp53 due to the 
aggressiveness of the disease and lack of targeted therapies 100,101. The TMD231 
orthotopic NSG model used here provides a feasible pre-clinical approach to further 
determine and validate the best set of biomarkers that can be used to assess biological 
effect of the combination carboplatin and Nutlin-3a treatment. In this research, as we 
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continue to delineate the underlying mechanisms leading to cell death, incorporation of 
PDX models, and clinically utilized Mdm2 inhibitors can be used to increase the 
understanding of the benefit of using dual carboplatin and Mdm2 protein-protein 
inhibition. Additionally, it will be important to perform detailed PK/PD studies to further 
validate targets that are modulated by the dual carboplatin and Nutlin-3a treatment. 
Understanding how long and to what extent the blocking of Mdm2–p73 protein-protein 
interactions must be modulated to observe therapeutic effects will be critical for 
development of clinical trials in the future.  
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SECTION II. MATERIALS AND METHODS 
 
Chapter 1. In Vitro Studies 
 
A. Cell Culture and Reagents 
1. Cells and Cell Culture. MDA-MB-231 (ATCC® HTB-26™) and MDA-MB-468 (ATCC® 
HTB-132™) were purchased from ATCC. TMD231 cells were a kind gift of Dr. 
Harikrishna Nakshatri and were developed as described in Helbig et al. 17. TMD231 
cells were grown in MEM-α medium (Gibco®) containing 10% FBS (Atlanta 
Biologicals) and 1% HEPES (Gibco®). MDA-MB-231 and MDA-MB-468 cells were 
grown in DMEM medium (Gibco®) containing 10% FBS (Atlanta Biologicals). Cells 
were cultured at 37°C with 5% CO2.  
2. Mycoplasma Detection. Cells were tested for mycoplasma using MycoAlert™ 
Mycoplasma Detection Kit (Lonza). Cell culture medium was collected from cultured 
cell lines and if mycoplasma was present, the addition of MycoAlert™ Substrate, 
catalyzed the conversion of ADP to ATP. The levels of ATP were detected following 
the addition of the MycoAlert™ Reagent. The before (read A) and after the addition 
of the MycoAlert™ Substrate (read B) reads allowed for a ratio to be determined 
(B/A). If the ratio was above 1, the sample was contaminated with mycoplasma. Cell 
lines were tested regularly for the presence of mycoplasma and were negative. 
3. Drugs and Small Molecules. Nutlin-3a was synthesized at the IUPUI Chemical 
Synthesis and Organic Drug Lead Development Core and confirmed through HPLC-
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MS analysis. Nutlin-3a was dissolved in DMSO up to 100mM stock solutions. 
Carboplatin was purchased from Sigma and dissolved in H2O at 10mM stock 
solution. RG7112 was dissolved in DMSO with stock concentrations up to 50mM 
(ApexBio and ChemScene).  
B. Proliferation Assays 
a. Methylene Blue Proliferation Assay. The methylene blue proliferation assay was 
derived from Oliver et al. which utilized 5% methylene blue stain to stain cells in 
microplate assay 102. The assay was high throughput with sensitive measures of cells 
present and fixed to the plate. The methylene blue stain bound to negatively 
charged moieties within cells including DNA and negatively charged portions of 
proteins. In all methylene blue assays, the outermost wells of 96-well plates were 
filled with 200µL PBS to diminish the effects of plate evaporation. To determine the 
optimal cell number to seed in 96-well plates for a 5-day proliferation assay, plating 
efficiencies were completed. All cell lines were plated in 96-well plates in increasing 
cell number starting from 500 cells/well and ranging up to 4.0x103 cells/well. Cells 
were mock treated with media and allowed to grow for 5 days as a drug treatment 
would have been given. At the end of treatment, the media was aspirated and the 
cells were fixed with methanol. Then, cells were stained with 5% methylene blue 
stain, washed in DI H2O, and air dried. Plates were destained with 100-150µL 0.5M 
HCl, and absorbances were read at 610nm. Optimal absorbance values were 
between 0.7-0.9. TMD231 cells were seeded with 500 cells/well in 96-well plates. 
MDA-MB-231 and MDA-MB-468 cells were seeded with 2x103 cells/well. Cells were 
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seeded on Day -1 and treated 24 hours later on Day 0. For drug treatments, each 
plate had a vehicle control, which consisted of DMSO for Nutlin-3a and H2O for 
carboplatin. Cells were treated with increasing concentrations of Nutlin-3a (0-
120μM), carboplatin (0-100μM), or 1:1 combination (0-100μM). For the combination 
treatments, the highest concentration used was 100μM, which was comprised of 
50μM Nutlin-3a and 50μM carboplatin. For shorter treatments, cell number was 
adjusted accordingly. Each plate contained untreated media controls and Vehicle 
controls. The Vehicle controls contained the amount of vehicle in each of the highest 
drug concentrations.  
b. Clonogenic Proliferation Assay. TMD231 cells were plated at low cell density with 
50 cells per 10cm dish on Day -1. On Day 0, TMD231 cells were treated with 0-60μM 
Nutlin-3a, 0-10μM carboplatin, or 0-6μM 1:1 combination. Colonies were allowed to 
grow for 14 days. The media was removed, cells were washed with PBS, and fixed 
with methanol. Colonies were stained with 5% methylene blue stain, washed in DI 
H2O, and air dried. Visible colonies were numerated using a digital counting pen to 
ensure accurate counts.  
c. Cell Counting Proliferation Assay. TMD231 cells were seeded with on 12-well plates 
on Day -1 with 6.5x103 cells per well. On Day 0, cells were treated with 15μM Nutlin-
3a, 15μM carboplatin, or 15μM Nutlin-3a+15μM carboplatin combination, or 
appropriate dilutions of DMSO in H2O as a Vehicle control. DMSO concentrations 
were kept below 0.1% in all experiments. Later experiments also used 7.5μM Nutlin-
3a, 7.5μM carboplatin, or 7.5μM Nutlin-3a+7.5μM carboplatin combination. Each 
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treatment was completed in triplicate to ensure accurate cell counts. Each day 
following treatment, cells were photographed to visualize changes in cell number 
and cell morphology. On the day of harvest, growth medium was removed, cells 
were washed with PBS, and trypsinized with 0.05% trypsin-EDTA (Life technologies). 
Trypsinized cells were resuspended in an appropriate volume of cell culture 
medium, mixed with trypan blue, and live cells were counted via hemocytometer. 
Total cell counts were calculated.  
d. Annexin V and 7-AAD Apoptosis Assay. Annexin V readily binds to 
phosphatidylserine, which is expressed the exterior of cells when undergoing early 
apoptotic signaling. Annexin V tagged with FITC (BD Biosciences) enabled its use 
with flow cytometry. 7-AAD (BD Biosciences) was used since it is a fluorescent DNA 
marker that intercalates into DNA in GC rich areas and is indicative of cell membrane 
leakage. When cells were positive for Annexin V alone, those cells were considered 
to be undergoing early apoptosis. When cells were positive for both Annexin V and 
7-AAD, those cells were considered to be undergoing late apoptosis or necrosis. To 
measure apoptosis, Annexin V-FITC and 7-AAD was used to determine the number 
of apoptotic cells following drug treatment. TMD231 cells were seeded on 10cm 
dishes on Day -1 in normal growth medium at an appropriate cell density for the 
treatment length to ensure proper cell numbers at the end of the study. On Day 0, 
the TMD231 cells were treated with 1:1, 3:1, or 1:3 combination and corresponding 
single drug IC50 value concentrations as derived from the 5-day methylene blue 
proliferation assays. TMD231 cells were treated with 0.8μM Nutlin-3a, 0.8μM 
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carboplatin, or 0.8μM Nutlin-3a+0.8μM carboplatin 1:1 combination, 3.75μM Nutlin-
3a, 1.25μM carboplatin, or 3.75μM Nutlin-3a+1.25μM carboplatin 3:1 combination 
or 0.7μM Nutlin-3a, 2.1μM carboplatin, or 0.7μM Nutlin-3a+2.1μM carboplatin 1:3 
combination in normal growth medium for a total of 96 hours. The Vehicle control 
was DMSO +H2O. On Day 4, cells were harvested. The medium was removed and 
saved in collection tubes. Cells were washed with PBS, and the PBS was also saved to 
ensure proper analysis of all cells present in the cultures. Accumax Cell Dissociation 
Solution (Innovative Cell Technologies) was used to free adherent cells. The 
dissociated cells were added to the appropriate collection tubes and spun down to 
pellet cells. Cells were washed with PBS and spun down again. Pellets were then 
resuspended in 1X Annexin V Binding Buffer (BD Biosciences). Each sample was 
stained using 5μL Annexin V-FITC (BD Pharmigen) and 5μL 7-AAD (BD Pharmigen). 
Single and double stained cells treated with carboplatin were used as controls to set 
the gating parameters of the flow cytometer to distinguish between negative and 
positive staining. 
e. Cell Cycle. Propidium iodide (PI) staining was used to determine cell cycle analysis. PI 
intercalates into DNA allowing the DNA content in cells to be measurable by flow 
cytometry. PI cannot pass through an intact cellular membrane and therefore cells 
must be permeable during PI staining solution incubation as described below. 
TMD231 cells were seeded on 10cm dishes on Day -1 in normal growth medium at 
an appropriate cell density for the treatment length to ensure proper cell numbers 
at the end of the study. On Day 0, the TMD231 cells were treated with 3.75μM, 
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7.5μM, or 15μM Nutlin-3a, carboplatin, and 1:1 combination in normal growth 
medium. The Vehicle control contained DMSO+H2O. For the combination 
treatments, 3.75μM combination was comprised of 3.75μM Nutlin-3a+3.75μM 
carboplatin so that the combination treatments have equal amounts of each drug as 
the single drug treated cells. On Day 3, cells were harvested. The medium was 
removed and saved in collection tubes. Cells were washed with PBS, and the PBS 
was also saved to ensure proper analysis of all cells present in the cultures. Accumax 
Cell Dissociation Solution (Innovative Cell Technologies) was used to free adherent 
cells. The dissociated cells were added to the appropriate collection tubes and spun 
down to pellet cells. Supernatant was removed, and cells were washed with PBS 
before spinning down again. Pellets were resuspended in PBS and mixed with PI 
staining solution: 0.1% (v/v) Triton X-100, 10 µg/mL PI, 100 µg/mL DNase-free 
RNaseA. Cells were incubated for 1 hour at room temperature before analysis with 
flow cytometry.  
C. Molecular Biology Assays 
1. Lentiviral Transduction. Cells were typically transduced with a multiplicity of 
infection (MOI) of 50. That is, there were 50 viral particles to each cell, and the total 
amount of viral supernatant was calculated and used in the transduction. When 
using highly concentrated (>107) lentiviral supernatants, cells were transduced for 4 
hours. Lentiviral supernatant containing media was removed and replaced with 
fresh media. Retronectin-coated plates were used to enhance transduction 
efficiency 103. Flow cytometry was used to validate the presence of fluorescent 
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proteins. Appropriate settings were used for optimal detection of the fluorescent 
protein of choice (eGFP, mCherry, E2-Crimson). Unmarked parental cells were used 
as background controls.  
a. Lentiviral Supernatant Production. Lentiviral supernatants were produced as 
described in Leurs et al. 104. Briefly, lentiviral supernatants were produced 
following co-transfection of 293T cells with vector plasmids and env expression 
plasmids, using FuGENE 6 (Roche, Basel, Switzer- land) or Polyfect (Qiagen, 
Valencia, CA) transfection reagents according to the manufacturer’s 
recommendations. Twenty-four hours after transfection, gene expression from 
the human spleen focus forming virus (SFFV) immediate-early gene 
enhancer/promoter was used for E2-Crimson levels. Forty-eight hours after 
transfection, supernatants were collected, filtered through a 0.45µm filter, and 
stored at -80°C. Lentiviral stocks were concentrated by centrifugation (10,000 x 
g; 45 min; 4°C), and the lentiviral titers were determined using HT1080 cells.  
2. Western Blot. Cells were lysed with 1% SDS lysis buffer containing 1%SDS, 1 
Complete-EDTA free mini tablet (Roche), and 1% phosphatase inhibitor 3 (Sigma). 
Growth medium was removed from cells and washed with PBS. An appropriate 
volume of 1% SDS lysis buffer was added directly to cells on the culture plates, and 
lysates were scraped with a cell scraper. Lysates were collected and placed in 
microcentrifuge tubes. The lysates were boiled at 95°C for 8-10 minutes. Lysates 
were sonicated to dissociate any DNA. Protein quantification was determined using 
the DC™ Protein Assay (Bio-Rad) as per manufacturer’s instructions. Standard curves 
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were determined using BSA standards. Samples were stored at -80°C until ready for 
use. Westerns were run using Criterion™ TGX™ Precast 4-20% Gels (Bio-Rad). 
Running buffer was comprised of 10% 10XTG buffer (Bio-Rad) and 0.1% SDS. 
Transfer buffer contained 10% 10XTG buffer (Bio-Rad) and 20% methanol. 
Nitrocellulose membranes were blocked with 5% BSA. Antibodies were diluted in 5% 
BSA and incubated with membranes overnight. Membranes were washed with 1X 
TBS containing 0.02% Tween-20 (TBST) for a total of three 12 minute washes. All 
antibodies were diluted 1:1,000 except GAPDH, which was 1:10,000. Mdm2 (90kDa 
band) antibody cocktail included SMP14 (sc-965, Santa Cruz), 2A9 (OP155T, 
Calbiochem), 4B11 (OP143, Calbiochem). E2F1 (55kDa, KH-95, Santa Cruz), p73 
(~80kDa, A300-126A, Bethyl Laboratories) PUMA (21kDa, #4976, Cell Signaling), p21 
(21kDa, DCS60, Cell Signaling), MdmX (55kDa, ab154324, abcam) and GAPDH 
(37kDa, 14C10, #2118, Cell Signaling) were also used. Secondary HRP-conjugated 
anti-mouse and anti-rabbit antibodies were diluted 1:5,000 in 1X TBST for 1-1½ 
hours. SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) was 
used to activate secondary antibodies and membranes were exposed with 
autoradiography film.  
a. Densitometry Measurements. Western blot densitometry was evaluated using 
ImageJ software (http://imagej.nih.gov/ij/). Blots were scanned and evaluated 
by ImageJ. All proteins of interest were normalized to appropriate loading 
control lanes and untreated controls.  
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3. Invasion Assay. Cell invasion was determined using CytoSelectTM Cell Invasion Assay 
Kit (Cell BioLabs). TMD231 cells were seeded into polycarbonate inserts with 3.5x103 
cells per insert on Day -2. Cells were serum starved overnight on Day -1. On Day 0, 
cells were treated with 7.5µM Nutlin-3a, carboplatin, 1:1 combination, or Vehicle for 
24 hours. Cytochalasin D was used as a negative control, which inhibited invasion by 
interfering with microtubule formation. The bottom chamber contained 10% FBS 
containing medium, which served as a chemoattractant. The cells that were able to 
invade through the dried basement membrane matrix layer and pore layer were 
stained and quantified using a plate reader. Concurrent cell survival assays were 
conducted with 3.5x103 TMD231 cells seeded in a 24-well plate. Cells were serum 
starved and treated in the same drug conditions as the invasion assay. To confirm 
that treatments did not cause cell death, total number of cells and cell viability via 
trypan blue staining were determined.  
4. Stable Knockdown of Mdm2. TMD231-shcontrol and TMD231-shMdm2 were a kind 
gift of Dr. Lindsey Mayo. TMD231-shcontrol and TMD231-shMdm2 cells were first 
evaluated for Mdm2 protein levels using Western blot. TMD231-shcontrol or 
TMD231-shMdm2 were grown in medium containing 2.5μg/mL puromycin to keep 
selective pressure on the cells throughout the experiments. Cells were lysed with 1% 
SDS lysis buffer and examined by Western blot. For methylene blue proliferation 
assays, the TMD231-shcontrol and TMD231-shMdm2 cells were plated with 500 
cells per well in 96-well plates and treated with 0-120μM Nutlin-3a, 0-100μM 
carboplatin, or 0-100μM 1:1 combination for 5 days. Cells were grown in medium 
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with 2.5μg/mL puromycin to keep selective pressure throughout the experiment. 
Cells were fixed and stained with methylene blue and cell proliferation was 
examined. For shMdm2 cell counting assays, the experimental design was the same 
as the TMD231 cell counting experiment as described above.  
5. Transient knockdown of p73 with siRNA. ON-TARGETplus siRNAs were purchased 
from Dharmacon (GE Healthcare). p73 siRNA constructs included:  
1. GAGACGAGGACACGUACUA 
2. GCAAUAAUCUCUCGCAGUA  
3. GAACUUUGAGAUCCUGAUG 
4. CCACCAUCCUGUACAACUU.  
Since p73 has several N-terminal and C-terminal isoforms, we BLAST searched the 
p73 siRNA sequences to ensure that proper coverage of the mRNA would be 
accomplished leading to a reduction in total p73 levels. These p73 siRNA constructs 
target p73 within the DNA binding and oligomerization domain to ensure 
knockdown of the numerous isoforms of p73. On Day -1, 5x105 TMD231 cells were 
seeded into 6-well plates, which yielded an appropriate cellular confluency on the 
day of transfection. Liprofectamine® RNAiMAX (Life Technologies) was used to 
transfect 9pmol control ON-TARGETplus Non-Targeting Pool siRNA or ON-
TARGETplus SMARTpool p73 siRNA into TMD231 cells on Day 0. The siRNA 
effectiveness was evaluated on Day 1-3 post transfection by Western blot. For 
proliferation assays, TMD231 cells were transfected on Day 0 with either control 
siRNA or p73 siRNA. On Day 1 post transfection, cells were counted and 2.5x103 cells 
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were seeded into 96-well plates. The cells were treated with 0-120μM Nutlin-3a, 0-
100μM carboplatin, or 1-100μM 1:1 combination treatments later that same day to 
increase the time that the treatment would be present in cells with reduced p73. 
Plates were incubated for a total of 3 days. DMSO and H2O were used as Vehicle 
controls. Methylene blue proliferation assay procedure was used and IC50 values 
were determined. 
6. Stable Knockdown of p73. We purchased a panel of p73 shRNA constructs from 
Sigma Mission shRNA, and they were expressed in a pLKO (Sigma) lentiviral 
backbone.  
1. TRCN0000284787 
2. TRCN0000006511 
3. TRCN0000272587 
4. TRCN0000006508 
5. TRCN0000006509 
6. TRCN0000272526 
7. TRCN0000272525 
TMD231 cells were transduced with the lentiviral vectors and positive cells 
expressing either the scrambled control or shp73 constructs were selected with 
2.5µg/mL puromycin. p73 protein levels were evaluated by Western blot. 
Throughout the shp73 experiments, cells were grown in puromycin containing 
medium to ensure usage of positive cells only. Two shp73 constructs (shp73-3-500 
and shp73-4-500) produced the highest level of reduction in p73 protein levels as 
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measured by Western blot. We also utilized a scrambled control (Scr-500). TMD231-
Scr-500, TMD231-shp73-3-500, and TMD231-shp73-4-500 were seeded in 96-well 
plates and treated with 0-120μM Nutlin-3a, 0-100μM carboplatin, or 1-100μM 1:1 
combination for 5 days. DMSO and H2O were used as Vehicle controls. Methylene 
blue proliferation assay procedure was used and IC50 values were determined. 
7. Stable Knockdown of shE2F1. shRNA lentiviral constructs were purchased from 
Mission shRNA (Sigma). TMD231 cells were transduced with either shGFP or shE2F1 
constructs as described above:  
1. TRCN0000010327 
2. TRCN0000010328 
3. TRCN0000039658 
4. TRCN0000039659 
5. TRCN0000039660 
 Knockdown was evaluated by Western blot. shRNA positive cells were selected 
using 2.5µg/mL puromycin in the growth culture medium. TMD231-shGFP and 
TMD231-shE2F1 cells were seeded in 96-well plates and treated with 0-120μM 
Nutlin-3a, 0-100μM carboplatin, or 1-100μM 1:1 combination for 5 days. DMSO and 
H2O were used as Vehicle controls. Methylene blue proliferation assay procedure 
was used and IC50 values were determined 
a. shE2F1 Clonal Selection. Clones were developed using serial dilution methods. 
4.0x103 TMD231-shGFP, TMD231-327, and TMD231-328 cells were added into 
one well in a 96-well plate. In the first dilution, the cells were diluted 1:2 down 
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the first column. The first column was diluted it 1:2 across the whole plate to 
completed the second dilution. Wells with single cell colonies were then 
expanded to form clonal populations. Knockdown of E2F1 was evaluated by 
Western blot. shRNA positive cells were selected using 2.5µg/mL puromycin in 
the growth culture medium. 
8. Chromatin Association Assay. Chromatin association assays were performed in 
collaboration with Dr. Christine Eischen. We sent the TMD231 cells, FBS, drug 
aliquots, and detailed instructions in relation to cell culture and treatment 
conditions. In discussions with Dr. Eischen, we concluded this was the best way to 
inhibit as many differences between laboratories as possible. TMD231 cells were left 
untreated or were treated with 15μM Nutlin-3a, 15μM Carboplatin, 15μM Nutlin-3a 
and 15μM Carboplatin, or DMSO Vehicle control for 6 hours. Cells were harvested 
and soluble and chromatin bound proteins were separated with CSK buffer (10mM 
PIPES pH6.8, 100mM NaCl, 300mM sucrose, 1mM MgCl2, 1mM EGTA, 0.1% Triton X-
100) as previously described 105. The chromatin bound proteins were extracted with 
RIPA buffer containing protease inhibitors (1mM PMSF, 10mM BGP, 38μg/mL 
Aprotinin, 5μg/mL Leupeptin, 5μg/mL Pepstatin, 1mM NaF, 0.1mM NaVO4). Whole 
cell lysates were prepared as previously reported 106. Equal amounts of protein 
lysates (130μg whole cell and 170μg of chromatin-bound) were subjected to SDS-
PAGE. Proteins were transferred to nitrocellulose membranes and examined with 
Western blot. Antibodies were used as follows with anti-Mdm2 (3G9, 1:2000, 
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Millipore), anti-H2AX (A300-082A, 1:15,000, Bethyl), and anti-β-Actin (AC-15, 
1:5,000, Sigma), as previously reported 35. 
9. Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Cells were seeded on 
10cm dishes and treated with 15μM Nutlin-3a, 15μM carboplatin, or 15μM Nutlin-
3a+15μM carboplatin combination, or DMSO+H2O as a Vehicle control. Each 
treatment was completed in triplicate. Following appropriate time point, cells were 
lysed with modified Laird buffer (100mM Tris-HCl, pH 7.5, 5mM EDTA, 0.2% SDS, 
200nM NaCl, 100μg/mL Proteinase K) at 37⁰C 107. Total DNA was precipitated using 
one part isopropanol on a shaker. DNA was spooled and rinsed in 70% EtOH. DNA 
was dissolved in H2O and DNA concentration was determined via nanodrop. 50μg 
DNA was hydrolyzed overnight in 2.5% HNO3 at 70⁰C. Samples were diluted in 1% 
HNO3 and total platinum content was analyzed via ICP-MS. Standard curves using 
Platinum (Pt) were used, and Yttrium was used as an internal control.  
D. Statistical Analyses. IC50 values were calculated according to the linearization 
method of Chou and Talalay 108 and were used to construct isobologram graphs as 
previously described 109. Data were analyzed by one- or two-way ANOVA and 
Student’s T-test, as appropriate, with repeated measures across varying time points 
using SigmaPlot 11.2 (Systat Software, Inc.). Differences among individual pairs of 
means were determined by the Holm-Sidak post-hoc test. Kaplan-Meier survival 
plots were generated to determine any effect of treatment regimen on survival 
using SigmaPlot. Data were considered significant at p<0.05. 
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Chapter 2. In vivo Experiments 
 
A. Animal Studies. All studies were carried out in accordance with, and approval of, the 
Institutional Animal Care and Use Committee of Indiana University School of 
Medicine (Study #10463), and the Guide for the Care and Use of Laboratory Animals. 
Female NOD/scid and NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were obtained from 
the In Vivo Therapeutics Core of the Indiana University Simon Cancer Center and 
acclimated at least one week prior to commencement of the study. Animals were 
maintained under pathogen-free conditions and maintained on Irradiated Global 
2018 (Uniprim® 4100 ppm) (TD.06596, Harlan Laboratories USA) food pellets with ad 
libitum access to autoclaved, acidified tap water under a 12-hour light-dark cycle at 
22-24°C. Uniprim® food contains 275 ppm trimethoprim and 1,365 ppm of the 
sulfonamide sulfadiazine which helped to inhibit infections. 
B. Animal Strain Comparisons. NOD/scid and NSG mice were implanted with 1x106 
TMD231 cells into the mammary fat pad. Tumors were allowed to grow and caliper 
measurements were collected twice weekly to evaluate tumor growth of the 
primary tumors. Mice were sacrificed throughout the study to better understand 
longitudinal metastasis formation in the lungs. Lung metastases were examined 
following H&E staining.  
C. Fluorescent Imaging Validation Studies 
1. In vitro Imaging. TMD231-CR and TMD231 cells were counted and placed into 96-
well plates. The TMD231 parental cells were used as a control for any 
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autofluorescence. The cells were plated in PBS to reduce any noise that we may 
have encountered with fluorescence from components in the growth medium. In 96-
well plates, 4x106 TMD231 or TMD231-CR cells were plated and serial diluted 1:2 
across the plate resulting in 0.03125, 0.0625, 0.125, 0.5, 1, 2, and 4x106 cells. Each 
cell number was plated in triplicate. Imaging analysis was completed and fluorescent 
intensity was calculated.  
2. In vivo Imaging. Typical optical imaging for small animals consisted of animal being 
anesthetized in polycarbonate box with isoflurane (1-2% with 100% oxygen mix). 
Mice were shaved and depilatory cream was used to remove any remaining fur 
surrounding the primary tumor site. The mice were anesthetized using isoflurane 
gas during depilatory cream use and imaging. The mice were placed on the warmed 
imaging bed inside the Optix MX3 (ART Technologies). The muzzle was placed inside 
the built in nose cone of the imaging bed where constant isoflurane gas mixture was 
administered throughout the imaging process. Imaging proceeded with average scan 
times lasting from 5-10 minutes. Once imaging was complete, the mice were 
removed from the MX3 and placed back in their cages lying on their side until fully 
conscious. The cages were placed on heating pads to minimize hypothermia. While 
under anesthesia, it was unlikely the animal will not move so constraints were not 
necessary; however, medical tape could have been used to secure the legs of the 
animal while being imaged if necessary.  
3. In vivo Cell Number Imaging. Mice were implanted in the lower half of the 
mammary fat pad at 4 different nipple regions. Each mouse was implanted with 
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0.125, 0.25, 0.5, and 1x106 TMD231 or TMD231-CR cells. There were 3 mice imaged 
for each cell line. Following analysis, fluorescent intensity for each cell number was 
calculated. TMD231 parental implanted mice were used as a control for any 
background fluorescence. 
4. Longitudinal Animal Imaging. NSG mice were implanted with either 1x106 TMD231 
or TMD231-CR cells on Day 0. The TMD231 parental cell implanted mice were used 
as imaging controls to subtract background fluorescence. Throughout the study, the 
primary tumor was measured via caliper twice weekly. On Day 7 post implant, the 
mice were imaged with the Optix MX3 (ART Technologies). Mice were imaged three 
mice per scan. The mice were imaged once weekly for a total of 5 weeks. Imaging 
analysis yielded the fluorescent intensity of tumors for comparison to measured 
tumor volume via caliper.  
5. Ex-vivo E2-Crimson Levels. Mice from the longitudinal animal imaging study were 
used to examine the maintenance of E2-Crimson fluorescent protein in excised 
TMD231-CR tumors. The excised tumors were dissociated with a scalpel and grown 
ex-vivo in cell culture. Growth medium was changed frequently and contained 0.5% 
Gentamicin antibiotics. After stable lines were generated, the TMD231 parental and 
TMD231-CR tumors were examined with flow cytometry to determine the 
percentage of E2-Crimson positive cells. 
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D. Efficacy Studies 
1. Drug Treatments. Carboplatin was dissolved in PBS. Nutlin-3a was mixed in 0.5% 
methylcellulose and 0.05% Tween80 solution. Proper drug mixture was ensured 
following sonication in a sonicating water bath and mixing via vortex.  
2. Carboplatin Dose Finding Study. NSG mice were implanted with 1x106 TMD231 or 
TMD231-CR cells on Day 0. On Day 7, the mice were imaged to collect initial tumor 
fluorescent intensity for randomization purposes. The mice received carboplatin 
(Carb) or Vehicle (Veh) (PBS) through intraperitoneal (i.p.) injections once MWF for a 
total of 6 doses. Mice received 1m/kg, 3mg/kg, or 30mg/kg carboplatin. Throughout 
the study, mice were examined for overt toxicity. We continued to monitor primary 
tumor growth with caliper measurements twice weekly as well as collecting weekly 
body weights. The study endpoint was when the primary tumor reached ≥1000mm3. 
At the time of sacrifice, the primary tumor and lungs were collected for histology 
purposes and fixed in 10% buffered formalin.  
3. Combination Study 1. As in other studies, NSG mice were implanted with 1x106 
TMD231 or TMD231-CR cells in the mammary fat pad. Mice were imaged on Day 7 
with optical imaging. Primary tumor fluorescent intensity was used to randomize the 
mice into the treatment groups: Vehicle (PBS+methylcellulose) (Veh), 25mg/kg 
carboplatin (Carb), 200mg/kg Nutlin-3a (Nut), and 25mg/kg carboplatin+200mg/kg 
Nutlin-3a (Combo). There were 7-9 mice per group. Mice were dosed three times 
weekly for a total of 6 doses. Based on pharmacokinetic (PK) data from other animal 
studies in the lab, the dosing of carboplatin and Nutlin-3a were separated by at least 
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4 hours. We chose to dose with carboplatin first in the morning so that the drug 
could act on the primary tumor and lead to DNA damage in tumor cells, which in 
turn could activate DNA damage responses and lead to increased cell stress. When 
Nutlin-3a is dosed later in the afternoon, Mdm2 could be bound by Nutlin-3a 
allowing for proteins involved in the DNA damage response including p73 and E2F1 
to be free and lead to target gene activation. Carboplatin was dosed i.p. in the 
morning while Nutlin-3a was dosed orally (p.o.) in the afternoon. The combination 
and Vehicle groups were dosed twice a day on treatment days with the appropriate 
drug or Vehicle at the appropriate time, AM or PM. Throughout the study, the mice 
were examined for any overt toxicity. Body weights were collected weekly 
throughout the course of the study and primary tumors were measured via caliper 
twice weekly throughout the study. The endpoint for the study was when the first 
primary tumors reached ≥1000mm3. Mice were sacrificed on Day 47 post implant. At 
the time of sacrifice, the primary tumors and lungs were collected and fixed in 10% 
buffered formalin. Fixed tissues were set in paraffin blocks, cut and sectioned, and 
stained with H&E to evaluate primary tumor health and lung metastases.  
4. Combination Study 2. As in other studies, NSG mice were implanted with 1x106 
TMD231 or TMD231-CR cells in the mammary fat pad. Mice were imaged on Day 7 
with optical imaging. Mice were randomized into two groups of mice, repeat study 
mice (n=4 per group) and survival (n=8 per group). Within each group, the mice were 
randomized into the treatment arms: Vehicle (PBS+methylcellulose) (Veh), 20mg/kg 
carboplatin (Carb), 200mg/kg Nutlin-3a (Nut), and 20mg/kg carboplatin+200mg/kg 
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Nutlin-3a combination (Combo). Carboplatin was dosed i.p. in the morning while 
Nutlin-3a was dosed orally (p.o.) in the afternoon. The combination and Vehicle 
groups were dosed twice a day on treatment days with the appropriate drug or 
Vehicle at the appropriate time, AM or PM. The mice were dosed twice weekly 
(Tuesdays and Fridays) for a total of 8 doses. Throughout the study, the mice were 
examined for any overt toxicity. Body weights were collected weekly throughout the 
course of the study and primary tumors were measured via caliper twice weekly 
throughout the study. The endpoint for the repeat study mice was when the first 
primary tumors reached ≥1000mm3, which was 5 days following the completion of 
drug treatment. At the time of sacrifice, the primary tumors and lungs were 
collected and fixed in 10% buffered formalin. Fixed tissues were set in paraffin 
blocks, cut and sectioned, and stained with H&E to evaluate primary tumor health 
and lung metastases. Femurs were collected to determine bone marrow cellularity. 
The survival group of mice was sacrificed when primary tumor volume reached 
800mm3. When the mice reached the tumor volume endpoint, the mice were 
sacrificed and femurs were collected for total bone marrow cell counts. In the 
survival mice, they were sacrificed with about a 2-week recovery period following 
the completion of drug treatment. 
a. Bone Marrow Flow Cytometry. Mice from Combination study 2 were evaluated 
for the presence of bone metastases by examining isolated bone marrow cells 
from crushed femur bones for the presence of TMD231-CR cells using flow 
cytometry (See Histological analysis: Bone marrow cellularity).  
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5. Combination Study 3. NSG mice were implanted with 1x106 TMD231 or TMD231-CR 
cells in the mammary fat pad. We were unable to image the mice on Day 7 for 
randomization purposes due to failure of the motherboard on the MX3 Optix. Our 
previous imaging data, however, has demonstrated that we get a 100% tumor take 
in the NSG model and that tumor volumes are consistent amongst the animals. 
Therefore, we elected to randomize the mice based on body weights on Day 7 into 
the treatment groups: Vehicle (PBS+methylcellulose) (Veh), 20mg/kg carboplatin 
(Carb), 200mg/kg Nutlin-3a (Nut), and 20mg/kg carboplatin+200mg/kg Nutlin-3a 
(Combo). Carboplatin was dosed i.p. in the morning while Nutlin-3a was dosed orally 
(p.o.) in the afternoon. The combination and Vehicle groups were dosed twice per 
day on treatment days with the appropriate drug or Vehicle at the appropriate time, 
AM or PM. The mice were dosed twice weekly (Tuesdays and Fridays) for a total of 8 
doses. Mice were sacrificed when initial mice reached ≥1000mm3 tumor volume. 
Following necropsy, lungs, primary tumors, livers, spleens and femurs were 
collected. We performed H&E staining of the lungs, primary tumors, livers, spleens, 
and femurs. We repeated bone marrow cellularity and also evaluated the effects of 
the drug treatments on complete blood counts (CBCs) and progenitor assays. 
6. In vivo Pharmacodynamic Study. NSG mice were implanted with 1x106 TMD231-CR 
cells, and tumors were allowed to grow. Caliper measurements were taken twice 
weekly to monitor tumor volume. When tumors reached ~500mm3, mice were 
randomized based on tumor volume into treatment groups. Mice were dosed with 
Vehicle (PBS+methylcellulose) (Veh), 20mg/kg carboplatin (Carb), 200mg/kg Nutlin-
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3a (Nut), or 20mg/kg carboplatin+200mg/kg Nutlin-3a (Combo) for 3 consecutive 
days. Two house after the last drug dose, the mice were sacrificed and primary 
tumors were weighed and collected. Primary tumors were cut in half for human 
VEGF ELISA analysis and the other half for Western blot analysis and snap frozen in 
liquid nitrogen.  
a. Human VEGF ELISA. Tumors were lysed in an appropriate volume of 1X Lysis 
Buffer (Cell Signaling) on ice using the Omni Tissue Homogenizer (TH) (Omni 
International, Kennesaw, GA). Protein concentration was determined as 
described previously. Equal protein for each tumor sample was added to the 
VEGF ELISA plate and Human VEGF Quantikine ELISA Kit (R&D Systems) was 
completed per manufacturer’s instructions. Total VEGF levels were normalized 
to protein levels and average VEGF presence was graphed.  
b. Tumor Lysates for Western. Snap frozen tumors were lysed with 1% SDS lysis 
buffer using the Omni Tissue Homogenizer (TH) (Omni International, Kennesaw, 
GA). Samples were boiled and protein concentration was determined as 
described previously. Samples were examined by Western blot for protein levels 
as described previously.  
E. Histological Analyses 
1. Tissue Specimens. All mice tissue samples were collected following a detailed LARC 
approved lab animal protocol. 
2. Tissue Processing. Tissues were fixed in 10% neutral buffered formalin at 4°C for 24 
hours followed by tissue processing, and then embedded in paraffin. Five-micron 
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sections were cut and stained for routine H&E and Ki67 staining. 
3. Immunostaining. The slides were deparaffinized in xylene and rehydrated through 
graded alcohols ending in water. Antigen retrieval was performed by immersing the 
slides in Target Retrieval Solution (Dako) for 20 minutes at 90°C, cooling at room 
temperature for 10 minutes, washing in water and then proceeding with 
immunostaining. Slides were blocked with protein blocking solution (Dako) for 30 
minutes. All subsequent staining steps were performed using the Dako FLEX SYSTEM 
on an automated Immunostainer; incubations were done at room temperature and 
Tris buffered saline plus 0.05% Tween 20, pH 7.4 (TBS - Dako Corp.) was used for all 
washes and diluents. Thorough washing was performed after each incubation 
period.  
a. H&E Staining. Sections were stained with haemotoxylin and eosin (DAKO).  
b. Ki67 Staining. The primary antibody was anti-human Ki67 (Dako). Control 
sections were treated with an isotype control using the same concentration as 
primary antibodies to verify the staining specificity. For the Ki67 positive nuclei, 
(tumor areas) nuclei were measured in one section per xenograft tumor and 
expressed as the number of positive cells per 16X power field (160X) in the cross-
sectional area. For the immunohistochemical quantification, three randomly 
selected images (16X power fields) each (total area, 7.3 mm2) were analyzed by a 
pathologist hand count and averaged for each lung.  
c. Whole Slide Digital Imaging. The Aperio whole slide digital imaging system was 
used for whole slide imaging. The Aperio Scan Scope CS system (Leica 
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Biosystems) was used. The system imaged all slides at 20X. The scan time ranged 
from 1.5-2.25 minutes. The whole images were housed and stored in the 
Spectrum software system, and images were taken from the whole slides. 
d. Automatic Image Quantitation. Computer-assisted morphometric analysis of 
digital images was done using the Aperio software that came with the Aperio 
Imaging system (Leica Biosystems). An optimized algorithm for the positive pixel 
algorithm that was designed for H&E staining was used for imaging of the H&E 
lung tumor metastases. The positive pixel algorithm was modified to distinguish 
between the red and blue colors. The tumors were blue and it was easy to 
discern the difference between normal lung tissue and the tumors that filled the 
lung lobes using this algorithm. The total nuclear labeling index (Ki67) was 
generated using the Aperio Image Scope standard positive pixel algorithm. This 
Image Analysis software was used engraft and the software package (positive 
pixel algorithm) calculated the percent of positive pixels (brown staining) in one 
large cross section area from one lung lobe in the control and each drug treated 
group. 
F. Measures of Drug Toxicity 
1. Bone Marrow Cellularity. Mice were sacrificed at the end of the study and both 
femurs were collected. Bones were crushed with mortar and pestle and passed 
through a 70µm cells strainer. Red blood cells were lysed with RBC Lysis Buffer 
(Qiagen). Total cell counts were counted using a Beckman Coulter Counter.  
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2. Bone Marrow Smears. Femur bones were excised during necropsy. Bones were 
fixed in 10% buffered formalin and decalcified with Decal®. Bones were set in 
paraffin blocks, sectioned, stained with H&E, and evaluated by pathologist. 
3. Total Complete Blood Counts (CBCs). Tumor-bearing mice were treated with Vehicle 
control (Veh), carboplatin (Carb), Nutlin-3a (Nut) or carboplatin+Nutlin-3a 
combination (Combo). After a 2-week recovery period, an aliquot of peripheral 
blood was analyzed via hemavet for red blood cells, thrombocytes, and white blood 
cells. 
4. Progenitor Assay. After completing total bone marrow cell counts, 2x104 bone 
marrow cells were plated in triplicate in MethoCult™ GF M3434 (StemCell™ 
Technologies). Cells were allowed to grow for 2 weeks. Hematopoietic progenitor 
cells were counted for each plate and averages were taken for each of the mouse 
samples. Progenitor assays were conducted as described in Cai et al. 110.  
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SECTION III. RESULTS 
 
Chapter 1. Aim 1: Determination of cellular sensitivity to Nutlin-3a and carboplatin in 
triple-negative breast cancer cells in vitro 
 
A. Background and Rationale 
The overall objective of this thesis was to evaluate the therapeutic potential of a 
new combination therapy to treat TNBC. Based on front-line therapies currently being 
tested in clinical trials for TNBC, the platinum agent, carboplatin was selected for study. 
New molecular targets need to be elucidated to enhance treatment efficacy. Mdm2 is 
an unexplored target in breast cancers and Mdm2-mediated signaling can be altered 
using Nutlin-3a. Our first objective of this thesis was to determine the effects of 
combination carboplatin and Nutlin-3a treatment on TNBC cell proliferation, cell death, 
and cell cycle in vitro. To address this objective, drug sensitivity studies were conducted 
using Nutlin-3a and carboplatin alone and in combination. A panel of mutant p53 TNBC 
lines (MD-MB-231, MDA-MB-468, and TMD231) were utilized to determine to what 
extent modulation of Mdm2 via the protein-protein inhibitor, Nutlin-3a, can potentiate 
carboplatin-mediated cell death. Both the MDA-MB-231 and MDA-MB-468 cells are 
adenocarcinoma lines that were developed from metastatic pleural effusions. We also 
utilized the TMD231 cells, which were derived from the parental MDA-MB-231 cells 17 
and were a kind gift of Dr. Harikrishna Nakshatri (IUSM). Both the MDA-MB-231 (R280K) 
and MDA-MB-468 (R273H) cells have missense mutations within p53 in the DNA binding 
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domain resulting in the inactivation of normal p53 function and abnormally increases 
proliferation, invasion, and metastasis 19,47,101,111,112.  
Initially, cellular sensitivity to Nutlin-3a and carboplatin was determined using 
methylene blue proliferation assay so that relevant drug concentrations for future 
experiments could be utilized. Single drug sensitivities were needed for later design of 
combination treatments. Also, we were interested in determining if a broad or narrow 
range of dose ratios would result in decreased proliferation. The methylene blue 
proliferation assay is a reliable measure of cell growth over time. This assay measures 
the number of adherent cells, and there is a direct relationship between numbers of 
adherent cells to the optical absorbance. Methylene blue stain electrostatically binds to 
negatively charged particles in cells such as negatively charged phosphate groups in 
DNA and moieties of proteins 102. The methylene blue proliferation assay is not a 
metabolic assay, which is important if any drugs used alter metabolism. The methylene 
blue proliferation assay is a quick and easily replicated experiment to experiment with 
little variance between similarly treated wells.  
We also evaluated the effects of the single and dual treatment on the ability of 
the cells to form colonies in a 2D colony formation assay. The cells were seeded at low 
density and treated with single or combination treatments and allowed to grow for 2 
weeks. Following the initial drug sensitivity determination of Nutlin-3a and carboplatin 
in the MDA-MB-231, TMD231, and MDA-MB-468 cells, we also wanted to determine the 
effects of single and combination drug treatment on cell proliferation through cell 
counting assays. Longitudinal cell counting experiments allowed us to examine the 
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effects of the single and dual treatments on the cells ability to proliferate as well as 
determine if the cells are dying throughout the treatment window. To better 
understand how the single and combination carboplatin and Nutlin-3a treatment may 
affect cell viability, we also utilized flow cytometry to evaluate the impact of single and 
dual treatment on cell cycle and apoptosis. These assays allowed for a better 
understanding of whether apoptosis and/or cell cycle arrest might account for 
decreased cell growth.  
Cell cycle kinetics can play a major role in how normal and cancerous cells 
respond to therapy. When cells are treated with chemotherapeutic drugs, there is 
significant damage to DNA. The DNA damage will accumulate and as a survival 
mechanism, cells will undergo cell cycle arrest in either G0/G1, S, or G2 phase to 
determine if the damage can be repaired 113. If the damage is too great and cannot be 
sufficiently repaired, the cells can signal for pro-apoptotic and other cell-death 
mediators to be activated. Apoptosis and cell cycle analysis via flow cytometry uses 
dyes, like 7-AAD and PI with that stain DNA allowing for the amounts of DNA to be 
quantitated 114. In determining the populations of cells undergoing early and late 
apoptosis, DNA stains like 7-AAD can be used with minimal overlap with other 
conjugated antibodies like Annexin V-FITC that binds to phosphatidylserine, which is a 
sensitive marker of early apoptosis. In cell cycle analysis, cells are permeabilized and 
mixed with a DNA staining solution, and the stained DNA present will show which phase 
of the cell cycle the cells are accumulating. When cells are in the G0/G1 phase, the DNA 
content is 2N since each cell has 2 copies of DNA. The G2/M phase has double the 
 67 
amount of DNA as the G1 phase since the cells are getting ready to divide into two 
daughter cells 115. The DNA content measure in the S phase is between 2N and 4N as the 
DNA is being synthesized for separation into the daughter cells. There are several 
signaling mediators involved in successful cell division and can be aberrant in cancers 
allowing for genetically unstable cells to continue proliferating 115. Most normal 
mammalian cells are diploid in nature in that they carry two copies of each 
chromosome. However, in cancers, cells often become aneuploidy in that they have 
chromosomal aberrations such as alterations in total copies of chromosomes as well as 
chromosomal rearrangements with amplifications, deletions and translocations 116. 
These genetic abnormalities result in changes to multiple signaling pathways and 
promote survival and proliferation of cancer cells.  
Interestingly, Le et al. showed that in the MDA-MB-231 cells, the potential for 
metastases was enhanced in the MDA-MB-231 cells when the cells underwent 
hypertetraploidy which is a type of aneuploidy 117. It has been shown that in breast 
adenocarcinoma, patients with tumors exhibiting aneuploidy tumors had a worse 
prognosis and hypertetraploid tumors were the most aggressive tumor types 118,119. As 
the parental MDA-MB-231 cells were cultured over long periods of time, some of the 
cells developed spontaneous a hypertetraploidy state with DNA peaks just smaller than 
4N and 8N 117. More interestingly, the hypertetraploid cells showed an increased 
metastatic potential to the lungs and brain but not bone when compared to the 
parental cells 117 which may help to explain the increased aggressiveness of the 
hypertetraploidy cells.  
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B. Combination treatment had increased potency in cell proliferation, apoptosis, and 
cell cycle assays  
Initially, we tested the cellular sensitivity of the parental MDA-MB-231 cells to 
Nutlin-3a and carboplatin alone using methylene blue proliferation assays. The IC50 
value for Nutlin-3a was 40.2μM±0.6, carboplatin was 28.6μM±1.2, and 1:1 combination 
was 5.3μM±0.3 (Figure 5A). It is noteworthy that the IC50 values for Nutlin-3a are quite 
high relative to what is generally used for selective targeting of the Mdm2-p53 
interactions, and it is possible that off-target effects do come into play at high 
micromolar concentrations. Lau and colleagues showed IC50 values for Nutlin-3a to be 
around 30μM in p53-/- cells which is comparable to our mutant p53 cell system 66. 
However, as shown below, once Nutlin-3a is combined with carboplatin, the IC50 values 
for Nutlin-3a are in the low micromolar range, which is what is typically used in cells 
with wild-type p53 40. The MDA-MB-231 cellular proliferation assay was examined using 
isobologram analysis. Isobologram analysis was described by Tallarida to determine 
synergy between two different drugs 109. Briefly, the IC50 value for each single drug is 
plotted on a graph, and a line is drawn connecting the two points. In our studies, we 
plotted the IC50 of carboplatin on the x-axis while the IC50 of Nutlin-3a was plotted on 
the y-axis. A line was drawn connecting these two points, which becomes known as the 
‘line of additivity’. The line of additivity helps determine the interaction between the 
two different drugs. Following combination treatment, the IC50 values for the different 
drug combinations also known as the ‘isoboles’ are plotted on the graph. If the isoboles 
fall along the line of additivity, the interaction between the two drugs is considered to 
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be additive. If the isoboles fall below the line of additivity, the two drugs are determined 
to have a synergistic relationship while if the isoboles fall above the line of additivity, 
the interaction is considered antagonistic. These data indicate the Nutlin-3a decreased 
cellular resistance to carboplatin. When the IC50 value for a 1:1 Nutlin-3a:carboplatin 
combination treatment was determined, the isobole fell below the line of additivity, 
suggesting a synergistic effect (Figure 5B).  
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 Figure 5. Combination treatment increases potency and synergistic effects in MDA-
MB-231 cells. MDA-MB-231 cells were seeded in 96-well plates and treated with 
increasing concentrations of Nutlin-3a, carboplatin (Carbo), or combination (1:1 combo) 
for 5 days. Cells were fixed and stained with methylene blue. Cell proliferation was 
determined for each treatment. (A) Combination treatment had an increased potency in 
MDA-MB-231 cells compared to Nutlin-3a and carboplatin alone treated cells. (B) 
Following isobologram analysis, the 1:1 combination was examined with the isobole 
falling below the line of additivity, which indicated a synergistic effect.  
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Since the highly metastatic TMD231 cells were derived from the parental MDA-
MB-231 cells, we next investigated if the two cell lines had similar cellular sensitivity to 
Nutlin-3a, carboplatin and 1:1 combination treatment. Nutlin-3a, carboplatin, and 1:1 
combination inhibited cell proliferation in a dose-dependent manner, similar to the 
parental cells. Treatment of Nutlin-3a, carboplatin, and 1:1 combination inhibited 
cellular proliferation in a dose dependent manner with IC50 values of 19.4μM±3 for 
Nutlin-3a, 6.3μM±1.9 for carboplatin, and less than 0.7μM±0.5 for combination treated 
TMD231 cells (Figure 6A). Isobologram analysis was used to determine the type of drug 
interaction involved in the combination treatment. Several drug ratios of Nutlin-
3a:carboplatin were examined including 1:1, 3:1, 9:1, 1:3, and 1:9. The 1:1 combination 
had the most potent effect with the lowest IC50 values, which fell the furthest away from 
the line of additivity (Figure 6B). The 3:1 Nutlin-3a:carboplatin ratio had next lowest IC50 
value. Since the 1:1 ratio had the biggest effect, we elected to continue the experiments 
using the 1:1 combination in future experiments focused on mechanism of action 
(Figure 6B). Individual IC50 values were determined as shown in inset table (Figure 6B). 
There was some variability in cellular sensitivity to the drugs between different 
experiments especially with Nutlin-3a (IC50 values ranged from 20-40µM) as seen in 
Figure 6. However in all cases, Nutlin-3a concentrations required to inhibit 50% growth 
were in the low micromolar range in the presence of carboplatin-mediated DNA 
damage. 
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 Figure 6. Combination treatment increases potency and synergistic effects in TMD231 
cells. TMD231 cells were seeded in 96-well plates and treated with increasing 
concentrations of Nutlin-3a, carboplatin, or combination for 5 days. Cells were fixed and 
stained with methylene blue. Cell proliferation was determined for each treatment. (A) 
A 1:1 combination treatment showed an increased potency in TMD231 cells compared 
to Nutlin-3a and carboplatin alone treated cells with IC50 values compared to each single 
drug alone. (B) Several drug ratios of Nutlin-3a:carboplatin (1:1, 3:1, 9:1, 1:3, and 1:9) 
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were examined using isobologram analysis. All isoboles from the different combination 
treatments fell below the line of additivity indicating a synergistic effect. The 1:1 
combination had the smallest combined IC50 value. The IC50 values for each of the 
combinations were represented in the inset table.   
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To further confirm the effectiveness of the dual carboplatin-Nutlin-3a 
combination and also to determine if this approach is applicable to other TNBC cells 
with mutant p53, a secondary TNBC cell line was also evaluated. The MDA-MB-468 cells 
are another triple-negative breast cancer cell line that harbors a different p53 mutation 
(R273H) within the DNA binding domain. The MDA-MB-468 cells exhibited similar 
sensitivity to Nutlin-3a, carboplatin, and 1:1 combination treatment as seen with the 
TMD231 cells. The IC50 values for the MDA-MB-468 cells were 23.8μM±7 for Nutlin-3a, 
5μM±1.8 for carboplatin alone, and 1.3μM±0.3 for the 1:1 combination (Figure 7A). A 
broad range of dose ratios resulted in a synergistic inhibition of MDA-MB-468 cell 
growth; Nutlin-3a:carboplatin ratios including 1:1, 3:1, 9:1, 1:3, and 1:9 were evaluated 
and results were similar to those obtained with the TMD231 cells (Figure 7B). 
To assess the effect of Nutlin-3a, carboplatin, and 1:1 combination treatment on 
clonogenicity, 2D clonogenic assays were completed. Nutlin-3a, carboplatin, and 
combination treatments inhibited colony formation in a dose-dependent manner 
(Figure 8). Clonogenic assays were attempted with the MDA-MB-468 cells; however, 
these cells did not form measurable colonies and therefore could not be evaluated by 
this assay. 
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 Figure 7. Combination treatment increased potency and synergistic effects in MDA-
MB-468 cells. MDA-MB-468 cells were seeded in 96-well plates and treated with 
increasing concentrations of Nutlin-3a, carboplatin (carbo), or combination (1:1) for 5 
days. Cells were fixed and stained with methylene blue. Cell proliferation was 
determined for each treatment. (A) Combination treatment had an increased potency in 
MDA-MB-468 cells compared to Nutlin-3a and carboplatin alone treated cells. (B) 
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Following isobologram analysis, several drug ratios of Nutlin-3a:carboplatin (1:1, 3:1, 
9:1, 1:3, and 1:9) were examined with isoboles falling below the line of additivity, which 
indicates a synergistic effect. The 1:3 and 1:9 combinations had the smallest combined 
IC50 value. The IC50 values for each of the combinations were represented in the inset 
table.   
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 Figure 8. Combination treatment inhibits clonogenic cell growth. TMD231 cells were 
seeded at low density (50 cells per 10cm dish) to assess the effects of Nutlin-3a, 
carboplatin, and combination treatment on clonogenicity. Cells were treated with drug 
and allowed to grow for 2 weeks. Colonies were stained with methylene blue and 
counted using a cell counting pen. (A) Nutlin-3a significantly inhibited colony formation 
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in a dose dependent manner (n=3, *p<0.05 compared to untreated, mean±SD). (B) 
Carboplatin inhibited colony formation in a dose-dependent manner (n=3, *p<0.05 
compared to untreated, mean±SD). (C) Combination treatment inhibited colony 
formation with decreased amounts Nutlin-3a (Nut) and carboplatin (Carb) compared to 
single drug treatments (n=3, *p<0.05 compared to untreated, mean±SD).  
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To better understand potential cytotoxic versus cytostatic effects of Nutlin-3a, 
carboplatin, or 1:1 combination treatment on cell proliferation, we performed 
longitudinal cell counting assays. TMD231 cells exposed to Vehicle continued to grow 
and reached confluence around Day 5. The Vehicle treatment did not alter cell growth 
throughout the study (Figure 9). Based on the isobologram results, we elected to 
evaluate compound effects at a dose ratio of Nutlin-3a:carboplatin that resulted in a 
synergistic inhibition of cell growth. The ratio of 1:1 was selected and drug treatments 
were performed at 7.5-15µM of each compound. These values centered on the IC50 
value of carboplatin and about half of the IC50 of Nutlin-3a for TMD231 cells. We found 
that this dose ratio allowed us sufficient cells to be able to determine differences in 
combination treated cells versus each single drug in cell counting experiments and in 
the analysis of target modulation by Western blots. Low concentrations of Nutlin-3a 
alone do not affect cell proliferation to any significant degree (Figure 10). When 
TMD231 cells are exposed to 15µM carboplatin, this concentration only inhibits about 
50% of cells allowing for further reductions in cell proliferation when combined with 
Nutlin-3a.  
When TMD231 cells were exposed to 15µM Nutlin-3a, there was no effect on 
cell proliferation throughout the 5-day time course (Figure 10). Growth kinetics of 
cultures exposed to vehicle and Nutlin-3a were similar. Carboplatin induced a significant 
inhibitory effect on the growth of TMD231 cells compared to the Vehicle- and Nutlin-3a-
treated cells (Figure 13). By Day 3, carboplatin-treated cells were stressed exhibiting a 
more rounded and swollen appearance, and this correlated with a significant reduction 
 80 
in cell number (Figure 11 and 13). When evaluating Day 3 cultures, a noticeable change 
in cell number was observed; the 1:1 combination showed a significant reduction in 
total cell number compared to all groups (Figure 13). The 1:1 combination cells were 
very stressed by Day 3 with morphological changes showing large flattened cells with 
elongated spindle formation (Figure 12). There was a significant reduction in total cell 
number between Day 3 and 4 for both the carboplatin alone and 1:1 combination 
treated cells with further decreases in total cell number by Day 5 in the combination 
treated cells compared to other groups (Figure 11 and 12). The cell counting experiment 
was also repeated using lower drug concentrations, (1:1, carboplatin, and Nutlin-3a at 
7.5μM of each drug). At the7.5μM concentrations of carboplatin and Nutlin-3a, cell 
proliferation was inhibited in a similar manner as the 15μM drug treatments. As would 
be expected, total cell counts were ~50% higher in the 7.5µM treated compared to the 
15µM treated cells (Figure 14).  
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 Figure 9. Vehicle treated TMD231 cell proliferation is not inhibited over time. TMD231 
cells were seeded in 12-well plates with 6,500 cells on Day -1. Cells were treated with 
Vehicle on Day 0, and cell number was evaluated daily for a total of 5 days. (A) Pictorial 
representation of Vehicle (Veh) treated TMD231 cells over time. (B) Graphical 
representation of Vehicle treated TMD231 cells over time showed an increase in cell 
proliferation.   
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 Figure 10. Nutlin-3a treated TMD231 cell proliferation is not inhibited over time. 
TMD231 cells were seeded in 12-well plates with 6,500 cells on Day -1. Cells were 
treated with Nutlin-3a, and cell number was evaluated daily for a total of 5 days. (A) 
Pictorial representation of 15µM Nutlin-3a (Nut) treated TMD231 cells over time. (B) 
Graphical representation of 15µM Nutlin-3a treated TMD231 cells over time showed an 
increase in cell proliferation.   
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 Figure 11. Carboplatin inhibits TMD231 cell proliferation after Day 3. TMD231 cells 
were seeded in 12-well plates with 6,500 cells on Day -1. Cells were treated with 
carboplatin, and cell number was evaluated daily for a total of 5 days. (A) Pictorial 
representation of 15µM carboplatin (Carb)-treated TMD231 cells over time. (B) 
Graphical representation of 15µM carboplatin-treated TMD231 cells over time showed 
an increase in cell proliferation until Day 3 after which cell number significantly 
decreased (One-Way ANOVA, *p<0.05, n=3, mean±SD).   
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 Figure 12. Combination treatment inhibits TMD231 cell proliferation after Day 3. 
TMD231 cells were seeded in 12-well plates with 6,500 cells on Day -1. Cells were 
treated with 1:1 combination, and cell number was evaluated daily for a total of 5 days. 
(A) Pictorial representation of 15µM Nutlin-3a + 15µM carboplatin combination 
(Combo) treated TMD231 cells over time. (B) Graphical representation of 15µM Nutlin-
3a + 15µM carboplatin combination treated TMD231 cells over time showed a 
significant inhibition of cell proliferation after 3 days drug treatment (One-Way ANOVA, 
*p<0.05, n=3, mean±SD)..  
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 Figure 13. Carboplatin and combination treatment significantly inhibits cell 
proliferation by Day 3 post treatment. TMD231 cells were seeded in 12-well plates with 
6,500 cells on Day -1. Cells were treated with Vehicle (Veh), Nutlin-3a (Nut), carboplatin 
(Carb), and 1:1 combination (Combo). There was also an untreated control (Untx), and 
cell number was evaluated daily for a total of 5 days. (A) Pictorial representation of 
TMD231 cells on Day 3 post treatment showed stressed and dying cells in carboplatin 
(Carb) and combination (Combo) treatments. (B) The cell counts for the carboplatin and 
combination treated TMD231 cells showed significant reductions in total cell number at 
Day 3. There was a statistically significant reduction in the combination treated cells 
compared to the carboplatin alone cells (Student’s t-test, *p<0.05, n=3, mean±SD).   
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 Figure 14. Dose-dependent decreases in number of TNBC cells exposed to combination 
carboplatin and Nutlin-3a. TMD231 cells were seeded in 12-well plates at 6,500 cells 
per well, and treated with 7.5μM or 15μM Vehicle, Nutlin-3a, carboplatin, or 1:1 
combination. Total cell counts were evaluated Day 3-5 post treatment to examine the 
effects of drug treatment on cell proliferation. (A) Nutlin-3a in both treatments had 
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similar effects with slight decreases in both the 7.5μM and 15μM treated cells on Day 5. 
(B-C) Both the 7.5μM and 15μM carboplatin and 1:1 combination drug treatments 
inhibited cell proliferation and resulted in a decline in total cell number. The effects 
were about half in the 7.5μM treated cells compared to the 15μM treated cells which 
would be expected.  
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  We next examined how the combination carboplatin and Nutlin-3a leads to 
decreased cell growth. Utilizing flow cytometry, we compared single and combination 
treatments and determined the frequency of early and late apoptotic cells. We began by 
using Annexin V-FITC and 7-AAD to determine if Nutlin-3a, carboplatin, and three 
different Nutlin-3a:carboplatin combination ratios (1:1, 3:1, and 1:3) promote apoptosis 
and/or necrosis. The drug concentrations used for these single and combinations were 
derived from TMD231 methylene blue proliferation data. TMD231 cells were treated for 
4 days, which was determined based on cell counting assays as the cells reach a critical 
point between Day 3 and Day 4 (Figure 11 and 12). Following Annexin V-FITC and 7-AAD 
staining, flow cytometry indicated that at Day 4 post treatment, low levels of Nutlin-3a 
and carboplatin lead to moderate increases in both early and late apoptosis (Figure 
15A), while the 1:1, 3:1 and 1:3 Nutlin-3a:carboplatin combinations lead to further 
increases in total apoptosis/necrosis when compared to each single drug alone 
(Student’s T-test, p<0.05, n=3, ±SEM) (Figure 15B). Flow cytometry experiments show 
that TMD231 cells are undergoing apoptosis following low level combination treatment 
for all ratios (1:1, 3:1, and 1:3) (Figure 15B) while single drug treatments did not 
significantly increase the number of apoptotic cells compared to Vehicle treated cells. 
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 Figure 15. Combination treatment enhances apoptosis in TMD231 cells. TMD231 cells 
were treated with three different Nutlin-3a:carboplatin dose ratios (1:1, 3:1, and 1:3) 
and corresponding single drug treatment concentrations, which were the IC50 values 
determined from isobologram analysis in Figure 6B. (A) Flow cytometry analysis showed 
that Nutlin-3a, carboplatin, and combination caused increases in early and late 
apoptotic TMD231 cells following Annexin V and 7-AAD staining. (B) Combination 
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treatment caused significantly increased total apoptotic TMD231 cells compared to 
carboplatin and Nutlin-3a alone treated cells following flow cytometry Annexin V and 7-
AAD staining (Student’s T-test, *p<0.05, n=3, ±SEM).   
 91 
  To gain insight into treatment effects on cell cycle in the context of a mutant 
p53 background, we treated the TMD231 cells with increasing concentrations of Nutlin-
3a, carboplatin, or 1:1 combination. Numerous cancer cell lines have aneuploid 
subpopulations, and in our model, the TMD231 cells have about 50% diploid and 50% 
aneuploid cellular subpopulations. In both the diploid and aneuploid populations, 
Nutlin-3a as a single agent did not induce cell cycle arrest in G1 or G2/M (Figure 16). In 
carboplatin and combination treated TMD231 cells, there was a dose-dependent 
increase in diploid and aneuploid cells in the S-phase compared to vehicle control which 
is consistent with previously published reports 120 (Figure 16). During this accumulation 
in the S-phase, cell could be undergoing an intra-S-phase checkpoint in which replication 
is reduced following DNA damage allowing cells more time to determine cell fate 121. 
Cell cycle arrest may play a small role in the big picture; however, based on the cell 
counting experiments, the total cell number in the carboplatin and combination treated 
cells continued to decline after 3 days of treatment indicating that the cells were dying 
(Figures 11-12). 
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 Figure 16. Carboplatin and combination treatment leads to S and G2/M accumulation 
while Nutlin3-a does not affect cell cycle. TMD231 cells were seeded on 10cm dishes 
and treated with 3.75, 7.5, and 15µM Nutlin-3a, carboplatin or 1:1 combination for 3 
days. Cells were harvested and stained with a PI staining solution to examine DNA 
content in cell cycle analysis via flow cytometry. (A-B) Nutlin-3a had no effect on cell 
cycle in both diploid and aneuploid cells. In both diploid and aneuploid cells, carboplatin 
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treatment led to cell accumulation in S-phase. The percentage of cells accumulating in 
the G2/M phase increased in a carboplatin-dose-dependent manner in both cell types. 
The combination treatment lead most cells to accumulate in S-phase in both diploid and 
aneuploid cells.  
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C. Discussion and Future Directions 
In summary, Nutlin-3a and carboplatin inhibited cell proliferation in methylene 
blue proliferation assays in the MDA-MB-231, TMD231, and MDA-MB-468 cell lines. The 
combination treatment led to an enhanced inhibition of cell proliferation as measured 
by methylene blue proliferation assays. Using isobologram analysis as described by 
Tallarida 109, the combination Nutlin-3a:carboplatin treatment led to a synergistic effect 
in all combinations tested. Nutlin-3a, carboplatin, and 1:1 combination treatment 
inhibited colony formation in a dose-dependent manner in the highly aggressive 
TMD231 cells while the MDA-MB-468 cells did not readily form colonies in vitro. In the 
colony formation assay, the number of colonies was significantly inhibited with 
increased amounts of each drug when compared to number of colonies in the single 
drug treated plates. For example, there was about a 50% decrease in number of 
colonies following 2.5µM carboplatin treatment while combined 1.5µM Nutlin-
3a+1.5µM carboplatin also inhibited about 50% of colonies. To better understand how 
the single and combination treatment inhibited cell proliferation, cell counting assays 
were used to examine the total number of cells present over a 5-day period. The 
TMD231 cells were treated with 7.5µM or 15µM Nutlin-3a, carboplatin or 1:1 
combination, and carboplatin and combination treated cells were greatly inhibited with 
significant reductions in total cell number after Day 3. The inhibition of total cell number 
was concentration-dependent with increased inhibition in cells treated with 15µM drug 
compared to 7.5µM drug treatments. There were significant differences in total cell 
number between the combination and carboplatin alone treated with the most effect 
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seen in the combination treated cells adding further support to the enhanced effect of 
dual Nutlin-3a and carboplatin treatment. In contrast to single agent, there was a 
potentiation in total apoptosis (early and late) following low concentrations of Nutlin-
3a:carboplatin combination (1:1, 3:1, and 1:3) treatments in TMD231 cells. Low 
concentrations of Nutlin-3a and carboplatin alone did not increase apoptosis and/or 
necrosis compared to Vehicle treated cells. Additionally, carboplatin alone and 
combination treatment lead to increased cell cycle arrest in the S and G2/M phases 
compared to Vehicle or Nutlin-3a. Nutlin-3a alone did not lead to increased cell cycle 
arrest.  
In our model, we utilized TNBC cell lines that do not have Brca1/2 mutations. 
However, the dual treatment of Nutlin-3a and carboplatin may have further efficacy in 
TNBC cell lines that also have mutations in the Brca1/2 gene. Recent studies have shown 
improved complete response rates of patients with germline mutations in Brca1/2 when 
standard of care paclitaxel or paclitaxel plus doxorubicin was combined with carboplatin 
122. Additionally, if drug treatment was combined with the PARP inhibitor, iniparib, there 
was an improved complete response rate in those patients who had Brca1/2 mutations 
compared to Brca1/2 wild-type patients 122. Synthetic lethality is an emerging area of 
research since TNBCs with mutant Brca1/2 in combination with a DNA damaging drug 
like carboplatin and PARP inhibitors can lead to increased cell death due to inhibition of 
key DNA repair pathways. Combination Nutlin-3a and carboplatin treatment coupled 
with a PARP inhibitor may lead to further efficacy in TNBCs that have concomitant 
Brca1/2 mutations.  
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In these cellular models of TNBC, there was increased sensitivity to Nutlin-3a in 
combination with carboplatin. Dr. Martin Smith showed that Mdm2 overexpression 
increased sensitivity to platinum agents by inhibition of wild-type 53 and thus inhibition 
of the NER pathway and removal of platinum adducts 123. Mdm2-mediated inhibition of 
wild-type p53 resembled similar cellular responses to platinum agents in mutant p53 
cancer cells in which platinum treatments led to a strong S-phase cell cycle arrest123, 
which was similar to our results. While cell cycle arrest was evident in treated cells, the 
arrest in G2/M or S phase was not sufficient to allow for repair and cell survival of 
combination treatment since we saw significant reductions in total cell numbers 
between Days 3 and 4 post treatment in cell counting assays. It has been shown that 
Mdm2 affects p21WAF1/Cip1 by acting to decrease the half-life of p21WAF1/Cip1 and by 
increasing proteasomal turnover of the p21WAF1/Cip1 protein independent of 
ubiquitylation 124. Jin and colleagues also showed that in p53 null cells, Mdm2 inhibits 
p21WAF1/Cip1-mediated cell cycle arrest, which could play a role in the analysis of cell cycle 
following drug treatment 124. Additionally, based on flow cytometry experiments, there 
was increased cell death (apoptosis and/or necrosis) in the combination treated 
TMD231 cells compared to single drug treated cells. This was particularly evident when 
cells were exposed to low concentrations of Nutlin-3a and carboplatin (0.8µM Nutlin-
3a:carboplatin used in apoptosis flow assay versus 15µM Nutlin-3a:carboplatin used in 
cell counting assays) with >50% cells undergoing apoptosis. Future studies would 
include further analysis of apoptotic markers including activated Caspases-3, -7 and -9 to 
better understand the role of apoptosis at the molecular level in our model system. 
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Additionally, the role of senescence should be examined following combination 
carboplatin and Nutlin-3a treatment to see if senescence also plays a role in the effects 
observed following combination treatment 125,126. Senescence staining could be 
completed using β-galactosidase staining. The effects of the combination carboplatin 
and Nutlin-3a treatment on isolated cancer stem cells should also be evaluated to see if 
these cell are also sensitive to the combination treatment since these cells could give 
rise to recurrent tumors. The role of combination treatment could also be examined on 
normal tissue toxicity. MCF10A, which are a non-transformed mammary epithelial cell 
line, could be used in proliferation assays to examine the effects of dual treatment on 
normal human cells as well.  
Cell cycle analysis showed that carboplatin and combination treatment lead to 
increased populations in S-phase and some increases in G2/M. There has also been 
evidence for cancer cells to undergo mitotic catastrophe in which during the cell cycle, 
the cells undergo aberrant chromosome segregation 127, and this area of study is an 
emerging area of interest in our laboratory. Aberrant chromosome segregation leads to 
the generation of aneuploid cells as the cells 127. In the TMD231 cells, Vehicle treated 
cells contained about 50% aneuploid cells, whereas following some carboplatin and 
combination treatments, there were small increases in the aneuploid populations 
(>60%). As the TMD231 cells accumulate in S-phase, cell could be undergoing an intra-S-
phase checkpoint in which replication is reduced following DNA damage, which could 
allow cells more time to determine cell fate 121. During accumulation in the S-phase, 
there may be some cells undergoing mitotic catastrophe as a means of survival, which 
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could possibly explain the slight increases in aneuploid cells in the DNA damage treated 
groups. There has been much discussion in the literature to describe the phenotype of 
mitotic catastrophe. Some reports describe that the mitotic catastrophe phenotype is 
similar to apoptosis since there are instances where the cells have condensed chromatin 
aggregates 127. The formation of micronuclei have also been implicated in the mitotic 
catastrophe phenotype 127. Treated cells could be stained with acridine orange, which is 
fluorescent dye that is specific for nucleic acids allowing for specific staining rather than 
non-specific Giemsa-stains, which can lead to overestimation of nuclear abnormalities 
128,129.  
Based on our results, the combination of Nultin-3a and DNA damaging drug 
carboplatin could be used in other cancer models. In our laboratory, we are also 
investigating the combination of Nutlin-3a with standard of care, temozolomide, in 
primary gliobalstoma (GBM) models with both mutant and wild-type p53. We have 
observed Nutlin-3a mediated sensitization to temozolomide in vitro and in vivo in GBM. 
Other standard of care chemotherapeutic drugs could be combined with Mdm2 
inhibition in other cancer models especially in those cancers where Mdm2 is 
overexpressed.  
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Chapter 2. Aim 2: Determination of signaling mechanisms operative in response to 
combination carboplatin and Nutlin-3a treatment in vitro  
 
A. Background and Rationale 
Several studies have demonstrated that Nutlin-3a can affect cells in a p53-
independent manner. Nutlin-3a effectively inhibited the binding of p73α, E2F1, and HIF-
1a to the hydrophobic pocket of Mdm2 in cancer cells 62,65,66. In this next series of 
experiments, our objective was to gain insight into the p53-independent effects of 
Nutlin-3a in combination with carboplatin in the TMD231 mtp53 TNBC cells. We have 
shown that the combination treatment has enhanced effects in inhibiting cell 
proliferation in methylene blue, clonogenic, and cell counting assays as well as increased 
apoptosis and cell cycle arrest. To better understand the signaling mechanisms active in 
our model system following dual carboplatin and Nutlin-3a treatment in vitro, we used a 
series of experiments to understand changes in protein levels, effects of target protein 
knockdown, as well as intracellular localization of Mdm2 following single and dual 
treatment.  
In a p53 mutant background, we reasoned that Mdm2, p73α, and E2F1 could be 
key players in promotion of cell death in the context of carboplatin-mediated DNA 
damage. To gain information on the potential role of these proteins and if they are 
involved in carboplatin/Nutlin-3a-mediated cell death, we tested a series of cell lines 
with stable or transient knockdown of Mdm2, p73 and E2F1. Additionally, carboplatin is 
a DNA damaging drug which leads to the incorporation of Pt adducts leading to bulky 
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lesions in the DNA 14. These Pt adducts can lead to intra and interstrand DNA crosslinks 
and can also lead to DSBs if left unrepaired and ultimately cell death 14.  
As background, Mdm2 has been shown to lead to genomic instability by binding 
to Nbs1, a member of the DNA damage sensing MRN complex 35. Mdm2 binds to Nbs1 
and inhibits its function at recruitment of DNA repair machinery to sites of double 
strand breaks 35. This delay in DNA damage sensing, leads to a delay in DNA repair and 
thus leads to increased genomic instability. With Mdm2 able to antagonize Nbs1 and 
inhibit DNA repair, the increased DNA damage window may allow the threshold of the 
cells to undergo stress to be reached leading ultimately cell death. We wanted to test 
the effects of Mdm2 protein reduction using cells stably expressing shRNA to Mdm2. If 
Mdm2 was a major player in the system, reductions in Mdm2 levels should lessen the 
effects of Mdm2-mediated inactivation of the MRN complex. This would allow the MRN 
complex to sense the DNA double strand breaks and if DNA repair (NHEJ and HR) is 
adequate in the cell, the DNA breaks would be repaired and the cell would survive. We 
found that while a 70% reduction in Mdm2 could be achieved with stable shRNA 
knockdown, this did not change cellular sensitivity to combination treatment. The 
remaining Mdm2 may have been sufficient to block the function of the MRN complex 
and thereby inhibiting repair of DNA double-strand breaks. It appears that there is a 
very small threshold at which Mdm2 can still antagonize DNA repair (personal 
correspondence with Dr. Christine Eischen). As mentioned previously, 27% of breast 
cancers overexpress MdmX with concurrent p53 inactivation as well as 30% of 
aggressive breast cancers also have increased MdmX levels with mutant p53 99. These 
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findings are particularly important since MdmX has also been implicated in genomic 
stability as it plays a role in DNA repair by binding to Nbs1 and inhibiting DNA repair 
independent of p53 and Mdm2 which would be an interesting avenue to follow up in 
this system 99. 
 Additionally, since it has been shown that p73 can upregulate Mdm2 levels by 
binding to the Mdm2 promoter as well as E2F1-mediated upregulation of p73 following 
DNA damage, we wanted to explore the dependency of p73 or E2F1 in our signaling 
mechanism 130,131. E2F1 is a transcription factor that is also important in cell 
proliferation as well pro-apoptotic signaling depending on the cellular context. E2F1 is 
tightly regulated by the retinoblastoma (RB) protein. Following DNA damage, RB is 
phosphorylated by the Chk1/2 kinases leading to decreased association of E2F1 and RB, 
which allows E2F1 to increase its transcriptional activity 131. Following DNA damage, 
E2F1 is involved in pro-apoptotic signaling through upregulation of pro-apoptotic genes 
including p73 and caspase-7 as well as the downregulation of cell cycle progression 
genes including cyclin A2 131. p73 is a family member of p53 and has similar effects 
following DNA damage by increasing PUMA, p21, and Mdm2 78,79,82,130,132,133. We utilized 
lentiviral constructs to stably express shRNA for either p73 or E2F1. Our rationale was 
that if Mdm2, p73, or E2F1 were major signaling mediators in our model system then 
the reduction in protein levels would lead to decreased drug sensitivity. In cells with p73 
and E2F1 transient or stable knockdowns, exposure to carboplatin and Nutlin-3a would 
not lead to enhanced cells death since there would little to no p73 or E2F1 available to 
upregulate pro-apoptotic gene levels. This lack of gene upregulation would lead to 
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increased resistance to treatment due to the lack of apoptosis. While incomplete 
knockdown of the target RNA can preclude one from obtaining interpretable data, the 
levels of shRNAs from stably integrated lentiviral vectors can have a downside and yield 
variable results. Lentiviral vectors randomly integrate into the genome and this can 
result in nonspecific effects on levels of other genes.134. For example, we found that 
some but not all cell lines generated with control vectors that express a GFP shRNA 
(shGFP) could lead to significant changes in drug sensitivity. One shGFP clone used in the 
shE2F1 experiments caused the cells have the highest drug resistance compared the 
shE2F1. The control shRNA vectors made the results difficult to interpret. Because of 
these issues with the stable shRNA transductions, we elected to evaluate p73 
dependency using transient transfections of siRNA specific for p73. In the TMD231 cells, 
the non-targeting control siRNA did not affect cellular sensitivity to drug treatment 
when compared to parental cells in our experiments.  
Nutlin-3a was selected for this project since it was the only Mdm2 inhibitor 
available at the time this project was initiated. It has served as a reliable research tool to 
probe how inhibition of Mdm2 mediated signaling in combination with carboplatin 
mediated-DNA damage affects the growth and survival of TNBC cells with mutant p53. 
Since the advent of Nutlin-3a, there have been several second generation molecules to 
Nutlin-3a (RG7112, Roche/Genentech) as well as numerous Mdm2 inhibitors from 
competing companies: SD-3032b (Baiichi Sankyo Inc.), SAR4058338 (Sanofi), CGM-097 
(Novartis), and AMG-232 (Amgen). Because there are more clinically relevant small 
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molecules being used, we also tested more recently the Nutlin-3a derivative RG7112 in 
combination with carboplatin in our model system.  
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B. Combination treatment affects Mdm2 cellular localization and cellular sensitivity is 
altered following transient transfection of p73 siRNA 
After examining the effects of Nutlin-3a, carboplatin, and combination treatment 
at the cellular level, we wanted to examine the effects of the drug treatments at the 
molecular level. We first used Western blot experiments to evaluate changes in protein 
levels in the treated TNBC cells. Following Nutlin-3a treatment, there were increases in 
Mdm2 protein levels, which has been consistent through my studies (Figure 17) as well 
as the literature 65,66. There were also concentration-dependent increases in p21 
following Nutlin-3a treatment. The 1:1 combination treatment resulted in modest 
increases in Mdm2 protein levels and this correlated with slight decreases in MdmX. 
Mdm2 levels in the combination treated cells were not as high as protein levels in the 
Nutlin-3a alone treated cells though the combination still showed an increase in Mdm2 
levels compared to untreated cells. Interestingly, in the combination treatment, there 
were reductions in MdmX levels whereas the other treatments showed high baseline 
levels that did not change in the single Nutlin-3a or carboplatin treated cells. In wtp53 
cells, it has been shown that following ionizing radiation, MdmX is degraded by Mdm2, 
which allows the levels of p53 to increase leading to DNA repair and/or apoptosis 135,136. 
MdmX is degraded following posttranslational modifications in which ATM is activated 
following DNA damage, which allows for phosphorylation at S403 137. This 
phosphorylation site allows for Mdm2 to target MdmX for degradation by the 
proteasome 137. In our model system, we hypothesize that p73 would induce Mdm2 
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levels and following DNA damage, may then lead to decreased MdmX levels in the 
combination treated TMD231 cells. 
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 Figure 17. Nutlin-3a upregulates Mdm2 protein levels with dose-dependent increases 
in p21 while combination treatment downregulates MdmX. TMD231 cells were seeded 
in 10cm dishes and treated with increasing concentrations of Nutlin-3a, carboplatin, or 
1:1 combination for 24 hours. Cells were treated with vehicle controls (V). Cells were 
lysed with 1% SDS lysis buffer. Following Nutlin-3a and combination treatment, levels of 
Mdm2 were increased with the highest levels of Mdm2 in the Nutlin-3a alone treated 
cells when compared to the untreated control cells. There were dose-dependent 
increases in p21 following Nutlin-3a treatment. Interestingly, Mdm2 levels were slightly 
increased in the combination treated cells while there was a downregulation of MdmX 
in the combination treated cells.   
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 There are several studies indicating the increased capacity of mutant p53 cancer 
cells to have increased invasion 112. There are also studies showing that Mdm2 
overexpression drives invasion through upregulation of MMP9 37. Following Nutlin-3a 
and combination treatments, we observed increases in Mdm2 levels following Western 
blot analysis (Figure 17). We therefore, wanted to test the effects of single Nutlin-3a and 
carboplatin as well as combination treatment on TMD231 cell invasion. The invasion 
assay was designed to measure the amount of cells that are able to pass through a dried 
basement membrane matrix solution and subsequently pass through an 8µm pore-filled 
layer towards a chemoattractant (FBS) containing medium. The cells must be able to 
secrete enough enzymes to be able to pass through the basement membrane matrix. 
This assay not only tests the ability of the cells to migrate into the bottom layer but also 
the ability for the cells to invade through the basement membrane matrix. Following 24-
hour 7.5µM treatment of Nutlin-3a, carboplatin, or combination, there was no 
difference in TMD231 cell invasion between treatment groups compared to Vehicle 
treated cells (Figure 18A). Cytochalasin D was used as a negative control and inhibited 
about 50% of cell invasion compared to Vehicle controls (Figure 18A). Cytochalasin D is a 
mycotoxin that inhibits actin filaments important in cell invasion and migration by 
inhibiting the addition of actin monomers to the end of actin filaments 138. A concurrent 
cell survival experiment was conducted to ensure that the drug treatment did not affect 
total cell survival, which may have made the invasion data difficult to interpret. There 
was no difference in cell survival based on cell counting experiments between single 
drug and combination treatments when compared to Vehicle treated cells at the 24-
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hour time point (Figure 18B). Cytochalasin D itself led to some inhibition of cell viability 
due to its mechanism of action by inhibition of actin filaments, which would be critical 
for normal cell division. This modest inhibition of TMD231 cell viability following 
Cytochalasin D treatment was similar to results as described by Fronczak and colleagues 
using MDA-MB-231 cells (Platypus Technologies, 2011 AACR Abstract #4897).  
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 Figure 18. Single and combination treatment does not affect cell invasion. TMD231 
cells were seeded in cell culture invasion inserts and corresponding 24-well plate with 
3,500 cells per well. Cells were serum starved overnight and treated with 7.5µM Nutlin-
3a, carboplatin, 1:1 combination, or Vehicle for 24 hours. (A) Single drug and 
combination treatment did not affect cell invasion. Cytochalasin D inhibited about 50% 
of cellular invasion. (B) Concurrent cell survival assays showed that the drug treatments 
did not affect total cell number. Cytochalasin D treatment lead to decreased cell 
survival, however this result is expected as inhibition of actin monomers is critical for 
normal cell division.   
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There is a growing body of evidence that Mdm2 has numerous p53-independent 
functions and plays a role in genome stability by binding to Nbs1, which is part of the 
MRN complex, at sites of DNA damage 35. The MRN complex acts as an initial sensing 
mechanism at sites of double strands breaks in the DNA. When the MRN complex 
recognizes these sites, a series of phosphorylation events occur with ATM leading to 
downstream DNA repair signaling. Since we observed increased levels of Mdm2 
following Nutlin-3a and 1:1 combination treatment, we investigated if Mdm2 could be 
differentially localizing in the chromatin fraction where it would presumably inhibit DNA 
repair as described above. In collaboration with Dr. Christine Eischen’s laboratory, 
chromatin association assays were conducted. Following 24-hour treatments, the 
chromatin fraction was isolated and evaluated for Mdm2 protein via Western blot. 
Following a 6-hour drug treatment, Mdm2 levels associated with the chromatin fraction 
in the combination treated cells were higher compared to the single drug treated cells 
or vehicle control (Figure 19A). Whole cell lysates indicated that there were about equal 
amounts of Mdm2 in the Nutlin-3a and combination treated cells (Figure 19B). 
Therefore, in the combination treated cells, more Mdm2 associated with the chromatin 
fraction compared to the single drug-treated cells. It is possible that the increased level 
of Mdm2 at the chromatin could be inhibiting DNA repair by Mdm2 binding to Nbs1 
within the MRN complex. This delay in DNA repair could allow an increased amount of 
DNA damage to accrue causing cells to be pushed towards increased cell death when 
exposed to carboplatin and Nutlin-3a in combination.  
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 Figure 19. Mdm2 protein levels were increased in the chromatin bound fraction in 
combination treated cells. TMD231 cells were treated with Vehicle (DMSO), Nutlin-3a, 
carboplatin (Carbo), or 1:1 combination (Nutlin+Carbo) for 6 hours. Cells were lysed and 
the soluble protein fraction was collected. (A) The chromatin bound fraction was then 
collected and evaluated for Mdm2 levels. H2AX was used as a loading control for the 
chromatin fraction. Graphical representation of densitometry following ImageJ protein 
quantification showed increased levels of Mdm2 in the combination treated chromatin 
fraction compared to the single drug treated Mdm2 levels. (B) Western blot of whole 
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cells lysates showed similar amounts of Mdm2 protein in both the Nutlin-3a and 
combination treated TMD231 cells. β-actin was used as a loading control for whole cell 
lysates. ImageJ densitometry analysis showed a subtle increase in Mdm2 levels in 
combination treated cells compared to Nutlin-3a alone. This was repeated 2 times with 
similar results. 
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Since there were increased amounts of Mdm2 at the chromatin, we used a 
shRNA knockdown approach to evaluate if Mdm2 dependency of drug effect could be 
assessed. We utilized lentiviral transduced TMD231 cells expressing shcontrol or 
shMdm2 that were a kind gift of Dr. Lindsey Mayo. Western blot analysis showed that 
TMD231-shMdm2 had about 70% reduction in Mdm2 compared to the TMD231-
shcontrol cells as evaluated by densitometry using ImageJ software (Figure 20A). All 
densitometry measurements were normalized to GAPDH loading control for each lane. 
Next, we evaluated the effects of Nutlin-3a, carboplatin, or combination treatment on 
cell proliferation in the TMD231-shcontrol and TMD231-shMdm2 cells using methylene 
blue staining. When TMD231-shcontrol and TMD231-shMdm2 cells were compared, 
there were no differences in cell proliferation following Nutlin-3a, carboplatin, and 
combination treatment. No differences in IC50 values between the two cell lines (Figure 
20B) were observed. Based on the methylene blue cell growth assay, knockdown of 
Mdm2 levels by 70% was not sufficient to demonstrate Mdm2-dependency of drug 
effect. In discussions with Dr. Christine Eischen (Vanderbilt University), only small 
amounts of Mdm2 can still block DNA repair. Additionally, partial or complete knock-
down of Mdm2 experiments are difficult to interpret due to potential redundancies of 
Mdm2 and MdmX in blocking the DNA damage response 35,99. As shown in Figure 17, 
while the combination treatment led to a downregulation of MdmX protein levels, 
MdmX was still detected.  
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 Figure 20. Mdm2 protein levels are reduced in TMD231-shMdm2 cells, but this does 
not confer cellular resistance to drug treatment. TMD231 cells were transduced with a 
lentiviral vector either expressing shMdm2 or shcontrol. (A) Western blot analysis 
showed decreased levels of Mdm2 in shMdm2 cells compared to the shcontrol cells. 
ImageJ analysis was used to determine that there was a 72% reduction in Mdm2 protein 
levels in the shMdm2 cells compared to the shcontrol cells. Protein levels were 
normalized to GAPDH loading control. (B) TMD231-shMdm2 and TMD231-shcontrol 
cells were treated with increasing concentrations of Nutlin-3a, carboplatin, or 1:1 
combination for 5 days. Cells were fixed and stained with methylene blue, and cellular 
proliferation was evaluated. shMdm2 and shcontrol cells showed no difference in cell 
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proliferation following increasing Nutlin-3a, carboplatin or combination drug 
treatments. (C) Isobologram analysis for 1:1 combination treatment showed similar 
cellular sensitivity in both TMD231-shcontrol and TMD231-shMdm2 cells.  
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To confirm the effects on growth inhibition we observed using the methylene 
blue proliferation assay, we also used cell counting methods to examine changes in cell 
proliferation in the TMD231-shcontrol and TMD231-shMdm2 cells. TMD231-shcontrol 
and TMD231-shMdm2 cells were treated with DMSO, 15μM Nutlin-3a, 15μM 
carboplatin, and 15μM combination. Total cell counts were determined at Day 3-5 post 
treatment. Pictures of the TMD231-shcontrol and TMD231-shMdm2 cells on Day 3 of 
treatment showed morphological changes in the carboplatin and combination treated 
cells (Figure 21A). Interestingly, according to total cell counts, the shMdm2 cells were 
slightly more sensitive to Nutlin-3a treatment compared to TMD231-shcontrol cells on 
Day 3 and 4 (Figure 21B-C). However, there were no differences in total cell numbers in 
the TMD231-shcontrol and TMD231-shMdm2 cells for all treatments by Day 4 and 5 
(Figure 21C), which is consistent with data from the methylene blue proliferation assay. 
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 Figure 21. Decreased Mdm2 levels do not affect cell growth in the presence of Nutlin-
3a, carboplatin, or combination treatment. TMD231 cells were seeded at 6.5 x 103 per 
well in 12-well plates on Day 0 and treated with 15μM Vehicle (Veh), Nutlin-3a (Nut), 
carboplatin (Carb), or 1:1 combination (Combo). (A) Pictorial representation of TMD231-
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shControl and TMD231-shMdm2 cells on Day 3 post treatment. Magnification was 20X. 
(B) Graphical representation of cell counts on Day 3 from 15µM Nutlin-3a, 15µM 
carboplatin, or 15µM Nutlin-3a + 15µM carboplatin treated TMD231-shControl and 
TMD231-shMdm2 cells. In TMD231-shControl cells, there was no difference in cell 
number between 15µM carboplatin and 15µM Nutlin-3a + 15µM carboplatin 
combination treated cells. In the TMD231-shMdm2 cells, there was a significant 
reduction in total cells in the combination treated cells compared to the carboplatin 
alone treated cells (Student’s t-test, n=3, p<0.05). (C) By Day 4 and 5, the TMD231-
shControl cell counts closely resembled TMD231-shMdm2 and parental TMD231 cells 
with differences in cell numbers between the carboplatin and combination treated cells.   
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In this thesis, our objective was to investigate the p53-independent therapeutic 
potential of Nutlin-3a in combination with carboplatin. To this end, we elected to 
evaluate the role of the p53 family member, p73. Both p73 and p53 function similarly in 
the presence of DNA damage, and can activate the transcription of key target proteins 
involved in apoptosis 78,79,82,132. We first determined to what extent the inhibition of cell 
growth was dependent p73 levels. Two approaches, transient and stable knockdown 
strategies, were utilized to knockdown p73 in TMD231 cells.  
We opted to test the effect of a transient p73 siRNA knockdown approach. We 
utilized the SMARTpool: ON-TARGETplus siRNA for p73 and the ON-TARGETplus non-
targeting pool as a control from Dharmacon (GE Healthcare). The SMARTpool: ON-
TARGETplus siRNA is comprised of 4 different siRNA constructs pooled together for the 
gene of choice. There was significant p73 knockdown in the cells collected on Day 1 and 
2-post transfection with reductions of p73 by 79% as measured by densitometry (Figure 
22A). By Day 3 post transfection, the levels of p73 started to increase with knockdown 
of p73 less than 50% (data not shown). Wang et al. have demonstrated that Mdm2 can 
be a downstream transcription target of p73 and our data are consistent with their 
observations (Figure 22BA) 130. Western analysis confirmed that decreased p73 levels 
correlated with decreased Mdm2 levels. (Figure 22B). The reductions in Mdm2 were 
about 71% and 65% at Day 1 and Day 2 post transfection, respectively. In the transient 
siRNA approach Mdm2 was knocked down to a larger degree (65-75% reduction) than in 
cells with the stable shp73 approach (30-37% reduction) (Figure 23B and Figure 24C). All 
densitometry measurements were normalized to GAPDH loading control for each lane. 
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We also probed sip73 cell lysates for MdmX, which has also been shown in the literature 
to bind to Mdm2 as well as have similar effects at the chromatin (Figure 22B) but did not 
observe any changes in MdmX levels 99.  
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 Figure 22. Transient transfection inhibited p73 levels for 2 days post transfection and 
this correlated with decreased Mdm2 levels. p73 knockdown increases resistance to 
carboplatin mediated-DNA damage. TMD231 cells were transfected with SMARTpool: 
ON-TARGETplus TP73 siRNA or ON-TARGETplus Non-targeting Pool. (A) Western blot 
analysis of p73 levels TMD231-sicontrol and TMD231-sip73 cells showed decreases in 
p73 in the TMD231-sip73 cells compared to TMD231-sicontrol cells. Graphical 
representation of p73 protein levels showed 79% reduction in p73 protein levels the 
TMD231-sip73 compared to TMD231-sicontrol cells on both 1 and 2 Days post 
transfection. Blot densitometry was evaluated using ImageJ. Protein levels were 
normalized to GAPDH loading control. (B) Interestingly, the levels of Mdm2 were 
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decreased in the TMD231-sip73 cells compared to the TMD231-sicontrol cells. Reduced 
p73 levels did not affect the levels of MDMX. Graphical representation of Mdm2 
densitometry as determined using ImageJ showed 71% and 67% decreases in Mdm2 
levels in the TMD231-sip73 on Days 1 and 2-post transfection, respectively. Protein 
levels were normalized to GAPDH loading control.  
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Next, we evaluated treatment sensitivity of p73 siRNA transfected cells 
compared to a non-targeting siRNA control cells using methylene blue proliferation 
assays. There were no differences in the IC50 values for the Nutlin-3a treated TMD231-
sicontrol and TMD231-sip73 treated cells (Figure 23). However, in both the carboplatin 
alone and combination treated cells, there was a significant increase in IC50 values for 
the TMD231-sip73 cells compared to the TMD231-sicontrol cells (Figure 23). These 
results support our hypothesis that reduced p73 levels would decrease sensitivity to 
drug treatment. p73 signaling is important following DNA damage, which is caused by 
carboplatin. When p73 levels are reduced, there is less protein available to signal for 
pro-apoptotic proteins to be produced. Additionally, with less p73 present, there is also 
less Mdm2 present. It is not clear at this time why we did not see decreased sensitivity 
in the shp73 model but this could be related to differences in Mdm2 reduction seen in 
the stable versus transient knockdown approaches.  
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 Figure 23. Sensitivity to carboplatin mediated-DNA damage is dependent on p73 levels 
in mtp53 TMD231 cells. TMD231 cells were transfected with SMARTpool: ON-
TARGETplus TP73 siRNA or ON-TARGETplus Non-targeting Pool siRNA. On Day 1 post 
transfection, cells were seeded and treated with increasing concentrations of Nutlin-3a, 
carboplatin, and 1:1 combination for 3 days. Cell proliferation was evaluated using 
methylene blue staining. IC50 values were determined using Calcusyn. Cellular sensitivity 
to Nutlin-3a treatment was not inhibited by p73 knockdown. p73 inhibition led to 
decreased sensitivity to carboplatin treatment compared to non-targeting control cells. 
There was a significant increase in IC50 value for the carboplatin treated sip73 cells 
(80.1±13.4µM) compared to the control cells (37.7±3.3µM) (Student’s t-test, *p<0.05, 
Carb siCon vs sip73, n=5, ±SD). Similar effects were seen with the 1:1 combination 
treated cells with the p73 knockdown cells being less sensitive to drug treatment. There 
was a significant increase in IC50 value for the 1:1 combination treated sip73 cells 
(20.8±6.3µM) compared to the control cells (11.7±2µM siCon) (Student’s t-test, 
**p<0.05, Combo siCon vs sip73, n=5, ±SD).  
 125 
For stable p73 knockdown, TMD231 cells were first transduced with 7 different 
lentiviral constructs to generate stable lines, and positively transduced cells were 
selected with puromycin. p73 levels were evaluated by Western blot. Two of the clones 
shp73-3-500 and shp73-4-500 exhibited the most knockdown and were selected for 
further study. We examined the levels of p73 and both of the shp73 constructs resulted 
in >90% knockdown of p73 (Figure 24A-B). Since we observed decreased levels of Mdm2 
in the sip73 cells, we also examined the effects of shRNA to p73 on Mdm2 protein 
levels. In non-treated TMD231 cells with the shp73 constructs, there was about 30-40% 
reduction in Mdm2 levels as determined by densitometry using ImageJ software (Figure 
24C). All densitometry measurements were normalized to GAPDH loading control for 
each lane. It has been shown in the literature that p73 can bind to the promoter of 
Mdm2 in increase its levels. Therefore, with less p73 present in the cells, there is a 
reduction in Mdm2 being produced by p73 activation 130.  
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 Figure 24. p73 protein levels are reduced in TMD231 cells stably transduced with 
shp73 lentiviral vectors and p73 decreases correspond to decreases in basal Mdm2 
protein levels. TMD231 cells were transduced with lentiviral vectors expressing 
Scrambled control (Scr-500) and two constructs for shp73 (3-500 and 4-500). 
Transduced cells were selected using 2.5μg/mL puromycin for 2 days. All experiments 
were conducted under selective pressure. (A) Western blot analysis of p73 and Mdm2 in 
two different TMD231-shp73 cell lines. (B) p73 levels were greatly reduced in two shp73 
(3-500 and 4-500) lines compared to the scrambled (Scr-500) control using ImageJ 
analysis. Protein levels were normalized to GAPDH loading control. (C) Interestingly, the 
two TMD231-shp73 cells lines also showed decreased levels of Mdm2. The Mdm2 
protein levels were quantified using ImageJ. Protein levels were normalized to GAPDH 
loading control.   
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Next, we evaluated the effects of reduced p73 protein levels on cellular 
sensitivity to Nutlin-3a, carboplatin, or combination treatment using methylene blue 
proliferation assays. We expected that if p73 protein levels were reduced, the cells 
would less sensitive to drug treatment since there would be less p73 available to be 
involved with pro-apoptotic signaling. Also, with less p73 present, there would be less 
Mdm2 present. With less Mdm2 present, there would be less Mdm2 available to go to 
the nucleus and inactivate Nbs1 in the MRN complex. However, through discussions 
with Dr. Christine Eischen, very small amounts of Mdm2 can still locate to the chromatin 
and antagonize DNA repair through interactions with Nbs1. Knockdown of Mdm2 may 
lead to confounding data especially with the Mdm2/MdmX interplay and both of their 
roles on genomic instability. In the shp73 experiments, there was no difference on cell 
proliferation without any changes in IC50 values between the scrambled control and 
shp73 cells for Nutlin-3a, carboplatin, and combination treatments (Figure 25).  
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Figure 25. Possible off-target effects of stable lentiviral vector integration in TMD231 
cells (shp73 versus shGFP control) impact ability to determine cellular sensitivity to 
single or dual drug treatment. TMD231-Scr and two TMD231-shp73 (3-500 and 4-500) 
cell lines were seeded in 96-well plates and treated with increasing concentration of 
Nutlin-3a, carboplatin, and 1:1 combination for 5 days. Cells were under selective 
pressure throughout the experiment with the presence of 2.5μg/mL puromycin. Cells 
were fixed and stained with methylene blue. Cell proliferation was examined, and both 
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TMD231-shp73 lines showed that cell proliferation was not different from TMD231-Scr 
cells following Nutlin-3a (A), carboplatin (B), or 1:1 combination (C) drug treatment.   
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 In the literature, it has been shown that Mdm2 can also bind E2F1. The binding 
of E2F1 to Mdm2 can be inhibited with Nutlin-3a 65. We wanted to evaluate the effects 
of E2F1 in our cellular mode by utilizing shRNA for E2F1. Several constructs were 
transduced into TMD231 cells, and following initial Western blot screening, constructs 
327 and 328 showed the best knockdown of E2F1 (data not shown). However, the 
knockdown was about 50% and 30% for constructs 327 and 328 respectively, we opted 
to select TMD231 clones of the shGFP and shE2F1 327 and 328 to see if we could get 
clonal populations with a high efficiency of E2F1 knockdown. A series of clones were 
screened for E2F1 protein levels by Western blot (Figure 26A). One clone in particular, 
328-6, had >90% knockdown of E2F1 (Figure 26B). Proliferation assays were completed 
with the shE2F1 clone 328-6 and two shGFP clones, GFP-3 and GFP-6, to evaluate the 
effects of E2F1 knockdown on cell sensitivity to Nutlin-3a, carboplatin, and combination 
treatment using methylene blue proliferation assays. Following analysis, the effects of 
drug treatments were difficult to interpret due to the shGFP control clones being 
similarly resistant to treatment or more resistant than shE2F1 clones (Figure 27). Since 
we have had trouble with the shcontrol vectors in the p73 model, it would be of great 
interest to repeat these experiments using siRNA to E2F1 and examine the effects of 
Nutlin-3a, carboplatin, and 1:1 combination treatment.  
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 Figure 26. TMD231-shE2F1 clone 328-6 had a significant reduction in E2F1 protein 
levels. TMD231 cells were transduced with lentiviral vectors expressing shGFP or 
shE2F1. (A) Clones were derived from the shGFP and shE2F1-327, and -328 constructs. 
Western blot analysis for several different clones showed one clone with significant 
reductions in levels of E2F1 (328-6). Protein levels were normalized to GAPDH loading 
control. (B) E2F1 levels were greatly reduced in one clone, shE2F1-328-6 compared to 
shGFP-3 using densitometry analysis with ImageJ software. 
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 Figure 27. Lentiviral transduction of shRNA to E2F1 results in confounding data due to 
cellular drug resistance in shGFP control cells. TMD231 parental, TMD231-shGFP-3, 
TMD231-shGFP-6, and TMD231-shE2F1 (328-6) cells were evaluated for cellular 
sensitivity to Nutlin-3a, carboplatin, and 1:1 combination treatment using methylene 
blue proliferation assays. Cells were seeded in 96-well plates and treated with increasing 
concentrations of Nutlin-3a, carboplatin, and 1:1 combination for 5 days. (A-B) TMD231-
shE2F1-328-6 cell proliferation was not different from TMD231-GFP-3 cells following 
Nutlin-3a and carboplatin. (C) shGFP cells were not different from shE2F1 cells following 
combination treatment.   
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As mentioned previously, Nutlin-3a was the first generation Mdm2 PPI to be 
studied in detail by Vassilev and colleagues 40 and has been used by many laboratories 
as a pre-clinical tool to study the effects of inhibiting protein-protein interactions with 
Mdm2 and its binding partners. As of 2014, there are now numerous second and third 
generation inhibitors some of which are currently being tested in clinical trials 
(www.clinicaltrials.gov). One these second generation molecules is a Nutlin-3a 
derivative compound, RG7112, which has increased potency (about 2X more potent 
than Nutlin-3a) and also has improved bioavailability and PK parameters in vivo. RG7112 
has been used in Phase I clinical trials treating solid tumors and hematological 
neoplasms. In the past year, the RG7112 has become available to the research 
community. Therefore we elected to compare effects of RG7112 in combination with 
carboplatin. In TMD231 cells, RG7112 was approximately 2X more potent than Nutlin-3a 
as indicated by IC50 values (Figure 28A). However, the 1:1 combination of RG7112 and 
carboplatin was not as robust as Nutlin-3a+carboplatin and tended to produce an 
additive effect instead of a synergistic effect (Figure 28B). Additionally, RG7112- and 
Nutlin-3a-mediated effects on Mdm2 levels were compared via Western blot. RG7112 
and Nutlin-3a treatment both induced Mdm2 levels, with RG7112 and Nutlin-3a 
inducing Mdm2 levels following 5µM and 10µM drug treatment (Figure 28C). At 20µM 
of RG7112 there was decreased levels of Mdm2, however, the cells were highly stressed 
and beginning to break down which may have affected the protein levels observed 
(Figure 28C).  
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 Figure 28. Nutlin-3a analogue, RG7112 alone, is more potent in TMD231 cells. TMD231 
cells were treated with Nutlin-3a and second generation, RG7112, alone and in 
combination with carboplatin. TMD231 cells were seeded in 96-well plates and treated 
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with increasing concentrations of Nutlin-3a, RG7112, carboplatin, and combination 
treatments for 5 days. Cell proliferation was evaluated using methylene blue staining. 
(A) RG7112 alone is about twice as potent as Nutlin-3a alone with IC50 values half that of 
Nutlin-3a. However, RG7112 in combination with carboplatin is not as potent as Nutlin-
3a in combination with carboplatin. (B) Isobologram analysis for 1:1 Nutlin-
3a+carboplatin and 1:1 RG7112+carboplatin was evaluated. Nutlin-3a in combination 
with carboplatin had lower IC50 values compared to the combination of RG7112 and 
carboplatin. (C) RG7112 and Nutlin-3a treatment both induced Mdm2 levels, with 
RG7112 and Nutlin-3a inducing Mdm2 levels following 5µM and 10µM drug treatment.  
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C. Discussion and Future Directions 
Nutlin-3a treatment increased Mdm2 levels with a corresponding dose-
dependent increase in p21. Lau and colleagues showed that in p53 null cells, Nutlin-3a 
treatment led to increases in Mdm2; however, the mechanism by which Mdm2 
increased was not determined 66. Wang et al. demonstrated that p73α can bind to the 
promoter of Mdm2 and increase Mdm2 levels using luciferase constructs 130, which may 
explain why levels of Mdm2 increase following Nutlin-3a treatment and why when p73 
is knocked down, there are decreases in basal levels of Mdm2. Through collaborations 
with Dr. Lindsey Mayo, we have luciferase constructs bearing the Mdm2 promoter in 
which we can test if p73 plays a role in promoting Mdm2 levels. We can also utilize the 
siRNA to p73 with co-transfection with the Mdm2 promoter luciferase constructs to 
visualize the dependency of p73 in this system. Additionally, we have p21 and PUMA-
promoter-luciferase constructs to examine the effects on down targets in our model 
system. These experiments are ongoing in the laboratory. We did not observe notable 
changes in p73 or E2F1 protein levels following Western blot following increasing Nutlin-
3a, carboplatin, or 1:1 combination treatment at 24 hours. While we did not observe 
increases in protein levels, increased protein stabilization, post-translational 
modifications, and/or subcellular relocalization of the protein may lead to downstream 
molecular changes in the cell. The protein-protein interactions between Mdm2 and 
E2F1 and Mdm2 and p73 should be examined following Nutlin-3a to ensure that in our 
system, Nutlin-3a inhibits the binding of Mdm2 from both E2F1 and p73. Preliminary 
results show decreased Mdm2 and p73 association following Nutlin-3a treatment in co-
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immunoprecipitation experiments. Additionally, Dr. Mayo has generously provided 
dominant negative p73 and control constructs (p73DD and p73DD (L371P)) which can 
oligomerize with wild-type p73 and inhibits downstream p73-mediated effects by 
blocking the p73 DNA-binding 132,139. The use of the dominant negative p73 construct 
could be used to confirm our siRNA p73 experiments showing that p73-mediated 
signaling is important following carboplatin-induced DNA damage. Also, there may be 
small changes in protein levels that cannot be detected by Western blot that may lead 
to important protein signaling events. Our next step is to utilize quantitative RT-PCR to 
examine the effects of single and dual treatment on mRNA levels changes in Mdm2, 
p73, E2F1, and PUMA. These data may be a more sensitive measure of the activity of 
mRNA upregulation in our system. The role of ΔNp73 should also be evaluated since it 
acts to negatively regulate Tap73 isoforms 140. The ΔNp73 isoform also can act to 
negatively regulate wild-type p53, which would be important in that molecular context 
if ΔNp73 is signaling aberrantly 140. Additionally, ΔNp73 can inhibit TAp73 and p53 by 
competing for binding sites at the chromatin and thus inhibiting target gene expression 
141. More studies would need to be completed to more fully understand the role of 
ΔNp73 in our model system. 
While we did not see increases in PUMA protein levels (Figure 17), expanded 
time course studies and cell synchronization studies may help to discern if PUMA is a 
major player in our model system. Through collaborations with Dr. Lindsey Mayo, we 
also have luciferase constructs for the p21 and PUMA promoters, which may help to 
understand the effects of dual Nutlin-3a and carboplatin treatment on gene levels. 
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Expanded time courses may show increased protein levels, however, as mentioned 
above, some of these drug effects may mediate increased protein activity and/or re-
localization of proteins rather than increases in protein levels. These studies are ongoing 
in the laboratory. In the TMD231 model, some experiments have shown increases in 
p73 protein levels following carboplatin or combination treatment while other 
experiments exhibited very high levels of basal p73α. It has also been shown in the 
literature, that the epidermal growth factor receptor (EGFR) and a constitutively active 
variant (EGFRvIII) can play a role in inhibition of apoptosis by inhibiting PUMA. In some 
instances, EGFR is able to evade lysosomal-mediated degradation and can traffic to 
other organelles within in the cell including the mitochondria 142. When EGFR is located 
at the mitochondria, it was shown to bind to PUMA inhibiting pro-apoptotic signaling 
143. Constitutively and while under stress conditions, EGFR and EGFRvIII can bind to 
PUMA, sequester PUMA in the cytoplasm, and inhibit its translocation into the nucleus 
143. In our model system, >95% of the TMD231 cells express the EGFR on the cell surface 
(data not shown) and whether PUMA interacts with EGFR in TMD231 cells has not been 
studied. More work would need to be completed to better understand the interplay 
between EGFR and PUMA interactions within our model system. 
It has also been shown in the literature that Yap1 plays dual roles in the cell by 
blocking upregulation of Itch (ligase that can ubiquitinate p73α) as well as stabilizing 
p73α and increasing upregulation of pro-apoptotic gene levels 75-77. Enhancement of 
Yap1 interaction with p73 in the context of DNA damage may lead to an enhanced 
cellular response when combined with Nulin-3a and carboplatin in our model system. It 
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has been shown that the inhibition of Akt-mediated phosphorylation of Yap1 led to 
increased nuclear localization of Yap1 to bind to p73 and induce apoptosis 144. Studies 
by Mayo and Donner showed that Mdm2 is phosphorylated at Serine 166 and 186 by 
Akt, resulting in the relocation of Mdm2 to the nucleus 43. If Akt signaling is aberrant in 
our model, there could be increased Akt activity leading to more Mdm2 in the nucleus. 
Mass spectrometry could be used to examine the phosphorylation status of Serines 166 
and 186 in our model. There are also commercially available antibodies for both 
phospho- serine 166 and 186 to examine these phosphorylation sites by Western blot. 
These changes in Mdm2 localization could influence the fine balance between life and 
death. Several Akt inhibitors are currently being used in clinical trials specifically treating 
breast cancers including MK2206 145, GSK2141795 (GSK), and AZD5363 (AstraZeneca) 
(clinicaltrials.gov). Inhibition of Akt signaling may increase the multi-targeted effect of 
combination Nutlin-3a and carboplatin in TNBC cells with mutant p53. Ongoing studies 
in the laboratory have indicated that combination second-generation Mdm2 antagonists 
and AKT inhibitors are synergistic in inhibiting growth of primary patient-derived GBM 
cells in vitro (unpublished observations, Ding, Saadatzadeh, and Pollok). 
Following combination treatment, chromatin association assays revealed 
increased Mdm2 in the chromatin fraction compared to single drug alone. Increased 
association of Mdm2 with the chromatin fraction may account for why cells are more 
sensitive to combination treatment. As described earlier, Eischen and colleagues 
previously demonstrated that localization of Mdm2 in the chromatin fraction correlated 
with Mdm2 specifically binding to Nbs1 leading to inactivation of the MRN complex and 
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inhibition of DNA repair due to a block in the cell’s ability to signal that DNA damage has 
occurred 35. This delay in repair may be essential in deciding cell fate and pushing the 
treated cells towards cell death. To provide further information on the outcome of 
increased localization of Mdm2 in the chromatin following combination treatment, 
future studies could focus on determining to what extent Mdm2 specifically binds to 
Nbs1 in the MRN complex following treatment. Co-immunoprecipitation experiments 
could be conducted from lysates isolated from the chromatin fraction to examine the 
binding of Mdm2 and Nbs1. This is especially important as Mdm2 can also bind to the 
promoter of genes to upregulate transcription as well binding to other transcriptional 
factors at the chromatin 92,146,147. Additionally, it would be informative to follow up on 
determining the effects of combination treatment on MdmX levels at the chromatin 
since it has been shown that MdmX can act similarly as Mdm2 and inhibit Nbs1 in the 
MRN complex following DNA damage 5.  The knockdown of Mdm2 by shRNA were not 
interpretable due to the fact that Mdm2 levels could not be completely knocked down. 
As described in detail earlier, Mdm2 is a multi-functional protein that plays a role in 
numerous aspects of growth and survival; therefore, complete knockdown of Mdm2 is 
unlikely.  
Increasing our understanding of the DNA damage/repair kinetics following 
carboplatin and Nutlin-3a combination treatment will also be important in future 
studies. We explored technologies that would help us gain a better understanding of the 
DNA damage/repair kinetics in model systems used within our laboratory. In the 
TMD231 cells, inductively-coupled plasma mass spectrometry (ICP-MS) was used to 
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quantitatively ascertain the amount of platinum adducts bound to DNA from extracted 
DNA samples from single and combination treated cells overtime. However, while there 
were trends showing increased levels of Pt adducts bound to DNA in combination 
treated cells, the assay was highly variable and we elected to re-prioritize our approach. 
The role of combination carboplatin and Nutlin-3a treatment on the NER pathway 
should also be examined to see if Nutlin-3a leads to any inhibition in the NER pathway. 
Additionally, as DNA damage continues to accumulate in cells, the role of HR will also 
become important as DNA double strand breaks form and the role of Mdm2-mediated 
inhibition of Nbs1 should be examined in this context.  
Stable levels of shRNA that target p73 and E2F1 via lentiviral vectors led to 
decreased levels of target proteins. However this did not confer altered cellular 
sensitivity to any of the drug treatments. These data are difficult to interpret due to the 
off target effects of the control vectors used. Based on our data, transient transfection 
of p73 lead to decreased cellular sensitivity to carboplatin and combination treatments 
with significant increases in IC50 values in the p73 knockdown cells compared to control 
knockdown cells. Experiments are ongoing in the lab utilizing siRNA to E2F1 to 
determine if the effects of reduced E2F1 in our system following combined Nutlin-3a 
and carboplatin treatment. Our hypothesis is that when E2F1 levels are reduced, the 
cells should be less sensitive to DNA damaging treatment since there will be less E2F1 
present to upregulate pro-apoptotic genes.  
While the clinical grade Mdm2 antagonist RG7112 and carboplatin are 
synergistic in inhibiting growth of TMD231 cells, it is interesting to note that the growth-
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inhibition effect was less potent than the Nutlin-3a:carboplatin combination. The IC50 
for the RG7112:carboplatin combination was 7.1±0.4µM compared to 1.2±0.3µM for 
the Nutlin-3a:carboplatin combination. More studies would need to be completed with 
RG7112 or other Mdm2 inhibitors to better understand the differences in these 
compounds and the subsequent effects in cancer. This difference in potency when 
RG7112 is combined with carboplatin compared to Nutlin-3a/carboplatin combination 
treatments, may have to do with increased selectivity of the RG7112 for the Mdm2 
binding pocket in the context of p53 and not with other Mdm2 binding partners. While 
it is well documented that p73α interacts with N-terminal hydrophobic pocket, it is 
possible that binding in the pocket is slightly different. It is not known as this time to 
what degree RG7112 can block binding of p73α to the hydrophobic pocket of Mdm2 and 
this is currently being investigated in the laboratory. We have also seen similar 
differences in RG7112 and Nutlin-3a combinations with DNA damaging drug, 
temozolomide in wtp53 GBM and neuroblastoma cells suggesting that either selectivity 
for the Mdm2 binding site or other off-target effects could be the underlying reason for 
the difference in potency of effect between RG7112 and Nutlin-3a. 
RG7112 is currently being used in several Phase I clinical trials treating 
hematologic neoplasms (NCT00623870) and advanced solid tumors (NCT00559533) 
(clinicaltrials.gov). Results from clinical trials showed that the major dose-limiting factor 
toxicity was thrombocytopenia. Iancu-Rubin et al. reported that RG7112 leads to 
thrombocytopenia through two distinct mechanisms: the RG7112-mediated p53 
activation affected megakaryocytopoiesis and impaired platelet production 148. The 
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effects were reversible following cessation of treatment indicating that optimization of 
dosing schedules will be key for future trials. Higgins and colleagues showed dosing with 
another second generation Nutlin-3a compound, RG7388, that a 50mg/kg weekly dose 
was equivalent in efficacy to 10mg/kg daily dosing in an osteosarcoma model showing 
that intermittent dosing schedules may be better in the clinic since RG7112 did not have 
high patient tolerability 149. Drug dosing optimization will be important in the design of 
both animal and clinical studies utilizing these new therapeutic agents.  
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Chapter 3. Aim 3: Development and validation of in vivo animal model of human 
triple-negative breast cancer 
 
A. Background and Rationale 
The use of in vitro cell culture continues to be the initial screen for assessing the 
potential of new therapeutic approaches. In vitro cell culture allows the investigator to 
evaluate cellular sensitivity to drugs and delve into in signaling mechanisms altered by 
anti-cancer agents. However, to fully evaluate the promise of a new therapy, in vivo 
models that can assess drug efficacy and toxicity need to be included. In this thesis 
project, we focused on TNBC that forms metastatic lesions in the lung and first elected 
to determine if we could improve upon the current in vivo models that utilized Nude 
mice. While there are murine models of breast cancer, these models only study mouse 
cellular sensitivity to the drugs and are not as clinically relevant human models. To study 
human breast cancer in mouse models, we must utilize mouse models in which the 
immune system is not intact so that the human cells are not the targets of the murine 
immune system. As described previously, there have been numerous types of 
immunocompromised mouse models used to study human cancers through the years. 
However, based on available mouse models, we chose to examine the tumor growth 
and metastasis kinetics of the TMD231 human breast cancer cells in two different 
mouse strains, NOD/scid and NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. Both of these 
mouse strains have severely compromised immune systems.  
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 Nod/scid mice were developed following the development of nude mice to 
provide an enhanced immune compromised mouse strain better equipped to study 
human hematopoietic cells and human cancers. While Nod/scid mice produce defective 
natural killer (NK) cells, there is still some residual NK activity, and the mice have a high 
incidence of thymic lymphoma. NSG mice were developed in an effort to create mice 
suitable to study human blood diseases. NSG mice allow for the engraftment of human 
peripheral blood and bone marrow. In NSG mice, there is increased engraftment of 
malignant and nonmalignant human hematopoietic cells. NSG mice do not produce NK 
cells due to the lack of normal interleukin 2 (IL-2) receptor expression, which prevents 
normal NK-cell development. NSG mice also have a very low incidence of thymic 
lymphoma with increased life expectancy 23. NK cells are involved in recognizing cells 
that are in stressed states in which stress ligands are expressed on the exterior of the 
cell 150. Additionally, NK cells recognize ‘non-self’ ligands expressed on the cell surface 
and especially detecting circulating tumor cells. It was shown mouse NK cells can be 
involved in the rejection of tumors in vivo, and this was dependent on the tumor cells 
expressing NK ligands 151. The absence of NK cells in the NSG mice would allow for 
better tumor engraftment especially with the use of human cancer cells. The 
comparison of mouse strain allowed for the optimal mouse strain to be used to ensure 
consistent tumor take as well as validate the metastasis from the primary tumor to the 
lung.  
The need for a sensitive measure of tumor burden in a non-invasive manner is 
needed when using animal models to study human cancers. Measurements of primary 
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tumor volume by caliper have been an accepted way to determine tumor volume; 
however, the tumor must be palpable to ensure accurate measurements. When 
studying aggressive cancer models, the need to begin drug therapy at an early time 
point in tumor development is highly critical especially since in many tumors, there is a 
size threshold in which efficacy and length of treatment of window is impacted. To this 
end, our objective was to design an animal model in which the tumor cells could be 
visualized and accurately measured in non-palpable tumors growing under the 
mammary fat pad. There are numerous imaging modalities that would allow for the 
sensitive detection of tumors in vivo. Bioluminescent imaging is very sensitive but there 
are some disadvantages. The substrate for bioluminescent imaging must be injected 
into mice in which delivery can be impacted depending on tumor location. Additionally, 
the mice must be in general good health and well-hydrated otherwise blood flow can be 
altered and this could easily alter delivery of the luciferin substrate to the site of the 
tumor cells. Scans are typically 20-45 minutes for BLI. While bioluminescent imaging is 
very sensitive, the disadvantages outlined here would need to be evaluated in the 
design of animal studies and the questions posed.  
Using fluorescent imaging, the tumor cells express a fluorescent protein. Using 
an optical imager, the fluorescent protein can be excited using a laser and the emission 
can be captured using a camera. Fluorescent imaging allows for a snapshot of the 
fluorescent intensity to be collected in less than 10 minutes. The biggest advantage of 
fluorescent imaging is that it excludes problems associated with delivery of a substrate 
due to compromised blood flow to the tumor. There does need to be careful planning 
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when choosing a fluorescent protein to use for in vivo imaging. The excitation and 
emission spectra should be optimized for the specific laser/filter set in the optical 
imager. Also, some fluorescent proteins overlap with other proteins that auto-fluoresce. 
For example, the excitation/emission spectra for the green fluorescent protein (GFP) is 
also within the range of auto-fluorescence of hemoglobin as well as chlorophyll which is 
often added to murine food sources 152. The use of near-infrared (NIR) proteins 
eliminates much of the signal loss due to surrounding tissues as well as auto-fluorescent 
proteins 152. In our system, we opted to use the far-red fluorescent protein, E2-Crimson, 
which was optimal for the laser/filter set of the optical imager, Optix MX3 (ART 
Technologies). Following implant, the TMD231 cells expressing the E2-Crimson 
fluorescent protein (TMD231-CR) could be visualized as early as two hours following 
implant. We used the TMD231-CR cells to visualize and measure fluorescent intensity as 
a measure of tumor volume which could be used to randomize the mice into treatment 
groups at a very early time point (Day 7). 
 Throughout the fluorescent protein in vivo imaging validation process, a series 
of studies were used to determine the relationship between fluorescent intensities 
measured by in vitro and in vivo imaging and cell number. We tested the imaging 
sensitivity of the Optix MX3 (ART Technologies) with our TMD231-CR cells both in vitro 
and in vivo to better understand the fluorescent intensity measurements as they related 
to cell number. We also validated if fluorescent intensity correlated to tumor volume in 
vivo to determine if fluorescent imaging would be a feasible way to measure tumor 
volume in non-palpable tumors. Initial tumor burden could be accurately assessed by 
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this methodology and mice randomized into treatment groups based on the photon 
emission. However, we also discovered that evaluation of treatment effects by 
fluorescent imaging was not possible due to tissue attenuation of signal, lack of depth 
sensitivity, and possible presence of residual E2-Crimson protein in the tumor mass.  
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B. In vivo animal model optimization and validation of fluorescent imaging 
The types of immunodeficient mouse strains have vastly improved over the past 
decade and offer an opportunity to explore and optimize the use of the metastatic 
breast cancer cell line TMD231. Our laboratory as well as others has found that 
NOD/scid and NSG mice provide a tumor microenvironment that increases tumor take 
frequency and consistently provides mice with similar baseline tumor sizes. The MDA-
MB-231 cells were originally passed through Nude mice, and tumors were resected and 
grown in culture forming the TMD231 cell line 17. We compared two different 
immunodeficient mouse strains, NOD/scid and NSG to evaluate the kinetics of tumor 
growth and metastasis to the lung. Over time, the primary tumors in the NSG mice grew 
larger and at a faster rate compared to the tumors implanted in the NOD/scid mice 
(Figure 29A). During the study, groups of mice were also sacrificed starting at 28 days 
post-implantation of TMD231 cells. In NSG mice, metastases in the lungs were evident 
as early as 28 days post implant and the number of metastatic foci increased over time 
at Days 35 and 49 days post implant. However, in the NOD/scid mice, metastases in the 
lungs were not detected until 72 days post implant (Figure 29A inset graph). H&E 
staining of excised lungs confirmed metastases in the lungs of NSG mice implanted with 
TMD231 cells in the mammary fat pad (Figure 29B; compare normal mouse lung (i) to 
multiple metastatic foci (ii) in the lungs). Many of the lung foci were large and coalescing 
into one another (iii). Tumor emboli were observed in some mice blocking blood flow 
within in the lungs (iv). Circulating tumor cells were also observed within the blood 
vessels of the lungs (v). The mitotic index was high with about 4+ mitotic figures per 
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high power field (vi). Based on the increased tumor growth kinetics and improved 
metastasis to the lungs in the NSG mice, we chose to continue our future animal studies 
using NSG mice.   
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 Figure 29. TMD231 tumor and metastasis is increased in NSG mice compared to 
NOD/Scid mice. NOD/scid and NSG mice were implanted with 1x106 TMD231 cells into 
the mammary fat pad and allowed to grow. Tumor growth in the mammary fat pad was 
monitored via caliper over time. Mice were sacrificed throughout the study to evaluate 
the formation of lung metastases. (A) Tumors had increased growth kinetics in the NSG 
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mice compared to NOD/scid mice. Additionally, there were increased lung metastases 
with foci detected as early as 28 days post implant. Metastases were not detected in 
NOD/scid mice until 72 days post implant. (B) Histology using H&E staining confirmed 
metastases in the lungs of NSG mice implanted with TMD231 cells in the mammary fat 
pad. Normal mouse lung (i) compared to multiple metastatic foci (ii) in the lungs. 
Metastatic foci were numerable (>50 small to moderate foci to too numerous to count). 
Many of the foci were large and coalescing into one another (iii). Tumor emboli were 
observed in some mice blocking blood flow within in the lungs (iv). Circulating tumor 
cells were also observed within the blood vessels of the lungs (v). Mitotic index was high 
with about 4+ mitotic figures per high power field (vi). 
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In the development of the in vivo animal model to study human breast cancers, 
we discovered it was necessary to develop a more sensitive and accurate measure of 
early tumor burden especially since the TMD231 are very aggressive growing cells in 
vivo. We were looking for a non-invasive, easily measureable, and highly sensitive 
manner in which to determine early tumor burden. Once the mammary fat pad tumors 
become palpable, we determined that the treatment window is very short and can 
prevent the use of full treatment schemas. Before this model optimization was 
conducted, it routinely took nearly two weeks of tumor growth before most tumors 
would be measurable using a caliper. The endpoint of the studies was reached when the 
primary tumors reached ~1000mm3 tumor volume which took about 6-8 weeks when 
1x106 TMD231 cells were implanted into the mammary fat pad. Since the study time 
frame was typically about 8 weeks, there was not much time remaining for drug 
treatments. At the initiation of treatment, our objective was to start with a reasonable 
tumor volume so that the tumor to body size ratio of the mice was comparable to the 
tumor to body size ratio we might find in clinical situations (topic presented by Dr. Susan 
Clare, "Delivery of nanovectors in vivo by hitching a ride with the Immune System” at 
Drug Delivery and Cancer: Challenges and New Directions for Cancer Therapy, Purdue 
University, 2011). In collaboration with Dr. Helmut Hanenberg, we designed a lentiviral 
vector construct that expressed the E2-Crimson fluorescent protein (Figure 30A). The 
E2-Crimson fluorescent protein had excitation and emission spectra that best matched 
the laser/filter set of the in vivo fluorescent imaging machine, the Optix MX3 (Figure 
30C) (ART Technologies). The TMD231 cells were transduced with the E2-Crimson 
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lentiviral sup and became known as TMD231-CR. The TMD231-CR cells were evaluated 
using flow cytometry and TMD231 parental cells were used as a control. The TMD231-
CR cells were >80% positive for the E2-Crimson fluorescent protein and this allowed us 
to maintain the original population of TMD231 cells and not select for a subpopulation 
which could have different cellular and molecular responses to treatment (Figure 30B).  
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 Figure 30. TMD231 cells stably express the E2-Crimson fluorescent protein. (A) E2-
Crimson fluorescent protein was expressed in the puc2CL7CR2wo lentiviral vector under 
a SFFV promoter. (B) TMD231 cells were transduced with the E2-Crimson lentivirus. 
Transduction efficiency was determined using flow cytometry with about 80% positive 
cells (TMD231-CR). (C) The excitation and emission spectra was 611/646nm.  
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Since the TMD231-CR was transduced with a lentiviral vector, which can 
integrate at random into the genome, we wanted to test the cellular sensitivity of the 
TMD231-CR cells to our drug treatments using methylene blue proliferation assays. The 
TMD231-CR cells had similar sensitivity as the parental TMD231 cells (Figure 31). In the 
TMD231-CR cells, the IC50 value was 22.7µM±1.1 for Nutlin-3a, 7µM±0.3 for carboplatin, 
and 1.1µM±0.1 for the combination treatments (Figure 31B) compared to 19±3µM for 
Nutlin-3a, 6.3±1.9µM for carboplatin, and 0.7±0.5µM for combination treatments in 
TMD231 cells (Figure 31A).  
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 Figure 31. Combination treatment has similar enhanced potency in TMD231-CR cells 
when compared to TMD231 cells. TMD231-CR cells were treated with increasing 
concentrations of Nutlin-3a, carboplatin, or 1:1 concomitant combination treatment and 
allowed to grow for 5 days. Cell proliferation was determined using methylene blue 
staining. (A) Combination treatment had an increased potency in TMD231 cells 
compared to Nutlin-3a and carboplatin alone treated cells. (B) Combination treatment 
had an increased potency in TMD231-CR cells compared to Nutlin-3a and carboplatin 
alone treated cells.   
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To validate our imaging approach, pilot studies were next conducted to optimize 
cell dose for early imaging assessment. As first, we established the relationship between 
cell number and fluorescent intensity both in vitro and in vivo was determined. We 
hypothesized that there would be a cell number-dependent increase in fluorescent 
intensity as the cell number increased. For the in vitro imaging experiment, parental 
TMD231 served as the background control for the TMD231-CR cells. PBS alone was also 
imaged as an additional control. Images were collected to visualize relative fluorescent 
signals between the groups (Figure 32A). Images were analyzed and fluorescent 
intensity was calculated using the OptiView software (ART Technologies). Any 
fluorescence collected from the appropriate TMD231 parental cells was subtracted from 
the TMD231-CR cells resulting in fluorescent intensity represented by ‘normalized 
counts’ (NC) units. As expected, there was a cell number-dependent increase in 
fluorescent intensity with an R2=0.976 (Figure 32B).  
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 Figure 32. In vitro imaging of TMD231-CR cells shows a cell number-dependent 
increase in fluorescent intensity. (A) TMD231 and TMD231-CR cells were plated with 
0.03125, 0.0625, 0.125, 0.5, 1, 2, and 4x106 cells per well in triplicate and imaged in 
vitro. Parental TMD231 cells were used as a control for any auto-fluorescence. PBS was 
used as a control for background. (B) Graphical representation of the TMD231-CR 
fluorescent intensity showed that the fluorescent intensity increased in a cell number-
dependent manner. The fluorescent intensity of the parental TMD231 cells was used as 
background and subtracted from the fluorescent intensity of TMD231-CR cells.   
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To further support our in vitro imaging data, we then tested if there were cell 
number-dependent increases in fluorescent intensity in vivo. For in vivo imaging, four 
different TMD231 and TMD231-CR cell numbers (0.125, 0.25, 0.5, and 1.0 x106) 
implanted into mice, and two hours following implant the mice were imaged (Figure 
33A). There was a cell number-dependent increase in fluorescent intensity with 
R2=0.996 (Figure 33B). The TMD231 parental cell implanted mice had minimal 
background fluorescence as shown in Figure 33B. All of the TMD231-CR cell numbers 
implanted were detected during fluorescent imaging indicating the sensitivity of the in 
vivo Optix MX3 imaging system (ART Technologies).  
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 Figure 33. Fluorescent intensity increases in a cell number-dependent manner in vivo. 
(A) NSG mice were implanted with increasing cell numbers (0.125, 0.25, 0.5, and 1.0 
x106) of TMD231 or TMD231-CR in the mammary fat pad. At 2 hours post implant, the 
tumor bearing mice were imaged. (B) Graphical representation of fluorescent intensities 
for 0.125, 0.25, 0.5, and 1.0 x106 cells in vivo.  
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Following the in vitro and in vivo cell number imaging experiments, we next 
determine if in vivo imaging would be a viable way to measure tumor volume. We 
designed a longitudinal TMD231-CR imaging study to examine tumor growth coupled 
with in vivo imaging. Starting on Day 7 post implant and every week thereafter for a 
total of 5 weeks, mice were imaged and primary tumor fluorescent intensity was 
determined. Longitudinal images were collected and a representative picture shows the 
same three mice throughout the course of the study (Figure 34A). Mouse No. 1 is not 
pictured in the Day 35 image as its tumor reached the >1000mm3 endpoint before the 
last imaging date and was sacrificed. The tumor growth of the TMD231 parental and 
TMD231-CR tumors as measured by caliper were plotted over time, and there were 
similar growth rates for the two cell lines in vivo (Figure 34B). Additionally, fluorescent 
intensity was plotted as a function of tumor volume as measured via caliper showing 
fluorescent intensity and measured tumor volume correlated cell with R2=0.991 (Figure 
34C).  
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 Figure 34. TMD231-CR fluorescent intensity correlates with tumor volume over time. 
(A) NSG mice were implanted in the mammary fat pad with 1x106 TMD231-CR cells and 
imaged weekly after implant for a total of 5 weeks. These are representative images of 
the same mice over the course of the study. (B) Tumors from TMD231 and TMD231-CR 
bearing mice were measured via caliper twice weekly and tumor volume was recorded 
throughout the study. TMD231 and TMD231-CR tumors grew at similar rates and 
increased over time. (C) Longitudinal images were analyzed and compared to measured 
tumor volume. Increased fluorescent intensity correlated with increased tumor volume 
over time with an R2=0.991.   
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Since the TMD231-CR cell line is comprised of a transduced (80%) and non-
transduced (20%) cells (Figure 30B), we wanted to ensure that the cell line maintained 
the levels of the fluorescent protein following implant in the mice. At the termination of 
the longitudinal imaging study, two mice bearing tumors from TMD231 parental and 
TMD231-CR cells were excised from sacrificed mice and examined using flow cytometry 
for E2-Crimson levels. Following flow cytometry, the two TMD231-CR tumors from 
mouse numbers 207317-1 and 207317-2 maintained E2-Crimson fluorescence with 
>75% positive for the fluorescent protein compared to >80% from initial flow cytometry 
analysis of the TMD231-CR cell line (Figure 30 and 35). The percentage of transduced 
cells did not significantly change following passage in vivo and the mean fluorescence 
intensity of the population was stably maintained over the course of a long-term animal 
study, which would be useful for longitudinal imaging studies.  
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 Figure 35. TMD231-CR tumors stably express E2-Crimson over time in vivo. NSG mice 
were implanted with 1x106 TMD231 or TMD231-CR cells into the mammary fat pad and 
allowed to grow. At the completion of the study, tumors were excised from TMD231 
and TMD231-CR bearing mice, dissociated, and grown in culture. These cells were then 
analyzed using flow cytometry to evaluate E2-Crimson levels. Tumors from TMD231-CR 
mice (203317-1 and 207317-2) maintained the E2-Crimson fluorescent protein with only 
small losses compared to 80% positivity (Figure 30B).   
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Based on our pilot in vitro and in vivo imaging data, we concluded that 
fluorescent imaging was a sensitive measure of early tumor burden. We developed a 
standardized protocol for all subsequent dose finding studies and combination drug 
studies. We incorporated in vivo imaging as a measure of early tumor burden. Primary 
tumor was easily visualized with positive fluorescent intensity (Figure 36A). After 
analysis, each mouse received a fluorescent intensity value that was used to randomize 
the mice into different treatment groups. Each treatment group received an equal 
average amount of E2-Crimson fluorescent intensity as measured by fluorescent 
intensity of each mouse (Figure 36B). Using fluorescent imaging allowed mice to be 
randomized into treatment groups at a very early time with small tumor burden. If 
caliper measurements had been used for the randomization, this would not have been 
possible until at least days 18-21 post implant of TMD231 cells. At this time point, the 
tumors have entered a phase of exponential growth and due to the highly aggressive 
nature of this cell line, expand very quickly leaving the treatment window relatively 
small. Thus, our standard protocol for all subsequent animal studies was to image mice 
on Day 7 post implantation of TMD231-CR cells followed by randomization into 
treatment groups. An acclimation period following imaging and randomization was 
included and drug treatments began shortly thereafter, on Day 10.  
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 Figure 36. Fluorescent imaging allows for sensitive detection of early tumor burden. 
NSG mice were implanted with 1x106 TMD231 or TMD231-CR cells into the mammary 
fat pad on Day 0. (A) The primary tumor region of TMD231 and TMD231-CR bearing NSG 
mice were imaged on Day 7 post implant. (B) Non-palpable tumors were imaged using 
fluorescent imaging. Fluorescent intensity was determined for each mouse after imaging 
and used to randomize the mice into treatment groups (Veh, Carb, Nut, and Combo). 
Each treatment group received equal amounts of tumor as determined by fluorescent 
imaging.   
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C. Discussion and Future Directions 
Fluorescent imaging provided a sensitive measure of early tumor burden in vivo, 
which would allow drug treatment to begin at an early time point in tumor development 
allowing for a larger treatment window to be used. The TMD231 cells were transduced 
with the E2-Crimson fluorescent protein with a lentiviral vector allowing for stable levels 
of the protein over time. Flow cytometry confirmed that there was >80% TMD231 cells 
positive for E2-Crimson. A series of in vitro and in vivo experiments validated the use of 
TMD231-CR cells for the use in future animal studies as a measurement of non-palpable 
early tumor burden which is immeasurable with a caliper. The TMD231-CR cells were 
plated in increasing cell number on 96-well plates and imaged in vitro in the optical 
imaging machine, Optix MX3. There was a cell-dependent increase in fluorescent 
intensity in the TMD231-CR cells. To test the sensitivity of in vivo imaging, NSG mice 
were implanted with 0.125, 0.25, 0.5, and 1.0x106 TMD231-CR cells in the mammary fat 
pad and imaged two hours post implant. Fluorescent intensities were collected from all 
cell numbers and indicated cell number-dependent increases in fluorescent intensity 
when plotted graphically. Additionally, we wanted to correlate fluorescent intensity 
with tumor volume over time. We designed a longitudinal study to collect weekly 
imaging data and plotted the fluorescent intensities as compared to tumor volumes as 
measured by caliper. There were increases in fluorescent intensity as a function of 
increasing tumor volume. Taken together, these data suggest that fluorescent imaging is 
a sensitive measure of early tumor burden since fluorescent intensity is cell number 
dependent in vitro and in vivo and over time, tumor size-dependent in vivo. Fluorescent 
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imaging allowed for a non-invasive and relatively quick measure of non-palpable tumor 
burden allowing for a sufficient therapeutic window of time. Since the laser within the 
imaging apparatus excited the fluorescent protein expressed within the tumor, there 
was no need for an injected substrate as compared to bioluminescent imaging. Blood 
flow can greatly influence the movement of a substrate to the target tissues for 
bioluminescent imaging. Also, fluorescent imaging was relatively quick with scan times 
<5 minutes as compared to bioluminescent imaging (>20 minute scans). The length of 
time while under anesthesia and away from the animal room can add increased stress 
to the mice. We wanted to reduce the amount of stress that was exposed to the 
treatment mice for future studies since tumor burden not only increases the overall 
stress on the animal but coupled with the increased animal handling associated with the 
treatment dosing as well as effects from the drug treatments themselves. All of these 
factors contribute to the overall health of the mice and we wanted to decrease as much 
stress as possible. It is clear from numerous studies in the laboratory that a “stress 
threshold” exists and once this threshold is surpassed, the impact of therapy can no 
longer be assessed accurately. 
The use of fluorescent imaging could also be used to detect metastases. 
However, in our system, the use of fluorescent imaging of E2-Crimson with the Optix 
MX3 did not prove to be sensitive enough to measure lung metastases at the depth 
required in the whole animal. One study suggested that fluorescent imaging of GFP was 
sensitive enough to measure as small as 50 cells in vivo; however, the design of that 
experiment utilized a microscope connected directly to the camera 153. In other studies 
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windows were created in the skin to allow for imaging directly into the body cavity 152. 
This method would be quite invasive and would not be conducive for long-term studies. 
The use of NIR proteins allows for increased sensitivity of fluorescence measurement 
since there are fewer signals lost to surrounding tissues 152. Additionally, the use of NIR 
fluorescent proteins would lead to imaging with increased depth capacities allowing for 
deeper tissues to be examined 152. The use of NIR fluorescent proteins could allow for 
metastases to be detected within the lungs and other secondary tissues. More sensitive 
imaging modalities could be explored and validated in the future to measure primary 
tumor growth and metastases in vivo.  
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Chapter 4. Aim 4: Determination of efficacy of combination carboplatin and Nutlin-3a 
treatment in vivo 
 
A. Background and Rationale 
Carboplatin is currently being investigated in numerous clinical trials specifically 
treated metastatic TNBC: NCT01881230, NCT00691379, and NCT01281150 
(clinicaltrials.gov). Nutlin-3a is a pre-clinical tool being used to study the effects of 
modulating Mdm2 signaling. As described previously, Nutlin-3a is a small molecule 
inhibitor that was designed to bind into the hydrophobic pocket of Mdm2 and inhibit 
the binding of p53 40. In later studies, it was also discovered that Nutlin-3a also inhibiting 
the binding of p73, E2F1 and Hif-1α from Mdm2 62,65,66. These four binding partners of 
Mdm2 all have a conserved domain in which binds into the hydrophobic pocket of 
Mdm2 62. Due to the multi-functional role Mdm2 plays in several signaling pathways, we 
wanted to examine the combined effects of Nutlin-3a and standard of care 
chemotherapeutic, carboplatin, in vivo. Our in vitro results indicate a strong synergistic 
interaction when Nutlin-3a and carboplatin are used in a 1:1 ratio in cell proliferation 
with enhanced cell death and apoptosis (see Chapter 1). Mdm2 also plays an important 
role in DNA damage by antagonizing Nbs1 which is involved in DNA repair and thus 
increased Mdm2 leads to increased genomic instability by delaying DNA repair 35. We 
also observed increased levels of Mdm2 in the chromatin fraction isolated from cells 
treated with combination carboplatin and Nutlin-3a (see Chapter 2). Taken these data 
together, we wanted to design in vivo efficacy studies utilizing NSG mice implanted with 
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TMD231-CR cells in the mammary fat pad. The mice were randomized based on 
validated in vivo imaging studies as previously described (see Chapter 3).  
Before moving into combination efficacy studies, we next determined the dose 
of carboplatin that would inhibit ~50% of primary tumor growth in the carboplatin dose 
finding study. This dose of carboplatin would later be combined with Nutlin-3a, and 
therefore we did not want to completely abolish the primary tumor growth with 
carboplatin alone. Our primary goals in the combination efficacy studies were to 
determine the effects of combination treatment compared to each single drug on 
primary tumor growth and metastasis to the lung. Additionally, we needed to determine 
the drug dosing schema in which we had efficacy while balancing the stress on the 
animals as well as normal tissue toxicity. Dosing was further optimized between 
combination study 1 and combination study 2 in which changes to the dose of 
carboplatin was reduced as well as the time between drug dosing was lengthened to 
reduce stress on the animals. The effects of drug treatment on probability of survival 
were examined in combination study 2. We also examined the toxicity of the 
combination drug treatment with expanded toxicity examinations with each subsequent 
combination study by utilizing a number of toxicity measures including health of bone 
marrow, effects on blood cells, effects on other tissues, as well as body weights 
throughout the studies. Since the bone marrow is one of the most sensitive measures of 
normal tissue toxicity, we elected to evaluate possible effects of therapy in detail 110. 
The mice received Uniprim® (TD.06596, Harlan Laboratories) which is a specialty rodent 
diet that have 275 ppm trimethoprim and 1,365 ppm of the sulfonamide sulfadiazine to 
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help reduce the risk of infection. When the mice are taken to imaging, they are removed 
from their sterile environment and could be exposed to circulating pathogens. The NSG 
mice are particularly susceptible due to their compromised immune system. The mice 
received additional supportive care at the beginning of drug dosing by receiving water 
soaked Uniprim® chow which helped to maintain or restore losses in body weights after 
the start of drug treatment. The combination studies evolved from study to study taking 
the data and applying necessary changes to improve each subsequent animal study to 
increase knowledge and understanding.  
We also completed a small pharmacodynamic study to see if we could validate 
protein target modulation in vivo. Mice were implanted with the TMD231-CR cells and 
once the tumors reached about 500mm3, the mice were treated with an aggressive 
dosing regimen and then sacrificed shortly thereafter to study the effects of drug 
treatment on protein levels within the tumor. We also took a portion of the primary 
tumors and examined the levels of human VEGF to see the effects of Nutlin-3a 
treatment on the primary tumor.   
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B. In vivo combination drug efficacy studies  
Our overall experimental goal was to investigate the therapeutic potential of 
modulating the Mdm2 signaling network via Nutlin-3a in combination with carboplatin 
and to determine the molecular targets active in our system. Therefore, we next 
conducted complete carboplatin dose-finding studies to determine the appropriate dose 
of carboplatin that would inhibit ~50% tumor growth. The results from the carboplatin 
dose finding study would help design future efficacy combination studies conducted in 
combination with Nutlin-3a. The Nutlin-3a dose used for in vivo studies was selected 
based on other in vivo dose-finding studies already completed in the laboratory in 
human brain cancer models and was set at 200 mg/kg (Figure 37). The maximal Nutlin-
3a plasma concentration (Cmax) was measured to be 35µM, which was higher than the 
IC50 value of 19.4µM±3.3 determined for Nutlin-3a in vitro in the TMD231 cells (Figure 
6). The tmax or time to reach maximal plasma concentrations was 1 hour while the half-
life (t½) was calculated to be 5.5 hours. The apparent oral clearance (Cl/F) was calculated 
to measure the rate of clearance of the drug when given orally. Extensive 
pharmacokinetic studies were completed by Zhang and colleagues, which examined the 
distribution of Nutlin-3a in mice 154. In those studies, they showed that Nutlin-3a had 
high bioavailability and was well distributed from plasma to the tissues including the 
lungs indicating that Nutlin-3a should be present in the lungs in our model 154. Figure 38 
shows the carboplatin dose finding study schema.  
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 Figure 37. Pharmacokinetics of Nutlin-3a in NSG mice. (A) Mice received 100 mg/kg 
Nutlin-3a p.o. and plasma samples collected and processed from 1-24 hours for 
quantification (n= 3 mice per time point). Quantification of the compounds was 
determined using liquid-liquid extraction followed by HPLC-MS/MS (API 4000). Data are 
represented as the mean ± SD. For quantification of Nutlin-3a, the line illustrates the 
line of best fit (using the last four points). (B) Summary of Nutlin-3a PK parameters. The 
maximal Nutlin-3a plasma concentration (Cmax) was measured to be 35µM. The tmax or 
time to reach maximal plasma concentrations was 1 hour while the half-life (t½) was 
calculated to be 5.5 hours. The apparent oral clearance (Cl/F) was calculated to measure 
the rate of clearance of the drug when given orally. 
  
 176 
  
 177 
The carboplatin dose-finding study showed that carboplatin inhibited primary 
tumor growth in a dose-dependent manner compared to vehicle-treated mice. (Figure 
39A). At 3mg/kg and 30mg/kg carboplatin, the growth of primary tumors was 
significantly inhibited compared to Vehicle treated mice (Two-Way ANOVA, p<0.001, 
n=8-9). Additionally, mice were sacrificed when the primary tumor reached ≥1000mm3, 
and carboplatin treatment increased the probability of survival at this endpoint (Figure 
39B). Based on the carboplatin dose-finding studies, we elected to treat mice with 
25mg/kg carboplatin in combination efficacy studies.  
  
 178 
 Figure 39. Carboplatin inhibits tumor growth and increases survival in a dose-
dependent manner. NSG mice were implanted with 1x106 TMD231 as a background 
control for imaging or TMD231-CR cells into the mammary fat pad and allowed to grow. 
On Day 7, mice were imaged and randomized into treatment groups (Vehicle, 1mg/kg, 
3mg/kg, and 30mg/kg carboplatin). Mice started drug treatment on Day 12 post implant 
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and were dosed i.p. MWF for 2 weeks for a total of 6 doses. Primary tumor growth was 
evaluated twice weekly via caliper measurements. (A) Tumor growth was inhibited in a 
carboplatin dose-dependent manner. The 3mg/kg and 30mg/kg carboplatin treatments 
significantly inhibited tumor growth when compared to Vehicle treated mice (Two-Way 
ANOVA, *p<0.001 as compared to Vehicle treated, n=8-9, mean±SEM). (B) Carboplatin 
increased probability of survival at endpoint in a dose-dependent manner. Mice were 
sacrificed when primary tumors reached 1000mm3.   
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As we began to design the first combination animal study, our objectives were to 
evaluate the effects of the combination Nutlin-3a and carboplatin treatment on primary 
tumor growth and metastasis to the lung as well as evaluate in vivo imaging following 
drug treatment. Figure 40 illustrates the overall study design. The combination 
treatment significantly inhibited primary tumor growth compared to Vehicle- and single 
Nutlin-3a- and carboplatin-treated mice over the course of the entire study (Two-Way 
ANOVA, p<0.001, n=7-9, ±SEM) (Figure 41A). There was no difference between Vehicle- 
and Nutlin-3a-treated mice. Carboplatin alone inhibited tumor growth, however, the 
combination of carboplatin and Nutlin-3a further decreased primary tumor growth 
(Figure 41A). During this initial phase of developing a rational dosing regimen, mice 
were monitored daily for signs of therapy-induced stress and toxicity. The dosing 
schema in study one began with dosing three times weekly, but was subsequently 
altered to twice weekly dosing due to increased stress on the mice (decreased appetite, 
lack of grooming, and 10% body weight loss). These adjustments were made during the 
first combination study and continued in subsequent studies. When the first primary 
tumors reached ≥1000mm3, all of the mice were sacrificed, which was about a week 
after the completion of drug treatment in combination study 1. As a secondary measure 
of tumor size, following necropsy, the primary tumors were excised from mice and 
weighed. The average weight tumors from the combination treated mice were 
significantly smaller than tumors from Vehicle and single Nutlin-3a and carboplatin 
treated mice (One-Way ANOVA, p<0.001, n=7-9, ±SEM) (Figure 41B). A pictorial view of 
excised tumors from treated mice visually showed primary tumors from combination 
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treated mice were smaller in size compared to tumors from Vehicle and single Nutlin-3a 
and carboplatin treated mice (Figure 41C).  
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 Figure 41. Combination treatment significantly inhibits primary tumor growth in vivo. 
NSG mice were implanted with 1x106 TMD231 as a background control for imaging or 
TMD231-CR cells into the mammary fat pad on Day 0. Mice were imaged on Day 7 post 
implant and randomized into treatment groups using fluorescent intensity. Mice were 
dosed with Veh (PBS and 0.5% methylcellulose+0.05% Tween80), 25mg/kg carboplatin 
i.p., 200mg/kg p.o., or 25mg/kg carboplatin i.p. + 200mg/kg p.o. three times weekly for 
total of 6 doses. Primary tumor volume was evaluated using caliper measurements 
throughout the study. (A) Carboplatin alone, Nutlin-3a alone, and combination all 
significantly inhibited primary tumor growth compared to Vehicle treated mice with the 
combination treatment significantly inhibiting tumor growth when compared to both 
single drug treatments (Two-Way ANOVA, *p<0.001 as compared to Vehicle, # p<0.001 
as compared to Nut and Carb alone, n=7-9, ±SEM). (B) At study completion, mice were 
sacrificed and primary tumors were excised and weighed. Primary tumor weight was 
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significantly reduced in combination treated mice compared to Vehicle and single drug 
treated groups (One-Way ANOVA, *p<0.001, n=7-9, ±SEM). (C) Representative pictures 
of tumors from each treatment group.   
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Throughout the study, we evaluated the mice for overt toxicity to drug 
treatments. During the study, the mice did not lose more than 10% body weight overall 
(Figure 42A). The first drop in body weight occurred during the first week of drug 
treatment. The mice were supplemented with water soaked Uniprim® food which 
helped the mice recover lost body weight. All subsequent animal studies used water 
soaked Uniprim® food as supportive care. As an additional measure of drug toxicity, 
bone marrow cellularity was determined. There was a decrease in total bone marrow 
cell numbers from mice treated with the combination treatment compared to the 
Vehicle and single drug treated mice (Figure 42B) (One-Way ANOVA, p<0.001, n=7-9, 
±SD). While there were decreases in total bone marrow cell counts in the combination 
treated mice, this loss did not result in blast crisis (Figure 42B). Since the mice were 
sacrificed only 7 days following the completion of drug treatment, this presumably did 
not allow for an adequate recovery period of the bone marrow cells in response to 
carboplatin. Subsequent animal studies incorporated a revised study design that 
allowed us to evaluate potential toxicity to the bone marrow following an increased 
recovery period; in this study design, total bone marrow cell counts returned to normal 
levels (Figure 49).  
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 Figure 42. Drug treatment is well tolerated with minimal toxicity. (A) Body weight did 
not significantly change throughout study. Body weights of mice were evaluated 
throughout the study as a measure of overall mouse health. After the first week of drug 
treatment, mice were given water soaked Uniprim® food as supportive care after which 
body weights improved. (B) Total bone marrow cell counts were determined from 
excised femurs of treated mice. Bone marrow cell counts were significantly reduced in 
the combination treated mice compared to Vehicle treated mice (One-Way ANOVA, 
*p<0.001, n=7-9, ±SD).   
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Since the combination treatment inhibited primary tumor growth, we also 
examined the effects of combination treatment on metastatic lesions in the lung. 
Representative pictures of H&E slides of lungs were taken and combination mice had 
smaller sized and less numbered lung metastases (Figure 43A). The human tumor cells in 
the lungs appear purple in color due to the Haematoxylin dye, which stains basophilic 
structures in the cells like DNA, RNA, and endoplasmic reticulum (The Histology Guide, 
University of Leeds). Eosin stains acidophilic parts of the cells, which includes the 
cytoplasm. Due to the large and aneuploid structures of the tumor cells, they appear 
more purple in color compared to the much smaller diploid mouse cells in the lungs, 
which appear more pink in color. The Vehicle-treated mice had very large metastases 
that coalesced into one another forming large areas of tumor cells in the lungs. The 
carboplatin and Nutlin-3a alone treated mice had lower numbers and smaller 
metastases compared to the Vehicle-treated mice. A blinded pathologist scored the H&E 
slides of lung tissues with a scoring system based on Grade 1-5 (Figure 43D). The 
traditional scoring by pathologist showed that the combination treated mice had 
significantly smaller Grade metastatic lesions compared to Vehicle- and single drug-
treated mice (One-Way ANOVA, p<0.05, n=5, ±SD). As a secondary measure of 
metastases, H&E stained slides were also scanned using the Aperio ScanScope system 
(Leica Biosystems) and analyzed using ImageScope software (Leica Biosystems). Positive 
staining can be collected digitally allowing for a non-biased measure of pathological 
staining. Following ImageScope analysis for positivity, it was confirmed that lungs from 
combination treated mice had less lung metastases compared to Vehicle- and single-
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drug treated mice (One-Way ANOVA, p<0.05, n=5, ±SD) (Figure 43C). While the 
combination-treated mice had less lung metastases, the study design does not answer 
the question if the combination treatment inhibits the metastatic process or simply 
inhibits primary tumor growth, which would result in less metastatic cells entering the 
blood stream, and therefore less cells able to metastasize to the lungs. To answer this 
question, mice would need to be implanted with TMD231 cells and tumors allowed to 
grow until ~3 weeks post implant where metastases in the lungs have been visualized. 
At that point, the mice could be randomized based on tumor volume and treatment 
would begin. This way, the mice already have metastases present in the lungs. Following 
treatment, smaller lung metastases would indicate that the drug treatment inhibited 
tumor growth in the lungs. The disadvantage to this metastasis model would be the 
large size of the primary tumors. Metastasis begins around 21 days post implant, which 
does not leave a large treatment window due to the size of the primary tumor. The 
primary tumor would likely need to be resected so that they lung metastases could form 
and become large enough to visualize any differences in number and size following drug 
treatment. This study design would be similar to what is observed in the clinic in which 
women with breast cancer may have surgery to remove the tumor and then treated 
systemically for any metastatic sites.  
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 Figure 43. Combination treatment inhibits tumor growth in secondary sites. Following 
sacrifice, lungs were excised and fixed in 10% buffered formalin. Lungs were paraffin 
blocked, sections were cut, and stained for H&E. (A) Pictorial representation of primary 
tumor H&E staining of the lungs. Combination-treated mice had the smallest tumor 
Stage bearing the smallest number and size of lung metastases compared to the 
Vehicle- and single drug-treated mice (4X magnification). (B) Mice were scored by stage 
by a blinded pathologist. Stage parameters were determined in the table (D). The 
combination mice had significantly smaller lung metastases as determined by Grade 
compared to all other groups (One-Way ANOVA, *p<0.05, n=5, ±SD). Additionally, slides 
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were scanned using Aperio ImageScope system and analyzed for digital positivity of 
staining. (C) Combination-treated mice had a significant reduction in positivity 
compared to other treatment groups which confirmed traditional histology 
quantification (One-Way ANOVA, *p<0.05, n=5, ±SD).   
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To better understand the effects of drug treatment on cell proliferation within 
tumors at the time of mouse sacrifice, excised tumors were stained for Ki67. 
Representative pictures of tumors from Vehicle, Nulin-3a alone, carboplatin alone, and 
combination-treated mice showed that combination treated mice had less Ki67 staining 
(Brown) compared to the other groups (Figure 44A). ImageScope analysis confirmed 
that there was significantly less Ki67 staining in combination treated mice compared to 
Vehicle treated mice (One-Way ANOVA, p<0.05, n=4, ±SD) (Figure 44B). There was a 
downward trend in Ki67 staining in tumors from Nutlin-3a and carboplatin alone treated 
mice.  
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 Figure 44. Cellular proliferation is decreased in combination treated mice. Slides were 
also cut for Ki67 staining. (A) Pictorial representation of primary tumor Ki67 staining 
(brown stain) showed less staining in combination treated mice compared to Vehicle 
treated mouse tumors (40X magnification). (B) Graphical representation showed a 
significant reduction in Ki67 staining in combination treated mice compared to Vehicle 
treated mice (One-Way ANOVA, *p<0.05, n=4, ±SD). There was a downward trend in 
Ki67 staining in the Nutlin-3a and carboplatin alone treated mice.   
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In our second objective, we evaluated the primary tumor response to drug 
treatment using optical imaging. Mice were imaged on Day 7 as baseline fluorescent 
intensity analysis for randomization. The fluorescent intensity was highly variable after 
the drug treatment and did not yield statistical significance (Figure 45). There were 
downward trends in the combination treatment compared to Vehicle treated mice; 
however, there was no difference between combination and carboplatin alone treated 
mice. The measured tumor volume via caliper and tumor weights showed that the 
combination treated mice had significantly smaller tumors compared to the Vehicle- and 
single drug-treated mice and this was confirmed by tumor weight measurements taken 
at the end of the study. Our data indicate that fluorescence imaging in this model 
system does not provide an accurate measure of tumor volume following drug 
treatment and was also not sensitive enough to pick up fluorescence from metastatic 
lung foci. As the tumors grew larger, some developed necrotic cores and dead cells. And 
it is highly probable that due to tissue attenuation effects and remaining E2-Crimson 
protein in dying and/or necrotic cells was the reason for lack of correlation between 
imaging results and other measures of tumor growth. In discussions with the Indiana 
Institute for Biomedical Imaging Sciences, we also believe that the machine could not 
accurately detect fluorescence at the depth required to obtain accurate measure of 
response to treatment. If the depth of signal was variable between mice, this could have 
added to the overall variability of fluorescent intensity values. Additionally, imaging is an 
added stressor to mice already highly stressed following tumor implant and drug 
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treatment. In future studies, we elected to only use the in vivo imaging as a measure of 
early tumor burden in the mice.  
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 Figure 45. Fluorescent intensity is highly variable after drug treatment and does not 
correlate with other measurements of tumor growth. NSG mice were implanted with 
1x106 TMD231 and TMD231-CR cells into the mammary fat pad on Day 0. Mice were 
imaged on Day 7 and randomized into treatment groups. Mice were dosed with Vehicle 
(PBS and 0.5% methylcellulose+0.05% Tween80), 25mg/kg carboplatin i.p., 200mg/kg 
Nutlin-3a p.o., or 25mg/kg carboplatin+ 200mg/kg Nutlin-3a combination. Mice were 
allowed a week recovery period following the completion of drug treatment, and then 
the mice were imaged. Following imaging analysis on Day 38, there was a downward 
trend in fluorescent intensity for the combination mice compared to Vehicle and single 
drug treated mice. However, the fluorescent intensity was highly variable and did not 
denote significant differences (n=7-9, ±SEM).  
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 Based on positive data from the first combination animal study, we next 
designed an in vivo experiment that would repeat and also expand upon the 
combination animal study design to answer additional experimental questions (Figure 
46, see schema of study design). Combination study 2 was designed in a similar fashion 
to the first combination study. There were groups of mice that were designed to 
validate the first study with mice sacrificed when the first tumors reached ≥1000mm3. 
There were also groups of mice that were used to study the effects of the drug 
treatment on the probability to survive to the endpoint of 800mm3 tumor volume. We 
also wanted to further evaluate bone-marrow toxicity following drug treatment. Slight 
changes were made to the dosing schema with the carboplatin dose being reduced from 
25mg/kg to 20mg/kg due to decreased body weights in the carboplatin and combination 
treated mice in Combination Study 1. Mice were dosed twice weekly to reduce stress for 
a total of 8 doses. Mice were given supportive care with the addition of water soaked 
Uniprim® food, which helped to increase food uptake in the mice. Histology with H&E 
staining of the lungs was also repeated to confirm the first combination study.   
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Similar to the first combination study, the combination treated mice had 
significantly smaller primary tumors compared to Vehicle- and both single drug-treated 
(Two-Way ANOVA, p<0.05, n=12, ±SEM) (Figure 47A). The group of mice used to confirm 
the first combination study was sacrificed on Day 41, which was 5 days after the 
completion of drug treatment. During necropsy, the primary tumors, lungs, and femurs 
were excised for further analysis. Primary tumor weight was significantly reduced in 
combination treated mice compared to Vehicle and single carboplatin and Nutlin-3a 
treated mice (Figure 47B) (Student’s T-test, *p<0.05, n=3-4, ±SEM). Histology was used 
to examine primary tumors and lungs for H&E staining. Bone-marrow cellularity was 
also evaluated from excised femur bones (Figure 49). Since the sample size was small in 
the repeat study mice group coupled with innate variability in animal studies, the 
histology data from H&E stained lungs did not show significant differences between the 
treatment groups (data not shown).  
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 Figure 47. Combination treatment significantly inhibits primary tumor growth in vivo. 
NSG mice were implanted with 1x106 TMD231 or TMD231-CR cells into the mammary 
fat pad on Day 0. Mice were imaged on Day 7 post implant and randomized into 
treatment groups. Mice were dosed with Veh (PBS and 0.5% methylcellulose+0.05% 
Twenn80), 20mg/kg carboplatin i.p., 200mg/kg p.o., or 20mg/kg carboplatin i.p. + 
200mg/kg p.o. two times weekly for total of 8 doses. Primary tumor volume was 
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evaluated using caliper measurements throughout the study. (A) The combination 
treated mice had significantly smaller tumors compared to Vehicle and both single drug 
treated groups (Two-Way ANOVA, p<0.05, n=12, ±SEM). (B) At study completion, mice 
were sacrificed and primary tumors were excised and weighed. Primary tumor weight 
was significantly reduced in combination treated mice compared to Vehicle and single 
drug treated groups (Student’s T-test, *p<0.05, n=3-4).   
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To better understand the effect of combination drug treatment on probability of 
survival, a second group of mice from different treatment groups were examined for 
survival. The endpoint for survival mice was set as the time point when the primary 
tumor reached 800mm3. The combination treated mice a significant probability of 
survival at the time point at which the tumors reached 800mm3 compared to Vehicle 
and single drug treated mice (Figure 48A). Kaplan-Meier analysis using SigmaPlot 
showed that the survival time for Vehicle was 39.3±0.6 days, Nutlin-3a was 39±1 days, 
carboplatin was 47.5±1.8 days, and combination was 54.3±1.5 days (Figure 48B).   
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 Figure 48. Combination treatment increases probability of survival. Groups of mice 
were studied for probability of survival with the survival endpoint determined when the 
primary tumor reached 800mm3. (A) Following Kaplan-Meier analysis (SigmaPlot), the 
combination treated mice had a significantly increased probability of survival compared 
to Vehicle and single drug treated mice (n=7-8, p<0.05). (B) Survival for Vehicle was 
39.3±0.6 days, Nutlin-3a was 39±1 days, carboplatin was 47.5±1.8 days, and 
combination was 54.3±1.5 days.   
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When the mice reached the tumor volume endpoint, the mice were sacrificed 
and femurs were collected for total bone marrow cell counts. Measurements of bone- 
marrow cellularity are a sensitive measure of tissue toxicity, which is important since 
one of the side effects of carboplatin is myelosuppression155. In the group of mice 
examined for survival, the mice were not sacrificed until a later time point, which 
resulted in about a 2-weeks recovery period following the end of drug treatment. The 
total bone marrow cell counts were compared between the groups used to confirm 
combination study 1 which were harvested 5 days following the completion of drug 
treatment and the group in study 2 used to examine survival which were harvested after 
a two week recovery period following the completion of drug treatment. There was a 
significant reduction in total bone marrow cell counts in the combination treated mice 
compared to Vehicle treated mice in the group that only received a 5 day recovery 
period (Two-Way ANOVA, # p<0.05, n=4, ±SD) (Figure 49). However, the significant 
reduction in total bone marrow cell counts returned to normal levels in groups of mice 
used to examine survival after a two-week recovery period (Two-Way ANOVA, *p<0.05, 
n=3, ±SD) (Figure 49). Thus, bone-marrow toxicity in the combination treated mice is 
reversible and not a long lasting effect; bone-marrow cell counts returned to normal 
levels within 2 weeks following the completion of drug treatment. 
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 Figure 49. Total bone marrow cell counts recover to normal levels following recovery 
period after treatment. A group of mice were sacrificed 5 days after the end of 
treatment and bone marrow cell counts were determined as described in the Materials 
and Methods. The combination treated mice had a significantly reduced number of 
bone marrow cells compared to Vehicle treated mice (Two-Way ANOVA, # p<0.05, n=4, 
±SD). However, after a two-week recovery period, the levels of total bone marrow cell 
counts came back to normal levels in the combination treated mice (Two-Way ANOVA, 
*p<0.05, n=3, ±SD).  
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Breast cancers can metastasize to many tissue compartments including brain and 
bone. Since we already had processed femurs of mice for bone-marrow cellularity 
measurements, we next determined if there were any metastatic tumor cells present in 
the bone marrow compartment. Since the tumor cells are marked with the E2-Crimson 
fluorescent protein, detection of tumor cells could be readily determined by flow 
cytometry experiments. TMD231 parental cells were first used to set the gates for 
fluorescent protein negative cells (Figure 50A). TMD231-CR cells were used as a positive 
marker for the presence of the E2-Crimson fluorescent protein (Figure 50B). 
Additionally, we isolated bone marrow from a normal NSG mouse (WT BM) that was 
untreated and non-implanted (Figure 50C). We also used normal NSG bone marrow 
spiked with two different ratios of the TMD231-CR cells (1:1 WT:231-CR and 9:1 
WT:231-CR) as a positive marker for E2-Crimson cells present in mouse bone marrow. In 
the samples containing the mixtures of the bone marrow and TMD231-CR cells, flow 
cytometry showed E2-Crimson cell number-dependent increases in positive cells in the 
wild-type bone marrow (Figure 50D-E). Bone marrow cells from Vehicle- and Nutlin-3a-
treated groups were evaluated for the presence of TMD231-CR cells. Following flow 
cytometry analysis, there were no TMD231-CR cells present in isolated bone marrow 
(Figure 50F-G). A tabular summary of the data can be found in Figure 50H. At the time of 
these analyses, there were 3 Vehicle and 3 Nutlin-3a treated mice that were sacrificed 
on the same day so we elected to examine the bone marrow of these mice for the 
presence of E2-Crimson expressing tumor cells. The carboplatin and combination 
treated mice were much more variable in the time to reach the endpoint. We expected 
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the most tumor cells to be present in the Vehicle and Nutlin-3a treatment groups since 
their tumors were the largest and had significantly more lung metastases than the other 
two treatment groups. Since we did not detect any tumor cells in the bone marrow 
isolated from Vehicle or Nutlin-3a treated mice, we did not evaluate this in the other 
treatment groups.   
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 Figure 50. Tumor cells are not present in isolated bone marrow. Bone marrow cells 
were prepared by crushing excised femur bones with mortar and pestle. Crushed bones 
were passed through a 70μm cell strainer, and red blood cells were lysed with RBC lysis 
buffer. Isolated cells were washed with PBS and the presence of TMD231-CR tumor cells 
were assessed using flow cytometry. (A-C) TMD231 parental, TMD231-CR, and bone 
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marrow cells from a wild-type mouse were used as controls for flow cytometry. (D-E) 
wild-type bone marrow was spiked with two different ratios of TMD231-CR cells (1:1 
WT:231-CR and 9:1 WT:231-CR) as controls. Bone marrow from three mice from Vehicle 
and Nutlin-3a treated groups were evaluated for the presence of TMD231-CR cells. (F-G) 
Representative plots of Vehicle- and Nutlin-3a-treated mice show that there were no 
TMD231-CR cells present in isolated bone marrow. (H) Table shows numerical values of 
cells positive for the Crimson fluorescent protein.   
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 In combination study 3, we made further adjustments to the study design. Our 
objectives were to confirm combination study 1 with histology and added further 
assessments of carboplatin and Nutlin-3a combination treatment on toxicity by further 
examining bone marrow health and secondary tissues. During the time of combination 
study 2 and combination study 3, the motherboard of the Optix MX3 was damaged. 
Therefore, we were unable to image the mice on Day 7 for randomization purposes. We 
elected to randomize the mice based on body weights on Day 7 so that drug treatment 
could begin on Day 10 as in other studies. Following necropsy, lungs, primary tumors, 
livers, spleens and femurs were collected. We performed H&E staining of the lungs, 
primary tumors, livers, spleens, and femurs. We repeated bone marrow cellularity and 
also evaluated the effects of the drug treatments on complete blood counts (CBCs) and 
progenitor assays. An outline of combination study 3 can be found in Figure 51.  
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As in combination studies 1 and 2, the combination treatment significantly 
inhibited primary tumor growth when compared to Vehicle and single drug treated mice 
(Figure 52A) (Two-Way ANOVA, p<0.05, n=8, ±SEM). At study completion, mice were 
sacrificed, and the primary tumors were excised and weighed. The average primary 
tumor weight was significantly reduced in the combination treated mice compared to 
Vehicle and single drug-treated groups (Figure 52B) (Student’s T-test, p<0.05, n=7-8, 
mean±SEM). These results add further support to the combination treatment efficacy 
on primary tumor volume.  
  
 212 
 Figure 52. Combination treatment significantly inhibits primary tumor growth in vivo. 
NSG mice were implanted with 1x106 TMD231 or TMD231-CR cells into the mammary 
fat pad on Day 0. Mice were imaged on Day 7 post implant and randomized into 
treatment groups. Mice were dosed with Veh (PBS and 0.5% methylcellulose+0.05% 
Tween80), 20mg/kg carboplatin i.p., 200mg/kg p.o., or 20mg/kg carboplatin i.p. + 
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200mg/kg p.o. three times weekly for total of 8 doses. Primary tumor volume was 
evaluated using caliper measurements throughout the study. (A) The combination 
treated mice had significantly smaller tumors compared to Vehicle and both single drug 
treated groups (Two-Way ANOVA, *p<0.05 as compared other treatment groups, n=12, 
±SEM). (B) At study completion, mice were sacrificed and primary tumors were excised 
and weighed. Primary tumor weight was significantly reduced in combination treated 
mice compared to Vehicle and single drug treated groups (Student’s T-test, *p<0.05, 
n=7-8, mean±SEM).  
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To better understand the effects of combination carboplatin and Nulin-3a on 
bone marrow health, bone marrow cellularity was evaluated. At the time of sacrifice, 
the mice had about a two-week recovery period following the completion of drug 
treatment. There were no differences in bone marrow cellularity between all of the 
treatment groups, which confirmed results from combination study 2 that bone marrow 
returns to normal following a recovery period (n=8±SD) (Figure 53A). However, there 
was a measurable difference in frequency of hematopoietic progenitor cells in the 
carboplatin alone and combination treated mice compared to Vehicle treated mice 
(One-Way ANOVA, p<0.05, n=3, mean±SD) (Figure 53B).  
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 Figure 53. In vivo administration of carboplatin and Nutlin-3a does not affect overall 
bone marrow cellularity but causes a decrease in the frequency of hematopoietic 
progenitor cells. Tumor-bearing mice were treated with vehicle control (Veh), 
carboplatin (Carb), Nutlin-3a (Nut) or combination carboplatin and Nutlin-3a (Combo). 
After a 2-week recovery period, mice were sacrificed and femurs harvested. (A) Bone 
marrow cells were isolated and cellularity determined per femur (n=8, mean ± SD). (B) 
The number of hematopoietic progenitor cells was determined using a colony forming 
unit (CFU) assay. Bone marrow cells were plated in triplicate at 2x104 per dish in 
MethoCult GF M3434 and allowed to grow for 2 weeks. Carboplatin and combination 
treated mice formed less progenitor colonies compared to Vehicle treated mice (One-
Way ANOVA, *p<0.05, n=3, ±SD).   
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Additionally, just before sacrifice, an aliquot of peripheral blood was collected 
from each mouse to examine complete blood counts (CBCs). Peripheral blood was 
analyzed via hemavet for red blood cells, thrombocytes, and white blood cells. There 
were significant reductions in red blood cells, thrombocytes, and white blood cells in the 
combination treated mice compared to Vehicle treated mice (One-Way ANOVA, p<0.05, 
n=7-8, mean±SD) (Figure 54). While there were significant decreases in peripheral blood 
cells, these levels of toxicity were acceptable since decreased counts did not appear to 
affect overall health of the mice nor body weights. We also looked at bone marrow 
histology with bone marrow smears. There were no overt signs of toxicity in bone 
marrow smears from all treatment groups and also there was no detection of tumor 
cells, which confirmed our flow cytometry results from combination study 2 (Figure 55). 
In addition myeloid hyperplasia was noted by the pathologist to be present in all 
treatment groups with no notable differences between treatment groups (Figure 55). 
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 Figure 54. In vivo administration of carboplatin and Nutlin-3a leads to decreases in red 
blood cells, thrombocytes, and white blood cells. Tumor-bearing mice were treated 
with vehicle control (Veh), carboplatin (Carb), Nutlin-3a (Nut) or combination 
carboplatin and Nutlin-3a (Combo). After a 2-week recovery period, an aliquot of 
peripheral blood was analyzed via hemavet for red blood cells, thrombocytes, and white 
blood cells. The combination treatment led to decreased red blood cells, thrombocytes, 
and white blood cells (One-Way ANOVA, *p<0.05, n=7-8, mean±SD).   
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 Figure 55. Myeloid hyperplasia is evident in bone smears from all treatment groups 
but no changes are observed in overall bone marrow composition following 
treatment. Femur bones were excised during necropsy. Bones were fixed in 10% 
buffered formalin and decalcified with Decal®. Bones were set in paraffin blocks, 
sectioned, and stained with H&E. There were no overt signs of toxicity in bone marrow 
smears from all treatment groups. There was myeloid hyperplasia present in all 
treatment groups.  
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To examine other tissue toxicity to combination drug treatment, we evaluated 
the liver and spleen of treated mice. Spleens from all treatment groups exhibited 
increased myeloid stem cells in the spleens while only some of the livers from the same 
mice exhibited extramedullary hematopoiesis (EMH) in livers (Table 2). Three mice 
exhibited focal lesions in the livers, which did not correlate to the treatment groups 
indicating that the metastasis to the liver was a random event. Two mice from the 
carboplatin-treated group had one focal lesion in the liver while one Nutlin-3a treated 
mouse exhibited 2 focal lesions in the liver (Table 2). Despite exhibiting extramedullary 
hematopoiesis, the spleens and livers from all treatment groups appeared normal with 
no regions of necrosis or inflammation.  
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 Table 2. All spleens and some livers exhibit extramedullary hematopoiesis (EMH) with 
few focal lesions. Spleens and livers were collected from sacrificed mice. Tissues were 
embedded, sectioned, and examined using H&E staining. All spleens collected from each 
of the treatment groups exhibited increased myeloid stem cells in the spleens while only 
some of the livers collected from the same mice exhibited extramedullary 
hematopoiesis (EMH) in livers. Three mice exhibited focal lesions in the livers, which did 
not correlate to the treatment groups.  
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A pharmacodynamic study was conducted to begin to understand what the 
combination treatment may modulate at the molecular level in vivo. Based on in vitro 
results, we showed that the combination treatment led to synergistic effects in 
methylene blue proliferation assays. We also observed increases in Mdm2 protein levels 
in Nutlin-3a- and combination-treated TMD231 cells when examined with Western blot. 
It has been shown in the literature that Nutlin-3a inhibits the binding of Mdm2 to Hif-1α 
which led to decreased VEGF 62. With decreased levels of VEGF, the tumor cells would 
have limited angiogenesis capabilities. Based on these data, we determined the in vivo 
pharmacodynamic effects of the combination treatment on tumors by examining the 
effect of drug treatment on human VEGF levels and target protein modulation in 
primary tumors following a short treatment schema. Complete study design is outlined 
in Figure 56.  
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NSG mice were implanted with TMD231-CR cells and allowed to grow. Once the 
tumors reached ~500mm3 as measured by caliper, the mice were randomized into 
treatment groups so that each group received equivalent tumor sizes. The mice were 
dosed for 3 consecutive days and sacrificed 2 hours following the completion of drug 
treatment. The tumors were excised, cut in half, and snap frozen for use in VEGF ELISA 
and Western blot analysis. Tumors were lysed and equal protein was loaded into the 
Human VEGF Quantikine ELISA Kit (R&D Systems) plate as per manufacturer’s 
instructions. There was no difference in human VEGF levels present in any tumors 
between any of the treatment groups (n=5, mean±SD) (Figure 57). The Human VEGF 
Quantikine ELISA Kit utilizes antibodies raised against the most common form of VEGF, 
VEGF165. If there were any differences in any of the other VEGF isoforms, we would not 
have been able to detect these differences with this particular ELISA format.  
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 Figure 57. Human VEGF165 levels are not altered by drug treatment in vivo. NSG mice 
were implanted with 1x106 TMD231-CR cells, and when primary tumors reached 
approximately 500mm3, randomized based on tumor volume. Mice were dosed with 
20mg/kg i.p. carboplatin alone in the morning, 200mg/kg Nutlin-3a p.o. alone in the 
afternoon, or combination for 3 consecutive days. Mice were sacrificed 2 hours 
following the administration of the last dose of Nutlin-3a, and primary tumors were 
excised and collected. Tumors were homogenized using the Tissue Tearor™ 
Homogenizer, and evaluated for the presence of Human VEGF using an ELISA assay. 
There was no difference in Human VEGF165 present in tumors between any of the 
treatment groups (n=5, ±SD).  
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The other half of the primary tumors collected at the completion of the 
pharmacodynamic experiment was used to evaluate the effects of carboplatin and 
Nutlin-3a drug treatment in vivo. There were increases in Mdm2 protein levels in mice 
treated with Nutlin-3a alone while the increases in Mdm2 following combination 
treatment were not as robust (Figure 58). This result was similar to what we observed 
with in vitro experiments (Figure 17). There was a significant increase in MdmX, E2F1, 
and p21 levels in the combination treated mice compared to Vehicle (Mouse 1, 2, and 4) 
treated mice (Student’s T-test, p<0.05, n=3-4, mean±SEM) (Figure 58). Overall, there 
were no noticeable changes in PUMA levels when comparing the different treatment 
groups. This could be due to the time point at which the tumors were harvested. We 
may need to make alterations to the dosing schema to gain a better understanding in 
PUMA levels. In the future, time-course experiments could be done to better elucidate 
the signaling mechanisms that are operative in vivo following short-term drug 
treatment. Immunohistochemistry staining for Mdm2 localization (nuclear versus 
cytoplasmic) will be used in the future to better understand the mechanism in vivo.   
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 Figure 58. Combination treatment significantly increases MdmX, E2F1, and p21 protein 
levels in vivo. NSG mice were implanted with 1x106 TMD231-CR cells, and when primary 
tumors reached approximately 500mm3, randomized into treatment groups based on 
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tumor volume. Mice were dosed with Vehicle (PBS and 0.5% methylcellulose+0.05% 
Tween80) (Veh), 20mg/kg i.p. carboplatin alone (Carb) in the morning, 200mg/kg Nutlin-
3a p.o. alone (Nut) in the afternoon, or combination (Combo) for 3 consecutive days. 
Mice were sacrificed 2 hours following the last administration of Nutlin-3a and primary 
tumors were excised and collected. Tumors were homogenized using the Tissue 
Tearor™ Homogenizer and evaluated for changes in target protein levels by Western 
blot. There was a noticeable increase in Mdm2 protein levels the combination-treated 
mice however it was not as high as that observed in the Nutlin-3a-treated mice, which 
was similar to that of the in vitro data (Figure 17). There was a significant increase in 
E2F1 and MdmX levels in the combination treated mice compared to Vehicle (Mouse 1, 
2, and 4) and carboplatin-treated mice (Student’s T-test, p<0.05, n=3-4, ±SEM). There 
was a significant increase p21 levels in the combination treated mice compared to 
Vehicle (Mouse 1, 2, and 4) treated mice (Student’s t-test, p<0.05, n=4, ±SEM).  
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C. Discussion and Future Directions 
To summarize combination study 1, combination drug dosing schema was tested 
for feasibility, efficacy, and overall tolerability in mice. The combination treatment 
significantly inhibited primary tumor growth that was confirmed following post-
necropsy tumor weights when compared to tumor growth and weights of Vehicle- and 
single drug-treated mice. The number of metastases in the lungs in the combination-
treated mice was significantly reduced compared to Vehicle- and single drug-treated 
mice. The decreased lung metastases was confirmed with traditional pathologist scoring 
by hand as well as using measuring positivity of staining utilizing the Aperio ImageScope 
(Leica Biosystems) software analysis. The use of the automated image quantification 
increased speed of tissue analysis, decreased the cost of analysis and reduced any bias 
in analyzing tissue samples 156. The use of in vivo imaging was best used as a sensitive 
way to measure non-palpable tumors when the goal was to randomize mice at an early 
tumor burden.  
Overall in combination study 2, we further optimized the drug dosing schema by 
reducing the dose of carboplatin to 20mg/kg from 25mg/kg and lengthened the time 
between doses to decrease stress and drug induced toxicity on the animals. This dosing 
optimization is very important in vivo when trying to reduce toxicity in the animals. 
Studies examining the optimization of the dosing schema using a second generation 
Nutlin-3a derivative, RG7388, concluded that a 50mg/kg weekly dose was equivalent in 
efficacy to 10mg/kg daily dosing in an osteosarcoma model while reducing toxicity 149. 
Further drug dosing optimization could be completed in future studies to improve upon 
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efficacy while decreasing tissue toxicity. We determined that the combination 
treatment increased the probability of survival when compared to Vehicle and single 
carboplatin and Nutlin-3a treatment. The combination treatment significantly decreased 
total bone marrow cells immediately following drug treatment. However, after a 
recovery period of about 2 weeks, the levels of total bone marrow cells in combination 
treated mice come back up to normal levels. Additionally, while breast cancer cells can 
metastasize to bone, we did not detect any TMD231-CR present in isolated bone 
marrow cells from any of the treatment groups.  
Combination study 3 continued to validate the previous two studies as well as 
further expand on examining toxicity at the bone marrow as well as other tissues. As in 
the previous combination studies, the combination treatment significantly decreased 
primary tumor volume when compared to Vehicle and single carboplatin and Nutlin-3a 
treated mice. The mice were sacrificed after a 2-week recovery period after the 
completion of drug treatment. Bone marrow cellularity analysis indicated that there was 
no difference in the combination treated-mice compared to the Vehicle- and single-drug 
treated mice which further confirms that there is not a long lasting effect of drug 
treatment on total bone-marrow cell counts. Additionally, we used clonogenic 
progenitor assays to examine the effects of drug treatment on the progenitor cells from 
isolated bone marrow of treated mice. There was a significant reduction in number of 
progenitor cells in the combination-treated mice compared to the Vehicle- and single 
drug treated-mice. We also examined the effects of drug treatment on peripheral blood 
counts by completing CBC analysis. We saw a significant reduction in red blood cells in 
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combination treated mice compared to Vehicle and single drug treated mice. Also, there 
were significant reduction in white blood cells and platelets in the carboplatin and 
combination treated mice compared to the Vehicle and Nutlin-3a alone treated mice. 
While there were reductions in peripheral blood cell counts and progenitor assays, 
overall there did not seem to be any overt toxicity as a result of these changes. We also 
used histology to examine the effects of drug treatment on bone marrow using bone 
marrow smears, as well as spleens and livers of treated mice. Based on bone marrow 
smears, there was no overt toxicity present with all groups presenting with myeloid 
hyperplasia. The presence of tumor cells in the bone marrow was not detected during 
analysis. The livers and spleens of the mice did not appear to be different between 
treatment groups after analysis with H&E staining. There was extramedullary 
hyperplasia (EMH) present in all spleens from the all of the treatment groups. There was 
EMH present in some of the livers as well as a few mice that presented with focal lesions 
in the livers. The presence of the focal lesions did not correlate to the drug treatment 
groups and seems to be at random. There were no signs of overt tissue toxicity in the 
livers and spleens of mice with no areas of necrosis or abnormal cellular phenotypes.  
Combination therapies are common in treating cancer as the multi-targeted 
approach has been beneficial in improving treatments and patient outcomes. Finding 
new therapeutic targets is of great interest. Our studies show an improved outcome 
following the combination of Nutlin-3a and carboplatin. Additional therapeutic targets 
could be examined in our model system. One study showed in TNBC cells harboring 
mutant p53, that inhibition of Chk1 in combination with DNA damage led to a bypass of 
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Chk1-mediated checkpoint signaling and increased apoptosis in a patient xenograft 
model 157. In our system, Chk1 inhibitors could be added to potentially increased 
efficacy and lead to further tumor inhibition. Additionally, the TMD231 cells are very 
invasive as shown by in vitro cell invasion assays and the presence of in vivo lung 
metastases. Price and colleagues showed that in the parental MDA-MB-231 cells, 
activity of EGFR led to increased migration through Phosphatidylinositol 3′-Kinase (PI3K) 
and Phospholipase C- (PLC) dependent signaling 158. In these studies, it was shown that 
epidermal growth factor (EGF), which is the substrate for EFGR, led to increased cell 
migration while not affecting cell proliferation in the MDA-MB-231 cells 158. The 
migratory nature of the cells towards EGF was inhibited by the treatment of the cells 
with EGFR tyrosine kinase inhibitors, AG1478 and PD153035, the PI3K inhibitor, 
wortmannin, MEK inhibitor, PD098059, as well as the PLC inhibitor, U73122 158. 
Following flow cytometry experiments of TMD231 cells, we observed that a high 
percentage of cells (>95%) express EGFR (data not shown), which could help drive 
distant migration in vivo. Additionally, Ferraro and colleagues showed in vitro and in vivo 
model of TNBC that inhibition of EGFR using certain combinations of EGFR antibodies 
led to downregulation of the EGFR, inhibited EGFR recycling, and migration in vitro as 
well as inhibition of tumorigenic growth in vivo 159. While EGFR antagonists have not 
been highly successful in clinical trials, the authors propose that the use of combinations 
of EGFR antibodies in which there is no epitope overlap may lead increased efficacy 
compared to those antibody combinations where the epitope of EGFR overlaps between 
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the two antibodies 159. These treatment strategies could be integrated into our model 
system to further inhibit the tumorigenicity of TNBCs. 
The pharmacodynamic study was designed to better understand the 
combination treatment effects on protein levels in vivo. The pharmacodynamic study 
showed no difference in human VEGF165 levels following VEGF ELISA analysis. Further 
analysis would need to be completed to examine the other isoforms of VEGF since the 
VEGF ELISA utilized only looked at the presence of the most prevalent VEGF isoform, 
VEGF165. Western analysis from PD tumor lysates showed significant increases in E2F1, 
MdmX, and p21 compared to Vehicle treated mice in vivo following combination 
treatment. These in vivo results were different from in vitro results as the combination 
treatment led to decreases in MdmX following combination treatment in vitro. It has 
been in our experience that modulation of targets may differ between in vitro and in 
vivo settings since there are difference in tumor microenvironment with the lack of 
stromal cells in many in vitro settings as well as differences in oxygen content available 
to the tumor cells, which is especially true in vivo. Stromal cells may offer support to 
growing tumor cells by excreting growth factors 160. Often in tumors in vivo, the cells 
must adapt to surviving in hypoxic conditions due to decreased and/or abnormal blood 
flow to the tumor. In vitro, the cells typically are grown in 5% oxygen, which is much 
higher than found in tumor settings 161,162. These differences in microenvironment may 
lead to different signaling pathways to be altered in tumor cells especially following drug 
treatment. Further studies will need to be conducted to identify and validate 
biomarkers of efficacy following drug treatment in vivo. We observed increasing trends 
 233 
of Mdm2 in the Nutlin-3a and combination treated mice compared to Vehicle, which is 
similar to in vitro results, and we did not observe increases in PUMA levels across the 
treatment groups. We may need to alter the dosing schema for the pharmacodynamic 
study, possibly increasing the length of treatment to visualize the modulation of other 
molecular markers. We essentially took a snapshot in time when the tumors were 
harvested. We may have missed or not reached maximal protein levels of Mdm2 and 
PUMA in our system. Additionally, PUMA may not be playing a large role in our system 
due to other factors that inhibit PUMA signaling including antagonization by the EGFR 
receptor 143. Experiments would need to be completed to examine if EGFR is playing a 
role in our system. Further experiments would need to be conducted to better 
understand how the drug treatments affect signaling molecules that could be potential 
biomarkers of treatment effect in vivo.  
Overall the combination drug treatment was well tolerated in mice with minimal 
toxicity and high efficacy at inhibiting the primary tumor growth and metastasis in the 
lung. Preliminary pharmacodynamic studies show some evidence of target modulation 
following drug treatment. Further studies will need to be conducted to increase our 
understanding of the signaling mechanism in vivo. Similar studies could be completed 
with MdmX especially since it has been shown that MdmX has similar functions at 
inhibiting DNA repair by binding to Nbs1 99. It would be especially interesting since we 
saw increased Mdm2 levels in vitro following the combination treatment but did not 
observe significant increases in Mdm2 in vivo compared to Vehicle control mice. The 
opposite was true with MdmX levels in the tumors from combination treated-mice. In 
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vivo, MdmX levels were increased in the combination treated mice while there were no 
increases in MdmX levels in the in vitro experiments. Further experiments are being 
conducted to examine all seven-mouse tumors from the Vehicle and combination 
treated mice to see if there is a more robust effect when all samples are examined. We 
also plan on completing immunohistochemistry of tumor samples to look at Mdm2 
levels and cellular localization. The tumor samples from the PD study mice were 
completely lysed and there could be sub-compartments of the tumors that differentially 
express molecular targets. Possibly, there are significant changes in Mdm2 and MdmX 
levels in subsections of the tumors and following complete lysis, the signal was diluted 
to the point where differences were hard to visualize. Immunohistochemistry could 
provide increased understanding of protein level changes within the tumor. 
Additionally, it would be interesting to note the location of Mdm2 and MdmX within the 
cell to see if we indeed observe increased Mdm2 and MdmX in the nucleus. We could 
also conduct chromatin association assays from tumors to examine the levels of Mdm2 
and MdmX found at the chromatin in vivo. We also have the lung tissues from the PD 
study mice, which we could use to examine the effects of drug treatment on molecular 
target levels in metastatic site in vivo. The mice were not treated until Day 40 post 
implant allowing for metastases to be present in the lungs. The lungs could be lysed and 
target modulation could be examined by Western blot. Additionally, the lungs could be 
examined by immunohistochemistry staining to examine molecular target levels within 
the metastases from whole tissue slices. The use of combined Mdm2 inhibition through 
Nutlin-3a and DNA damaging-carboplatin shows a potential therapeutic benefit in TNBC 
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with reductions in primary tumor volume, reduced lung metastases, increased survival, 
and no notable long lasting toxicity. Further studies will need to be conducted to better 
understand the signaling mechanism, but potential molecular targets that could be 
tracked as markers of treatment response included MdmX, p21, and E2F1 in vivo in this 
in vivo model of TNBC.  
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Chapter 5. Modulation Of The Mdm2 Signaling Axis Sensitizes Triple-Negative Breast 
Cancer Cells To Carboplatin Summary 
 
In closing, this thesis showed the combined use of the PPI, Nutlin-3a, to inhibit 
Mdm2 and DNA damaging drug, carboplatin, led to decreased cell proliferation and 
increased apoptosis in vitro as well as decreased tumor growth and metastasis and 
increased survival in vivo. Nutlin-3a led to the potentiation of carboplatin-mediated DNA 
damage in vitro and in vivo allowing for several signaling pathways to be activated 
including p73-mediated apoptosis and delayed DNA damage response due to Mdm2 
antagonization of Nbs1 in vitro (Figure 59). The overall objective of this thesis was to 
evaluate the therapeutic potential of a new combination therapy to treat TNBC 
independent of wild-type p53. Based on front-line therapies currently being tested in 
clinical trials for TNBC, the platinum agent, carboplatin was selected for study. Novel 
drug targets need to be elucidated to improve treatment modalities especially in 
treating aggressive cancers like TNBC. Mdm2 is an unexplored target in breast cancers, 
and histological studies have indicated that more than half of breast cancer biopsies 
contain high levels of Mdm2. In this thesis, the potentiation of carboplatin-mediated 
DNA damage in the context of blocking some aspects of Mdm2 function was 
investigated. Pharmacodynamic studies were designed to gain insight into and validate 
molecular mechanisms that based on the literature could be operative following 
treatment. In our correlative PD studies, we also sought to identify targets that could 
potentially serve as biomarkers of treatment response and efficacy for future clinical 
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trials of TNBC. A humanized breast-to-lung model was optimized in NSG mice and can 
be used in the future to further screen and validate novel combination therapies. 
Further studies will need to be conducted to expand and build upon our knowledge to 
further validate key molecular targets and operative signaling pathways present in our 
model system. Additionally we plan on using primary patient xenograft models with the 
PDX breast cancer models from Jackson Laboratories. There are several PDX models that 
feature TNBC with mutant p53. These primary patient tumors have been characterized 
with gene levels, copy number variation, and histology data. These primary patient 
samples will allow for us to examine the effects of dual Nutlin-3a and carboplatin 
treatment in more clinically relevant models. The data presented in this thesis indicate 
that Mdm2 represents a valid therapeutic target in TNBC and is worthy of further 
exploration at the cellular and molecular levels. In closing, the in vitro and in vivo results 
provide solid confirmation that modulation of Mdm2 in the context of platinum-based 
cytotoxic therapy is a valid approach for improving treatment of TNBC.  
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 Figure 59. Mdm2 as a therapeutic target and potential molecular markers for TNBC 
using Nutlin-3a and carboplatin in combination. Nutlin-3a was designed as a small 
molecular inhibitor that bound into the hydrophobic pocket of Mdm2 inhibiting the 
binding of p53. It was later shown that Nutlin-3a also inhibited the binding of E2F1, p73 
and Hif-1α to Mdm2. In recent years, the use of platinum drugs has gained popularity in 
the treatment of breast cancers. Carboplatin causes DNA damage by causing intra and 
interstrand crosslinks in the DNA ultimately leading to cell death. In our model system of 
TNBC with mutant p53, we sought to understand the molecular targets being 
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modulated in vitro and in vivo. In vitro, we observed increased p21 and Mdm2 protein 
levels following drug treatment. There were concentration-dependent increases in p21 
following single Nutlin-3a treatment. Nutlin-3a alone and combination treatment led to 
increased Mdm2 levels following Western blot. We also observed increased Mdm2 
associated with the chromatin following combination treatment than each single drug 
alone. We hypothesized that increased levels of Mdm2 at the chromatin led to 
increased binding of Mdm2 to Nbs1, which in turn led to decreased DNA repair and was 
supported by Bouska and colleagues 35. Additionally, following siRNA-mediated 
knockdown of p73, we observed p73-dependent cellular sensitivity to carboplatin drug 
treatment. Following a PD study in vivo, we observed changes in MdmX, p21, and E2F1 
protein levels in combination treated mice compared to Vehicle and single drug treated 
mice. We did not observe significant changes in VEGF165 levels between treatment 
groups.  
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